UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report:

 

December 14, 2017

 

 

 

MERCARI COMMUNICATIONS GROUP, LTD.

(Exact name of registrant as specified in its charter)

 

Colorado   0-17284   84-1085935
State of   Commission   IRS Employer
Incorporation   File Number   Identification No.

 

Hongxing International Business Building 2, 14 th FL, No. 69 Qingyun South Ave., Jinjiang District

Chengdu City, Sichuan Province, China

(Address of principal executive offices)

 

1120 Avenue of the Americas, 4th floor, New York, NY 10036

(Former Address of principal executive offices)

 

86-400-6260600

(Issuer’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 

 

 

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

 

This report contains forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “would” and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on forward-looking statements. Forward-looking statements include, among other things, statements relating to:

 

  our goals and strategies;
     
  our future business development, financial condition and results of operations;
     
  our expectations regarding demand for, and market acceptance of, our products;
     
  our expectations regarding keeping and strengthening our relationships with merchants, manufacturers and end-users; and
     
  general economic and business conditions in the regions where we provide our services.

 

Also, forward-looking statements represent our estimates and assumptions only as of the date of this report. You should read this report and the documents that we reference and filed as exhibits to the report completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, even if new information becomes available in the future.

 

Use of Certain Defined Terms

 

Except where the context otherwise requires and for the purposes of this report only:

 

the “Company,” “Mercari,” “we,” “us,” and “our” refer, prior to December 12, 2017, the date of the reverse acquisition resulting from the share exchange transaction described in this report, to the registrant, Mercari Communications Group, Ltd., a shell company, and thereafter, to the business of (i) AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“ AiXin BVI”) recently organized for the sole purpose of acquiring all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), formed for the sole purpose of acquiring all of the outstanding shares of Chengdu AiXin Zhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXin Zhonghong”), which markets and sells innovative, premium-quality nutritional products in China.

 

“Exchange Act” refers to the Securities Exchange Act of 1934, as amended;

 

“Hong Kong” refers to the Hong Kong Special Administrative Region of the People’s Republic of China;

 

“PRC,” “China,” and “Chinese,” refer to the People’s Republic of China (excluding Hong Kong and Taiwan);

 

“Renminbi” and “RMB” refer to the legal currency of China;

 

“Securities Act” refers to the Securities Act of 1933, as amended; and

 

“US dollars,” “dollars” and “$” refer to the legal currency of the United States.

 

 

 

 

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

 

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

 

On December 12, 2017, we entered into and closed a share exchange agreement, or the Share Exchange Agreement, with AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“ AiXin BVI”) , and Quanzhong Lin, the sole stockholder of AiXin BVI (the “AiXin BVI Stockholder”), pursuant to which we acquired 100% of the outstanding capital stock of AiXin BVI in exchange for 227,352,604 shares of our common stock (the “Share Exchange” or the “AiXin Acquisition”). The foregoing description of the terms of the Share Exchange Agreement is qualified in its entirety by reference to the provisions of the Share Exchange Agreement filed as Exhibit 2.1 to this report, which are incorporated herein by reference. After giving effect to the Share Exchange, we had outstanding 317,988,089 shares of common stock.

 

As a result of the Share Exchange, AiXin BVI became our wholly-owned subsidiary, and we now own all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXin Zhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXin Zhonghong”), which markets and sells innovative, premium-quality nutritional products in Chengdu, China.

 

AiXin BVI was incorporated on September 21, 2017 to serve as a holding company and AiXin HK was established in Hong Kong on February 25, 2016 to serve as an intermediate holding company. AiXin Zhonghong was established in the PRC on March 4, 2013, and on June 1, 2017 the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXin Zhonghong by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

 

Prior to the AiXin Acquisition, Quanzhong Lin, our President and Chief Executive Officer, owned all of the outstanding shares of AiXin BVI and 29,521,410 shares of our common stock, approximately 65% % of the outstanding shares of Mercari Communications Group, Ltd. As a result of the Share Exchange, Mr. Lin now owns 256,874,014 shares of our common stock, approximately 80.78% of our outstanding shares, after giving effect to certain other issuances described under the caption “Market for Registrant’s Common Equity and Related Stockholder Matters.”

 

For accounting purposes, the acquisition has been accounted for as a reverse acquisition and has been treated as a recapitalization of Mercari Communications Group, Ltd. effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical financial statements of AiXin Zhonghong are now the historical financial statements of the registrant, Mercari Communications Group, Ltd., and have been included in Item 9.01(a) of this report. The assets and liabilities of AiXin Zhonghong have been brought forward at their book value and no goodwill has been recognized.

 

FORM 10 DISCLOSURE

 

As disclosed elsewhere in this report, on December 12, 2017, we acquired AiXin BVI pursuant to the Share Exchange Agreement Item 2.01(f) of Form 8-K states that if the registrant was a shell company like we were immediately before the AiXin Acquisition, then the registrant must disclose the information that would be required if the registrant were filing a general form for registration of securities on Form 10. Accordingly, we are providing below the information that would be included in a Form 10 if we were to file a Form 10. Please note that the information provided below relates to the combined enterprises after the AiXin Acquisition, except that information relating to periods prior to the date of the AiXin Acquisition only relate to Mercari Communications Group, Ltd, unless otherwise specifically indicated.

 

  1  
 

 

BUSINESS

 

Overview

 

We, through our indirectly wholly owned subsidiary, AiXin Zhonghong, market and sell innovative, premium-quality nutritional products in Chengdu, China. The products we market and sell are manufactured by unaffiliated parties. We currently offer 20 products, including Oleesa Milk Powder, CO Q10, D-Ribose Powder, and other nutritional supplements. We offer these products directly to our clients at events we organize and sponsor, at which our nutritional consultants/counselors and, on occasion, representatives of the manufacturer promote the products and discuss the benefits derived from using the products. We also rely on client recommendations to market and sell products and offer discounts to clients who purchase significant quantities of products for the purpose of marketing and selling the products to their friends, family members and others. We also offer clients who purchase significant quantities of products paid vacations, travel and other benefits. The products can be purchased at the events held by us, as well as any of the fourteen sales offices we maintain in Chengdu.

 

Before promoting a product, we research the product to determine whether the manufacturer is reputable and delivers unadulterated products, and whether there is a basis for claiming the product can deliver the benefits claimed. We do not independently test products to determine efficacy. Rather we rely upon third party reports and the information we can uncover in scientific and other literature. Once we determine to offer a product and believe that it will be purchased by our clients, we will purchase a bulk quantity, enabling us to acquire products at prices below those which are available to smaller distributors.

 

We offer our clients personalized services, including educating them through seminars conducted by our nutritional counselors on the benefits of the products we distribute, maintaining sales offices at which our clients can engage in recreational and social activities where the products we offer are prominently displayed and can be picked up, conducting promotions with representatives of the manufacturers of the products, and encouraging customer loyalty with incentives such as rewards and discounts based upon the quantities of products purchased for individual use or sold to others. We believe that our marketing strategy which emphasizes ongoing personal contact and support, coaching and educating our clients as to the benefits of the products we distribute is ideally suited for selling nutritional products and builds confidence in and customer loyalty to our company and the products we sell. We believe that this is particularly the case in China where the middle class is growing in size yet, due to lax enforcement and limited laws and regulations, many manufacturers and distributors, particularly those of new and innovative products, are not trusted by consumers. Thus, although our focus is our clients, the manufacturers we work with get the benefit of the trust our clients have placed in us. Consequently, although certain of the products we distribute are produced by a variety of manufacturers, we require the manufacturer or distributor from which we purchase a product to provide us with exclusive distribution rights within a prescribed territory or package the product so that it is distinct from products sold to our competitors.

 

The chart below presents our corporate structure:

 

Mercari Communications Group, Ltd. (a Colorado corporation)
   
100%
   
AiXin (BVI) International Group Co., Ltd (BVI)
   
100%
   
HK AiXin International Group Co., Limited (HK) (“AiXin HK”)
   
100%
   
Chengdu Aixin Zhonghong Biological Technology Co., Ltd (PRC) (“AiXin Zhonghong”)

 

Our executive offices are located at Hongxing International Business Building 2, 14 th FL, No. 69 Qingyun South Ave., Jinjiang District, Chengdu City, Sichuan Province, China, and our telephone number is +86-400-6260600.

 

  2  
 

 

Products We Offer

 

We offer a variety of nutritional products, which change over time. In 2015 we offered 8 products; in 2016 we offered 11 products, and we currently offer 20 products. Our most popular products are Oleesa Milk Powder, CO Q10 and D-Ribose Powder. We source and purchase all our products through third party distributors and manufacturers which we carefully research before determining to distribute a product.

 

We study the attributes of new products introduced to us from time to time and after understanding the benefits which they claim to offer we organize a group of professionals to experience and evaluate the products. After a series of detailed evaluations, we recommend the products to our clients generally at direct marketing events organized by us. This process ensures our clients get safe, quality products that suit their personal needs and upon which they can rely.

 

Marketing and Sales Strategy

 

We market and sell the products we offer directly to our clients, primarily utilizing person-to-person marketing to promote and sell our products. These personal marketing efforts are supported by various mediums, including our marketing content, educational events, open facilities and social business solutions. We believe our marketing strategy is effective because:

 

  our nutritional counselors can educate consumers about our products face-to-face, which we believe is more effective for differentiating our products than using traditional mass-media advertising, particularly when introducing a new product to an unsophisticated group of consumers in an environment where it is difficult to obtain accurate, reliable product information;
     
  it provides for actual product demonstrations and trial by potential consumers;
     
  it allows our nutritional counselors to provide personal testimonials of product efficacy; and
     
  as compared to other marketing methods, our nutritional counselors have the opportunity to provide consumers higher levels of service and encourage repeat purchases.

 

We market the products we offer to two types of clients: individuals who buy our products directly from us primarily for personal or family consumption; and individuals who personally buy, use and distribute our products to new clients.

 

We offer those clients who purchase for their own personal use high-quality, innovative products that provide demonstrable benefits. We attempt to obtain detailed personal information about each of our clients so that we can direct each of them to products that best suit their needs and begin to distribute new products that will appeal to our clients. We track the purchases made by every individual who purchases products directly from us. Based upon their purchasing history, we believe a significant majority of our clients purchase the products we sell primarily for personal or family consumption and are not actively pursuing the opportunity we offer to generate income by marketing and reselling products.

 

Our strategy for increasing the number of clients interested in selling the products we offer to others and developing new clients, and who demonstrate the ability to sell our products to others, is to provide them with compensation, often in the form of premiums such as paid travel or vacations, or quantity purchase discounts and other incentives. We track the amount of products purchased and frequency of purchases by those clients who sell the products we offer to others.

 

  3  
 

 

We offer our clients a customer satisfaction guarantee. Under this guarantee, any customer who is not satisfied with a product we offer for any reason may return it or exchange it for another product we offer based on customer’s claim and management’s approval.

 

Because of restrictions on direct selling and multi-level commissions in Mainland China, we have structured our business model based on several factors: the guidance we have received from government officials, our interpretation of applicable regulations, our understanding of the practices of other international direct selling companies operating in Mainland China, and our understanding as to how regulators are interpreting and enforcing the regulations.

 

Competition

 

Products

 

The category of nutritional products is very competitive and there are various channels through which such products are marketed to consumers, including direct selling, through the internet, in specialty retailers and the discounted channels of food, drug and mass merchandise. Aixin Zhonghong seeks to differentiate itself from this group by being familiar with its clients and providing a personalized sales experience, and focusing on after-sale services where sales employees focus on the consultative sales process through product education and the frequent contact and support that many sales employees have with the clients. From a competitive standpoint, there are many providers and sales outlets of nutritional products in China. We believe that none have effectively combined the product, personal coaching, education and the product access provided by our sales employees and, further, that these efforts are compounded by the peer pressure our clients generate through our organized sales presentations.

 

Our Competitive Advantages / Strengths

 

Client Base

 

We have clients who primarily join for a discount on products they consume and introductions to new products they might desire, along with clients who also choose to profit by reselling our products. As of September 30, 2017, we had 3,000 existing clients, which include preferred clients, who purchase products for personal and family use, and client distributors, who purchase products for their own use and for distribution to others, and more than 7,000 potential clients (defined as someone who had attended an event or purchased two products within the past two months).

 

People become Aixin Zhonghong clients for a number of reasons. Many first start out as consumers looking to improve their health through better nutrition. Some join simply to receive a better price on products they and their families can consume and enjoy, while others join so they can resell our products and generate income.

 

Competitive Advantages

 

  - We study the attributes of new products which become available and after researching the benefits which they claim to offer we organize a group of professionals to experience and evaluate the products. Only after we have determined that a product is safe, manufactured in conformance with appropriate standards, and has a basis for the claims made, do we recommend a product to our clients. This process ensures our clients get safe, quality products that suit their personal needs and upon which they can rely.
     
  - Our clients vary greatly in age, background, health and physical condition. We organize activities and events so that we might learn each client’s family background, physical condition and personal health needs, and categorize them into different groups for different products. For example: “cardiovascular and cerebrovascular group”, “bones and joints”, “heart health” …etc.
     
  - We also focus on after-sale services. Due to the large number of clients that are in the middle-to-older aged groups, we have the ability to have products delivered to our clients’ homes by sales personal who can explain the product and demonstrate its use. Our sales personnel are available on a 24 hour basis for questions from clients. Once a client purchases a product, our in-house health advisors will contact him or her to give appropriate professional advice and consultation both over the phone, of face-to-face if needed.

 

  4  
 

 

Our Strategies

 

  - On-site Publicity. We have rooms available at our 14 sales offices throughout Chengdu at which our clients can gather to play cards, enjoy afternoon teas, and engage in other activities. The products we distribute are displayed at each of these sites along with appropriate literature and can be purchased by clients and visitors.
     
  - Marketing Events. We host large-scale marketing events for approximately 1000 participants once or twice every month and conduct events for approximately 500 participants 4-5 times every month. These events are held at our premises or at restaurants and catering halls. During each event products are demonstrated and our personnel explain the benefits of the products and, if available, representatives of the manufacturer or distributor are on hand to respond to questions or make a presentation. We use holidays, such as “National Day,” “New Year Day,” and “Mid-Autumn Day” as an opportunity to host large-scale themed activities or events appropriate for the season.
     
  - One-on-one marketing. Sales people will explain and market products to clients one-on-one at our facilities, during marketing events or at a client’s home or office, which gives a personal touch and more detailed explanation of products.

 

Seasonality

 

In general, there is no seasonality in the sales of nutrition products.

 

Regulation

 

General

 

The distribution of nutritional products is subject to many laws, governmental regulations, administrative determinations and guidance and similar constraints. Such laws, regulations and other constraints exist at the national, provincial and or local levels, including regulations pertaining to: (1) the formulation, manufacturing, packaging, labeling, distribution, importation, sale and storage of products; (2) product claims and advertising, including direct claims and advertising by us, as well as claims and advertising by manufacturers and distributors of the products we offer, for which we may be held responsible; and (3) taxes.

 

Products

 

Prior to commencing manufacture or distribution of a product, the manufacturer or distributor may be required to obtain an approval, license or certification from the national, provincial or local government in China. Although we attempt to determine whether all regulatory requirements have been met, we cannot monitor the manufacture of products and cannot be certain that all applicable regulations are satisfied.

 

Regulation of Nutritional Products.

 

Dietary supplements are subject to regulation by the China Food and Drug Administration. Mainland China has highly restrictive nutritional supplement product regulations. Products marketed as “health foods” are subject to extensive laboratory and clinical analysis by government authorities, and the product registration process in Mainland China generally takes one to two years, but may be substantially longer. We market both “health foods” and “general foods” in Mainland China. As a secondary distributor, we are not in a position to obtain any required license, though we may be held liable if we were to distribute a product which had not been properly tested and registered with the authorities. There is some risk associated with the common practice in Mainland China of marketing a product as a “general food” while seeking “health food” classification. If government officials feel the categorization of a product distributed by us is inconsistent with product claims, ingredients or function, this could end or limit our ability to market such products.

 

  5  
 

 

As the middle class has grown, the number of manufacturers and distributors of nutritional supplements in China has dramatically increased. Many of these enterprises have often ignored applicable laws and distributed adulterated or inferior products. We believe this has created a marketing opportunity which we have tried to exploit as a trusted source of products on which our clients can rely. To the extent our reputation results from reviewing and testing products prior to distributing them, and then distributing only products determined to be safe, it is incumbent upon us to ensure that the manufacturers and distributors upon which we rely are trustworthy. A failure by any of these third parties could cause substantial damage to our reputation, business and financial results.

 

Direct Selling Regulations

 

Direct selling is regulated by various national, provincial and local government agencies in China. These laws and regulations are generally intended to prevent fraudulent or deceptive schemes, including “pyramid” schemes, which compensate participants primarily for recruiting additional participants without significant emphasis on product sales to consumers.

 

We believe we do not engage in direct selling activities subject to regulations prevalent in China. Nevertheless, the laws and regulations governing direct selling may be modified or reinterpreted from time to time, which may cause us to change our sales compensation and business models. In almost all of our markets, regulations are subject to discretionary interpretation by regulators and governmental authorities. There is often ambiguity and uncertainty with respect to the implication of direct selling and anti-pyramiding laws and regulations.

 

The regulatory environment in Mainland China is particularly complex and continues to evolve. Mainland China’s direct selling and anti-pyramiding regulations contain various restrictions, including a prohibition on the payment of multi-level compensation. The regulations are subject to discretionary interpretation by provincial and local level regulators as well as local customs and practices.

 

Employees

 

As of September 30, 2017 we had approximately 78 full-time employees, of which approximately 41 were sales personnel and 37 are in public relations and sales support.

 

Corporate History

 

Mercari Communications Group, Ltd., the registrant, was incorporated under the laws of the State of Colorado on December 30, 1987. From 1988 until early in 1990, Mercari was engaged in the business of providing educational products, counseling, seminar programs, and publications such as newsletters to adults aged 30 to 50. Mercari registered its common stock with the Securities and Exchange Commission (the “SEC”) under the Exchange Act in 1988. Mercari’s business failed in early 1990. Mercari ceased all operating activities during the period from June 1, 1990 to August 31, 2001 and was considered dormant. During this period, the registrant failed to file required reports with the SEC under the Exchange Act.

 

  6  
 

 

During 2001, Mercari was reactivated. Mercari has filed all delinquent documents with the Colorado Secretary of State and federal and state tax authorities, and all reports required under the Exchange Act since 2002 and is now current in its reporting obligations under the Exchange Act.

 

From November 30, 2001 to March 1, 2004, Mercari was in the development stage.

 

On November 9, 2009, Mercari entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) with Algodon Wines & Luxury Development Group, Inc. or “Algodon” (formerly Diversified Private Equity Corporation or “DPEC”), a then privately-held Delaware corporation, and Kanouff, LLC (“KLLC”) and Underwood Family Partners, Ltd. (the “Partnership”), of which KLLC and the Partnership were the majority shareholders of the Company (the “Stock Purchase”). In connection with the Stock Purchase, Algodon purchased and the Company sold, an aggregate of 43,822,001 shares of common stock for a purchase price of $43,822, or $0.001 per share. In addition, Algodon purchased 200 shares of common stock from KLLC and 200 shares of common stock from the Partnership for a purchase price of $180,000 payable to each selling shareholder. Immediately following the closing of the transactions contemplated by the Stock Purchase Agreement, Algodon owned an aggregate of 43,822,401 shares of our common stock, or approximately 96.5% of our outstanding shares.

 

During each of the years since Mercari was reactivated, we had no revenue and had losses approximately equal to the expenditures required to reactivate and comply with filing and reporting obligations. Expenditures have been paid by Mercari from capital contributions and loans made by Mercari’s principal stockholders and entities controlled by Mercari’s directors.

 

On January 20, 2017, Algodon sold all 43,822,401 shares of our common stock, approximately 96.5% of our outstanding shares of common stock as part of the transactions described under the caption “Security Ownership of Beneficial Owners and Management and Related Stockholder Matters – Change In Control”, which resulted in a change in control of our company.

 

Prior to the AiXin Acquisition on December 12, 2017, Mercari was a development stage company with nominal assets and without employees, and therefore was considered a “shell company,” as that term is defined in Rule 12b-2 under the Exchange Act. As a result of the AiXin Acquisition, we are no longer a shell company.

 

RISK FACTORS

 

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with all of the other information included in this report, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

 

Risks Related to Our Business

 

We require significant investment to expand our business.

 

We will require significant expenditures in the foreseeable future to fund our ongoing operations and future growth. We intend to fund our expenditures and growth out of internal sources of liquidity and/or through additional financing from external sources. Our ability to obtain external financing in the future at a reasonable cost is subject to a variety of uncertainties, including:

 

our future financial condition, results of operations and cash flows;
the condition of the global and domestic financial markets; and
changes in the monetary policy of the PRC government with respect to bank interest rates and lending practices.

 

  7  
 

 

If we require additional funds and cannot obtain them on acceptable terms when required or at all, we may be unable to fulfill our working capital needs, upgrade our existing facilities or expand our business. These factors may also prevent us from entering into transactions that would otherwise benefit our business or implementing our future strategies. Any of these factors may have a material adverse effect on our business, financial condition and results of operations.

 

We incurred a substantial net loss in 2016 and may not be able to continue to operate as a going concern.

 

We suffered net losses of $2.08 million for 2016 and $0.92 million for the nine months ended September 30, 2017 and had a shareholders’ deficit of $2.02 million as of December 31, 2016 and of $3.05 million as of September 30, 2017. The report of our independent registered public accountants on our financial statements as of and for the year ended December 31, 2016 states that these factors raise uncertainty about our ability to continue as a going concern.

 

We face intense competition, and if we do not compete successfully against existing and new competitors, we may lose market share and suffer losses.

 

We face intense competition. We believe that our ability to compete depends upon many factors both within and beyond our control. Some of our current and potential competitors may have greater financial, marketing, user traffic and other resources than we have. Certain of our competitors may be able to devote greater resources to marketing and promotional campaigns and devote substantially more resources to website and system development than us. Increased competition may reduce our market share and require us to increase our marketing and promotional efforts, which could negatively affect our operating margins or force us to incur losses. There can be no assurance that we will be able to compete successfully against current and future competitors, and competitive pressures may have a material adverse effect on our business, prospects, financial condition and results of operations.

 

We may have difficulty in managing our future growth and any associated increased scale of our operations.

 

We expect to expand through both organic growth and acquisitions. Our future expansion may place a significant strain on our managerial, operational, technical and financial resources. In order to better allocate our resources to manage our growth, we must hire, recruit and manage our workforce effectively and implement adequate internal controls in a timely manner. If we are unable to effectively manage our growth and the associated increased scale of our operations, our business, financial condition and results of operations could be materially and adversely affected.

 

Any damage to our reputation or our failure to enhance our recognition as a distributor of quality nutritional products may materially and adversely affect our business, financial condition and results of operations.

 

We believe that the market recognition and reputation we have achieved have significantly contributed to the success of our business. Maintaining and enhancing our reputation is critical to our success and ability to compete. Many factors, some of which are beyond our control, may negatively impact our reputation, such as:

 

  [  ] any failure to maintain a pleasant and reliable experience for clients;
     
  [  ] any adverse reaction of one or more of our clients to any product we distribute, including reactions caused by the delivery of inferior or adulterated products by one of our suppliers; and
     
  [  ] any negative publicity about us, including any actual or perceived product quality problems.

 

If we are unable to maintain a good reputation, further enhance our recognition as a distributor of quality nutritional products, continue to develop our user loyalty and increase positive awareness of the products we offer, our results of operations may be materially and adversely affected.

 

  8  
 

 

Changes in economic conditions and consumer confidence in China may influence the market for nutritional products, consumer preferences and spending patterns.

 

Our business and revenue growth primarily depend on the size of the market for nutritional products in China. As a result, our revenue and profitability may be negatively affected by changes in national, regional or local economic conditions and consumer confidence in China. In particular, as we focus on our expansion in metropolitan markets, where living standards and consumer purchasing power are relatively high, we are especially susceptible to changes in economic conditions, consumer confidence and customer preferences of the urban Chinese population. External factors beyond our control that affect consumer confidence include unemployment rates, levels of personal disposable income, national, regional or local economic conditions, and acts of war or terrorism. Changes in economic conditions and consumer confidence could adversely affect consumer preferences, purchasing power and spending patterns. A decrease in overall consumer spending as a result of changes in economic conditions could adversely affect our sales of nutritional supplements and negatively impact our profitability. In addition, acts of war or terrorism may cause damage to our facilities, disrupt the supply of the products we market and sell or adversely impact consumer demand. Any of these factors could have a material adverse effect on our business, financial condition and results of operations.

 

We may not be able to timely identify or otherwise effectively respond to changing customer preferences, and we may fail to optimize our product offering and inventory position.

 

The market for nutritional products in China is rapidly evolving and is subject to rapidly changing customer preferences that are difficult to predict. Our success depends on our ability to anticipate and identify customer preferences, and adapt our product selection to meet these preferences. In particular, we must optimize our product selection and inventory positions based on sales trends. We cannot provide assurance that our product selection will accurately reflect customer preferences at any given time. If we fail to accurately anticipate either the market for our products or customers’ purchasing habits or fail to respond to customers’ changing preferences promptly and effectively, we may not be able to adapt our product selection to customer preferences or make appropriate adjustments to our inventory positions, which could significantly reduce our revenue and have a material adverse effect on our business, financial condition and results of operations.

 

We market a relatively few nutritional products from a limited number of manufacturers.

 

We currently offer only 20 nutritional products from a limited number of manufacturers. Unless we are able to significantly increase the number of nutritional and other products we market and sell and the number of manufacturers who distribute their products through our distribution channel, we will be unable to increase our revenues and become profitable.

 

Our business depends substantially on the continuing efforts of our executive officers and key employees, and our business may be severely disrupted if we lose their services.

 

We currently depend on the continued services and performance of the key members of our management team, in particular Mr. Quanzhong Lin, our President and Chief Executive Officer. Mr. Lin is our founder and his leadership has played an integral role in our growth. Our future success depends substantially on the continued efforts of our executive officers and key employees. If one or more of our executive officers or key employees were unable or unwilling to continue their service, we might not be able to replace them easily, in a timely manner, or at all, and our business may be severely disrupted, our financial conditions and results of operations may be materially and adversely affected and we may incur additional expenses to recruit, train and retain personnel.

 

Our key executives do not devote full time to our operations .

 

Mr. Quanzhong Lin, our President and Chief Executive Officer, is involved in a number of businesses and does not devote full time to our operations. Our positive reputation is derived from Mr. Lin’s business success and standing in the community. If Mr. Lin does not devote sufficient attention to our business, our operations could suffer and our financial conditions and results of operations may be materially and adversely affected. If Mr. Lin’s other businesses should fail or if his reputation in the community should be impaired, our business could suffer and our financial conditions and results of operations may be materially and adversely affected.

 

  9  
 

 

Some of the other businesses operated by Mr. Lin or his affiliates may be deemed competitors of ours.

 

Mr. Quanzhong Lin is engaged in other businesses, such as the retail pharmacies and internet marketing, which distribute products which may be deemed competitive with products we distribute. Should such businesses prove more successful than ours, Mr. Lin could choose to focus his attention on such business which could cause him to fail to devote sufficient attention to our business, our operations could suffer and our financial conditions and results of operations may be materially and adversely affected

 

Our principal shareholder is not familiar with American business practices.

 

Mr. Quanzhong Lin, our founder and principal shareholder, is a citizen of the PRC and a successful entrepreneur in Chengdu. Mr. Lin is not familiar with American business practices  and is heavily influenced by the business culture in the PRC. Certain governmental entities pay bonuses or subsidies to individuals in China whose companies become publicly traded in America and there is a certain level of respect and prestige associated with being the Chinese principal of a company which is publicly traded in the U.S. Mr. Lin’s motivation for causing the business of AiXin Zhongdong to become a part of a U.S. publicly-traded company may differ from those of American entrepreneurs and his values may cause him to operate the business differently than would an American entrepreneur.

 

If we are unable to attract, train and retain qualified personnel, our business may be materially and adversely affected.

 

Our future success depends, to a significant extent, on our ability to attract, train and retain qualified personnel, particularly management, technical and marketing personnel with expertise in nutritional products. Our sales and customer service teams are critical to maintaining the quality of our services as they frequently interact with our clients. We must continue to attract qualified personnel at a fast pace to increase the number of our clients and products we distribute. As we are still a relatively young company, our ability to train and integrate new employees into our operations may not meet the growing demands of our business. If we are unable to attract, train, and retain qualified personnel, our business may be materially and adversely affected.

 

Our business, financial condition and results of operations, as well as our ability to obtain financing, may be adversely affected by the downturn in the global or Chinese economy.

 

It is unclear whether the Chinese economy will resume its high growth rate. There is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies that have been adopted by the central banks and financial authorities of some of the world’s leading economies, including the United States. Economic conditions in China are sensitive to global economic conditions, as well as changes in domestic economic and political policies and the expected or perceived overall economic growth rate in China.

 

The sale of nutritional products may be affected by economic downturns. Our products may be viewed as discretionary by our clients, who may choose to discontinue or reduce spending on such products during an economic downturn. In such an event, our ability to retain existing clients and increase or maintain our sales will be adversely affected, which would in turn negatively impact our business and results of operations.

 

Moreover, a slowdown or disruption in the global or China’s economy may have a material and adverse impact on financing available to us. There is a risk that our business, results of operations and prospects would be materially and adversely affected by any global economic downturn or disruption or slowdown of China’s economy.

 

  10  
 

 

Future strategic alliances or acquisitions may have a material and adverse effect on our business, reputation and results of operations.

 

We may in the future enter into strategic alliances with various third parties to further our business purposes from time to time. Strategic alliances with third parties could subject us to a number of risks, including risks associated with sharing proprietary information, non-performance by the counter-party, and an increase in expenses incurred in establishing new strategic alliances, any of which may materially and adversely affect our business. In addition, to the extent the strategic partner suffers negative publicity or harm to their reputation from events relating to their business, we may also suffer negative publicity or harm to our reputation by virtue of our association with such third parties, and we may have little ability to control or monitor their actions.

 

In addition, although we have no current acquisition plans, if we are presented with appropriate opportunities, we may acquire additional assets, products, technologies or businesses that are complementary to our existing business, including businesses that are owned or controlled by Mr. Lin or his affiliates. Future acquisitions and the subsequent integration of new assets and businesses into our own would require significant attention from our management and could result in a diversion of resources from our existing business, which in turn could have an adverse effect on our business operations. Acquired assets or businesses may not generate the financial results we expect. Furthermore, acquisitions could result in the use of substantial amounts of cash, potentially dilutive issuances of equity securities, the occurrence of significant goodwill impairment charges, amortization expenses for other intangible assets and exposure to potential unknown liabilities of the acquired business. Moreover, the costs of identifying and consummating acquisitions may be significant. In addition to possible shareholders’ approval, we may also have to obtain approvals and licenses from the relevant government authorities in the PRC for the acquisitions and to comply with any applicable PRC laws and regulations, which could result in increased costs and delay.

 

If we or our PRC subsidiaries acquire any domestic companies in China, such acquisition will be subject to PRC laws and regulations on foreign investment. We and our PRC subsidiaries are restricted or prohibited from directly acquiring interests in companies in certain industries under PRC laws and regulations. Our consolidated affiliated entities outside of the PRC are not subject to PRC laws and regulations on foreign investment and may acquire PRC companies operating in industries where foreign investments are restricted or prohibited. However, there are uncertainties with respect to the interpretation and application of PRC laws and regulations regarding indirect foreign investments in such industries.

 

We have limited business insurance coverage.

 

Insurance companies in China currently do not offer as extensive an array of insurance products as insurance companies do in more developed economies. We do not have any business liability or disruption insurance to cover our operations. We have determined that the costs of insuring for these risks and the difficulties associated with acquiring such insurance on commercially reasonable terms make it impractical for us to have such insurance. Any uninsured occurrence of business disruption may result in our incurring substantial costs and the diversion of resources, which could have an adverse effect on our results of operations and financial condition.

 

Risks Related to Doing Business in China

 

The PRC government exerts substantial influence over the manner in which we must conduct our business activities.

 

The PRC government has exercised and continues to exercise substantial control over virtually every sector of the Chinese economy through regulation and state ownership. Our ability to operate in China may be harmed by changes in its laws and regulations, including those relating to taxation, import and export tariffs, environmental regulations, land use rights, property and other matters. We believe that our operations in China are in material compliance with all applicable legal and regulatory requirements. However, the central or local governments of the jurisdictions in which we operate may impose new, stricter regulations or interpretations of existing regulations that would require additional expenditures and efforts on our part to ensure our compliance with such regulations or interpretations. Accordingly, government actions in the future, including any decision not to continue to support recent economic reforms and to return to a more centrally planned economy or regional or local variations in the implementation of economic policies, could have a significant effect on economic conditions in China or particular regions thereof.

 

  11  
 

 

Uncertainties in the interpretation and enforcement of PRC laws and regulations could limit the legal protections available to you and us.

 

The PRC legal system is based on written statutes. Unlike common law systems, it is a system in which legal cases have limited value as precedents. In the late 1970s, the PRC government began to promulgate a comprehensive system of laws and regulations governing economic matters in general. The overall effect of legislation over the past three decades has significantly increased the protections afforded to various forms of foreign or private-sector investment in China. Our PRC subsidiary is subject to laws and regulations applicable to various PRC laws and regulations generally applicable to companies in China. However, since these laws and regulations are relatively new and the PRC legal system continues to rapidly evolve, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involve uncertainties.

 

From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. However, since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore, the PRC legal system is based in part on government policies and internal rules (some of which are not published in a timely manner or at all) that may have retroactive effect. As a result, we may not be aware of our violation of these policies and rules until sometime after the violation. Such uncertainties, including uncertainty over the scope and effect of our contractual, property (including intellectual property) and procedural rights, and any failure to respond to changes in the regulatory environment in China could materially and adversely affect our business and impede our ability to continue our operations.

 

  12  
 

 

Changes in China’s economic, political or social conditions or government policies could have a material adverse effect on our business and operations.

 

All of our assets and all of our clients are located in China. Accordingly, our business, financial condition, results of operations and prospects may be influenced to a significant degree by political, economic and social conditions in China generally and by continued economic growth in China as a whole.

 

China’s economy differs from the economies of most developed countries in many respects, including the level of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. Although the PRC government has implemented measures since the late 1970s emphasizing the utilization of market forces for economic reform, the reduction of state ownership of productive assets, and the establishment of improved corporate governance in business enterprises, a substantial portion of productive assets in China is still owned by the PRC government. In addition, the PRC government continues to play a significant role in regulating industry development by imposing industrial policies. The PRC government also exercises significant control over the PRC economic growth through allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary policy, and providing preferential treatment to particular industries or companies.

 

While China’s economy has experienced significant growth over the past decades, growth has been uneven, both geographically and among various sectors of the economy, and may slow down in the future. Some of the government measures may benefit the overall Chinese economy, but may have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government control over capital investments or changes in tax regulations. Any stimulus measures designed to boost the Chinese economy may contribute to higher inflation, which could adversely affect our results of operations and financial condition. For example, certain operating costs and expenses, such as employee compensation and office operating expenses, may increase as a result of higher inflation.

 

If relations between the United States and China worsen, investors may be unwilling to hold or buy our stock and our stock price may decrease.

 

At various times during recent years, the United States and China have had significant disagreements over political and economic issues. Controversies may arise in the future between these two countries. Any political or trade controversies between the United States and China, whether or not directly related to our business, could reduce the price of our common stock.

 

The slowing economic growth in China may assert a negative impact on our operation and financial results.

 

According to several articles published by the Wall Street Journal, CNN, and BBC News in January 2016, after experiencing rapid growth for more than a decade, China’s economy has been hit by shrinking foreign and domestic demand, weak investment, factory overcapacity and oversupply in the property market, and has experienced a painful slowdown in the last two years. In 2015, China’s economy grew by 6.9%, compared with 7.3% a year earlier, marking its slowest growth in a quarter of a century. As the government tried to shift the growth engine away from manufacturing and debt-fueled investment toward the services sector and consumer spending, the outlook of the Chinese economy is uncertain.

 

In the next two to three years, China’s growth performance could deteriorate because of the overhang of its real estate bubble, massive manufacturing overcapacity, and the lack of new growth engines. The International Monetary Fund expected China’s economy to grow by 6.5% in 2017. If China’s economy fails to grow as previously expected, it may negatively affect our business operations and financial results.

 

  13  
 

 

Under the EIT Law, we may be classified as a PRC “resident enterprise” for PRC enterprise income tax purposes. Such classification would likely result in unfavorable tax consequences to us and our non-PRC shareholders and have a material adverse effect on our results of operations and the value of your investment.

 

Under the PRC Enterprise Income Tax Law, or the EIT Law, that became effective on January 1, 2008, an enterprise established outside the PRC with “de facto management bodies” within the PRC is considered a “resident enterprise” for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. Under the implementation rules to the EIT Law, a “de facto management body” is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances and properties of an enterprise. In addition, a circular, known as SAT Circular 82, issued in April 2009 and amended in January 2014 by the State Administration of Taxation, or the SAT, specifies that certain offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups will be classified as PRC resident enterprises if the following are located or resident in the PRC: senior management personnel and departments that are responsible for daily production, operation and management; financial and personnel decision making bodies; key properties, accounting books, company seal, and minutes of board meetings and shareholders’ meetings; and half or more of the senior management or directors having voting rights. Further to SAT Circular 82, the SAT issued a bulletin, known as SAT Bulletin 45, which took effect in September 2011, to provide more guidance on the implementation of SAT Circular 82 and clarify the reporting and filing obligations of such “Chinese-controlled offshore incorporated resident enterprises.” SAT Bulletin 45 provides procedures and administrative details for the determination of resident status and administration on post-determination matters. Although both SAT Circular 82 and SAT Bulletin 45 only apply to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreign individuals, the determining criteria set forth in SAT Circular 82 and SAT Bulletin 45 may reflect the SAT’s general position on how the “de facto management body” test should be applied in determining the tax resident status of offshore enterprises, regardless of whether they are controlled by PRC enterprises, PRC enterprise groups or by PRC or foreign individuals.

 

We are subject to the 25% enterprise income tax. However, since all of our activities are in China, we do not believe AiXin Zhonghong or our company meet all of the conditions to be classified as a PRC resident enterprise., However, if we engage in activities outside of Mainland China, the PRC tax authorities may classify AiXin Zhonghong or our company as a PRC resident enterprise, which would result in a number of unfavorable PRC tax consequences. First, we or our offshore subsidiaries will be subject to the uniform 25% enterprise income tax on our world-wide income, which could materially reduce our net income. In addition, we will also be subject to PRC enterprise income tax reporting obligations.

 

Furthermore, although dividends paid by one PRC tax resident enterprise to an offshore incorporated PRC resident enterprise controlled by PRC enterprises or PRC enterprise groups should qualify as “tax-exempt income” under the EIT Law and Bulletin 45, we cannot assure you that dividends paid by our PRC subsidiary to AiXin HK will not be subject to a 10% withholding tax, as the PRC foreign exchange control authorities, which enforce the withholding tax on dividends, and the PRC tax authorities have not yet issued guidance with respect to the processing of outbound remittances to entities that are treated as resident enterprises for PRC enterprise income tax purposes but not controlled by PRC enterprises or PRC enterprise groups.

 

Finally, dividends payable by us to our investors and gains on the sale of our shares may be become subject to PRC withholding tax.

 

  14  
 

 

We may not be able to obtain certain benefits under the relevant tax treaty on dividends paid by our PRC subsidiaries to us through AiXin HK.

 

We are a holding company incorporated under the laws of Colorado and as such rely on dividends and other distributions on equity from our PRC subsidiaries to satisfy part of our liquidity requirements. Pursuant to the EIT Law, a withholding tax rate of 10% currently applies to dividends paid by a PRC “resident enterprise” to a foreign enterprise investor, unless any such foreign investor’s jurisdiction of incorporation has a tax treaty with China that provides for preferential tax treatment. Pursuant to a Notice 112 issued by the SAT in January 2008 and the Arrangement between the Mainland China and the Hong Kong Special Administrative Region on the Avoidance of Double Taxation and Prevention of Fiscal Evasion, or the Double Taxation Arrangement (Hong Kong), such withholding tax rate may be lowered to 5% if the PRC enterprise is at least 25% held by a Hong Kong enterprise at all times within the 12-month period immediately prior to distribution of the dividends and is determined by the relevant PRC tax authority to have satisfied other conditions and requirements under the Double Tax Avoidance Arrangement (Hong Kong) and other applicable PRC laws. Pursuant to a SAT Circular 601 issued by the SAT in October 2009, non-resident enterprises that cannot provide valid supporting documents as “beneficial owners” may not be approved to enjoy tax treaty benefits, and “beneficial owners” refers to individuals, enterprises or other organizations which are normally engaged in substantive operations. These rules also set forth certain adverse factors on the recognition of a “beneficial owner”. Specifically, they expressly exclude a “conduit company,” or any company established for the purposes of avoiding or reducing tax obligations or transferring or accumulating profits and not engaged in actual operations such as manufacturing, sales or management, from being a “beneficial owner.” Whether a non-resident company may obtain tax benefits under the relevant tax treaty will be subject to approval of the relevant PRC tax authority and will be determined by the PRC tax authority on a case-by-case basis. In June 2012, the SAT further provides in an announcement that a comprehensive analysis should be made when determining the beneficial owner status based on various factors supported by documents including the articles of association, financial statements, records of cash movements, board meeting minutes, board resolutions, staffing and materials, relevant expenditures, functions and risk assumption as well as relevant contracts and other information. Our Hong Kong subsidiary has not applied for the approval for a withholding tax rate of 5% from the local tax authority as our PRC subsidiaries have not paid dividends due to their loss-making status in the past and will not be able to pay dividends in the future until they have achieved accumulated profits. We plan to have our Hong Kong subsidiary assume some managerial and administrative functions, as well as conduct other business functions in the future. Once we implement such a plan, we do not believe that our Hong Kong subsidiary will be considered a conduit company as defined under SAT Circular 601. However, our Hong Kong subsidiary as currently situated may be considered a conduit company and we cannot assure you that the relevant PRC tax authority will agree with our view when our Hong Kong subsidiary applies to obtain tax benefits under the relevant tax treaty in the future. As a result, although our PRC subsidiary is currently wholly owned by our Hong Kong subsidiary, we may not be able to enjoy the preferential withholding tax rate of 5% under the Double Taxation Arrangement (Hong Kong) and therefore be subject to withholding tax at a rate of 10% with respect to dividends to be paid by our PRC subsidiary to AiXin HK.

 

Enhanced scrutiny over acquisition transactions by the PRC tax authorities may have a negative impact on potential acquisitions we may pursue in the future.

 

In connection with the EIT Law, the Ministry of Finance and the SAT jointly issued a SAT Circular 59 in April 2009, and the SAT issued a SAT Circular 698 in December 2009. Both SAT Circular 59 and Circular 698 became effective retroactively on January 1, 2008.

 

According to SAT Circular 698, where a non-resident enterprise transfers the equity interests of a PRC “resident enterprise” indirectly by disposition of the equity interests of an overseas holding company, or an Indirect Transfer, and the overseas holding company is located in a tax jurisdiction that: (1) has an effective tax rate less than 12.5% or (2) does not tax foreign income of its residents, the non-resident enterprise, being the transferor, must report to the relevant tax authority of the PRC “resident enterprise” this Indirect Transfer. Using a “substance over form” principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing, avoiding or deferring PRC tax. As a result, gains derived from such Indirect Transfer may be subject to PRC withholding tax at a rate of up to 10%. SAT Circular 698 also provides that, where a non-PRC resident enterprise transfers its equity interests in a PRC “resident enterprise” to its related parties at a price lower than the fair market value, the relevant tax authority has the power to make a reasonable adjustment to the taxable income of the transaction. In addition, the PRC “resident enterprise” is supposed to provide necessary assistance to support the enforcement of SAT Circular 698.

 

  15  
 

 

There is little guidance and practical experience as to the application of SAT Circular 698, and it is possible that the PRC tax authorities would pursue our offshore shareholders to conduct a filing regarding our offshore restructuring transactions where non-resident investors were involved and would request our PRC subsidiary to assist in providing such disclosures. In addition, if our offshore subsidiaries are deemed to lack substance they could be disregarded by the PRC tax authorities. As a result, we and our non-resident investors may become at risk of being taxed under SAT Circular 698 and may be required to expend valuable resources to comply with SAT Circular 698 or to establish that we should not be taxed under SAT Circular 698, which may have a material adverse effect on our financial condition and results of operations or the non-resident investors’ investments in us.

 

By promulgating and implementing these circulars, the PRC tax authorities have enhanced their scrutiny over the direct or indirect transfer of equity interests in a PRC resident enterprise by a non-resident enterprise. The PRC tax authorities have the discretion under SAT Circular 59 and SAT Circular 698 to make adjustments to the taxable capital gains based on the difference between the fair value of the equity interests transferred and the cost of investment. Although we currently have no confirmed plans to pursue any acquisitions in China or elsewhere in the world, we may pursue acquisitions in the future that may involve complex corporate structures. If we are considered a non-resident enterprise under the EIT Law and if the PRC tax authorities make adjustments under SAT Circular 59 or SAT Circular 698, our income tax costs associated with such potential acquisitions will be increased, which may have an adverse effect on our financial condition and results of operations.

 

PRC regulations establish complex procedures for some acquisitions of PRC companies by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.

 

Six PRC regulatory agencies promulgated regulations effective on September 8, 2006 that are commonly referred to as the M&A Rules. The M&A Rules establish procedures and requirements that could make some acquisitions of PRC companies by foreign investors more time-consuming and complex, including requirements in some instances that the Ministry of Commerce be notified in advance of any change-of-control transaction in which a foreign investor takes control of a PRC domestic enterprise. In addition, national security review rules issued by the PRC governmental authorities in 2011 require acquisitions by foreign investors of domestic companies engaged in military-related or certain other industries that are crucial to national security to be subject to prior security review. Moreover, the Anti-Monopoly Law requires that the Ministry of Commerce shall be notified in advance of any concentration of undertaking if certain thresholds are triggered. We may expand our business in part by acquiring complementary businesses. Complying with the requirements of the M&A Rules, security review rules and other PRC regulations to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval from the Ministry of Commerce, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share.

 

PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries’ ability to increase their registered capital or distribute profits to us, limit our ability to inject capital into our PRC subsidiaries, or otherwise expose us to liability and penalties under PRC law.

 

The PRC State Administration of Foreign Exchange, or the SAFE, promulgated in October 2005 a SAFE Circular 75 that requires PRC citizens or residents to register with SAFE or its local branch in connection with their establishment or control of an offshore entity established for the purpose of overseas equity financing involving a roundtrip investment whereby the offshore entity acquires or controls onshore assets or equity interests held by the PRC citizens or residents. In addition, such PRC citizens or residents must update their SAFE registrations when the offshore special purpose vehicle undergoes material events relating to increases or decreases in investment amount, transfers or exchanges of shares, mergers or divisions, long-term equity or debt investments, external guarantees, or other material events that do not involve roundtrip investments. Subsequent regulations further clarified that PRC subsidiaries of an offshore company governed by the SAFE regulations are required to coordinate and supervise the filing of SAFE registrations in a timely manner by the offshore holding company’s shareholders who are PRC citizens or residents. If these shareholders fail to comply, the PRC subsidiaries are required to report to the local SAFE branches. If our shareholders who are PRC citizens or residents do not complete their registration with the local SAFE branches, our PRC subsidiary may be prohibited from distributing its profits and proceeds from any reduction in capital, share transfer or liquidation to us, and we may be restricted in our ability to contribute additional capital to our PRC subsidiary. Moreover, failure to comply with the various SAFE registration requirements described above could result in liabilities for our PRC subsidiary under PRC laws for evasion of applicable foreign exchange restrictions, including (1) the requirement by SAFE to return the foreign exchange remitted overseas within a period specified by SAFE, with a fine of up to 30% of the total amount of foreign exchange remitted overseas and deemed to have been evasive and (2) in circumstances involving serious violations, a fine of no less than 30% of and up to the total amount of remitted foreign exchange deemed evasive. Furthermore, the persons-in-charge and other persons at our PRC subsidiary who are held directly liable for the violations may be subject to criminal sanctions.

 

  16  
 

 

These foreign exchange regulations provide that PRC residents include both PRC citizens, meaning any individual who holds a PRC passport or resident identification card, and individuals who are non-PRC citizens but primarily reside in the PRC due to their economic ties to the PRC. We have requested PRC residents holding direct or indirect interest in our company to our knowledge to make the necessary applications, filings and amendments as required under SAFE Circular 75 and other related rules. However, we cannot assure you that all of our shareholders who are PRC citizens and hold interests in us have registered with the local SAFE branch as required under SAFE Circular 75. In addition, we may not be informed of the identities of all the PRC residents holding direct or indirect interest in our company, and we cannot provide any assurances that these PRC residents will comply with our request to make or obtain any applicable registrations or comply with other requirements required by SAFE Circular 75 or other related rules. A failure by our PRC resident shareholders or future PRC resident shareholders to comply with the SAFE regulations, if SAFE requires it, could subject us to fines or other legal sanctions, restrict our cross-border investment activities, limit our PRC subsidiary’s ability to make distributions or pay dividends or affect our ownership structure, which could adversely affect our business and prospects.

 

Furthermore, it is unclear how these regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant government authorities. We cannot predict how these regulations will affect our business operations or future strategy. For example, we may be subject to a more stringent review and approval process with respect to our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect our financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, either we or the owners of such company, as the case may be, may not be able to obtain the necessary approvals or complete the necessary filings and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy and could adversely affect our business and prospects.

 

Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment.

 

Substantially all of our revenues and expenditures are denominated in RMB. As the functional currency for our PRC subsidiary and consolidated affiliated entities is RMB, fluctuations in the exchange rate may cause us to incur foreign exchange losses on any foreign currency holdings they may have. In addition, appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. If we decide to convert our RMB into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amount available to us.

 

The value of the Renminbi against the U.S. dollar and other currencies is affected by, among other things, changes in China’s political and economic conditions and China’s foreign exchange policies. On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the RMB to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. As a consequence, the Renminbi has fluctuated sharply since July 2008 against other freely traded currencies, in tandem with the U.S. dollar. It is difficult to predict how long the current situation may last and when and how it may change again. There remains significant international pressure on the PRC government to adopt a substantial liberalization of its currency policy, which could result in a further and more significant appreciation in the value of the Renminbi against the U.S. dollar. Significant revaluation of the Renminbi may have a material and adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from securities offering into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our common stock or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us. In August 2015, the PRC Government devalued its currency by approximately 3%, represented the largest yuan depreciation for 20 years. Concerns remain that China’s slowing economy, and in particular its exports, will need a stimulus that can only come from further cuts in the exchange rate.

 

  17  
 

 

In addition, appreciation or depreciation in the value of the Renminbi relative to the U.S. dollar would affect our financial results reported in U.S. dollar terms without giving effect to any underlying change in our business or results of operations. The income statements of our operations are translated into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens against foreign currencies, the translation of these foreign currencies denominated transactions results in reduced revenue, operating expenses and net income for our international operations. Similarly, to the extent the U.S. dollar weakens against foreign currencies, the translation of these foreign currency denominated transactions results in increased revenue, operating expenses and net income for our international operations. We are also exposed to foreign exchange rate fluctuations as we convert the financial statements of our foreign subsidiaries into U.S. dollars in consolidation. If there is a change in foreign currency exchange rates, the conversion of the foreign subsidiaries’ financial statements into U.S. dollars will lead to a translation gain or loss, which is recorded as a component of other comprehensive income. Very limited hedging transactions are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions. While we may enter into hedging transactions in the future, the availability and effectiveness of these transactions may be limited, and we may not be able to successfully hedge our exposure at all.

 

Fluctuation in the value of RMB may have a material adverse effect on your investment.

 

The value of RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions. Our revenues, costs, and financial assets are denominated in RMB, while our reporting currency is the U.S. dollar. Accordingly, this may result in gains or losses from currency translation on our financial statements. We rely entirely on dividends from our operating subsidiary in China. Therefore, any significant fluctuation in the value of RMB may materially and adversely affect our cash flows, revenues, earnings, financial position, and the value of, and any dividends payable on, our stock in U.S. dollars. For example, an appreciation of RMB against the U.S. dollar would, to the extent that we need to convert U.S. dollars into RMB for such purposes, make any new RMB denominated investments or expenditures more costly to us. An appreciation of RMB against the U.S. dollar would result in foreign currency translation gains for financial reporting purposes when we translate our RMB denominated financial assets into U.S. dollars, as the U.S. dollar is our reporting currency.

 

Dividends we receive from our subsidiaries located in the PRC may be subject to PRC withholding tax.

 

The EIT Law provides that a maximum income tax rate of twenty percent (20%) is applicable to dividends payable to non-PRC investors that are “non-resident enterprises,” to the extent such dividends are derived from sources within the PRC. However, the State Council has reduced such rate to ten percent (10%) through the implementation regulations. We are a Colorado holding company and all of our income is derived from our AiXin Zhonghong subsidiary located in the PRC. Therefore, dividends paid to us from China may be subject to the ten percent (10%) income tax if we are considered a “non-resident enterprise” under the EIT Law. If we are required under the EIT Law and its implementation regulations to pay income tax for any dividends we receive from our PRC subsidiaries, it may have a material and adverse effect on our net income and materially reduce the amount of dividends, if any, we may pay to our shareholders.

 

We may be exposed to liabilities under the Foreign Corrupt Practices Act and Chinese anti-corruption laws, and any determination that we violated these laws could have a material adverse effect on our business .

 

We are subject to the Foreign Corrupt Practice Act, or FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments and their officials and political parties by U.S. persons and issuers as defined by the statute, for the purpose of obtaining or retaining business. We have operations, agreements with third parties and we make the majority of our sales in China. PRC also strictly prohibits bribery of government officials. Our activities in China create the risk of unauthorized payments or offers of payments by the employees, consultants, sales agents or distributors of our Company, even though they may not always be subject to our control. It is our policy to implement safeguards to discourage these practices by our employees. However, our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants, sales agents or distributors of our Company may engage in conduct for which we might be held responsible. Violations of the FCPA or Chinese anti-corruption laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business, operating results and financial condition. In addition, the U.S. government may seek to hold our Company liable for successor liability FCPA violations committed by companies in which we invest or that we acquire.

 

  18  
 

 

Uncertainties with respect to the PRC legal system could limit the legal protections available to you and us.

 

We conduct all of our business through AiXin Zhonghong, our subsidiary in the PRC. AiXin Zhonghong is subject to laws and regulations applicable to foreign investments in China and, in particular, laws applicable to foreign-invested enterprises. The PRC legal system is based on written statutes, and prior court decisions may be cited for reference but have limited precedential value. Since 1979, a series of new PRC laws and regulations have significantly enhanced the protections afforded to various forms of foreign investments in China. However, since the PRC legal system continues to evolve rapidly, the interpretations of many laws, regulations and rules are not always uniform and enforcement of these laws, regulations and rules involves uncertainties, which may limit legal protections available to you and us. In addition, any litigation in China may be protracted and result in substantial costs and diversion of resources and management attention. In addition, all of our executive officers and all of our directors are residents of China and not of the US, and substantially all the assets of these persons are located outside the US. As a result, it could be difficult for investors to effect service of process in the US or to enforce a judgment obtained in the US against our Chinese operations, subsidiary and affiliate.

 

You may have difficulty enforcing judgments against us.

 

We are a Colorado holding company, but AiXin BVI is a British Virgin Islands corporation, AiXin HK is a Hong Kong company, and our operating subsidiary AiXin Zhonghong, is located in the PRC. Virtually all of our assets are located outside the US and all of our current operations are conducted in the PRC. In addition, all of our directors and officers are residents of China. Substantially all of the assets of these persons are located outside the US. As a result, it may be difficult for you to effect service of process within the US upon these persons. It may also be difficult for you to enforce in US courts judgments predicated on the civil liability provisions of the US federal securities laws against us and our officers and directors. In addition, there is uncertainty as to whether the courts of the PRC would recognize or enforce judgments of US courts. The recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. Courts in China may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based on treaties between China and the country where the judgment is made or on reciprocity between jurisdictions. China does not have any treaties or other arrangements that provide for the reciprocal recognition and enforcement of foreign judgments with the US. In addition, according to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates basic principles of PRC law or national sovereignty, security or the public interest. So it is uncertain whether a PRC court would enforce a judgment rendered by a court in the US.

 

Future inflation in China may inhibit our ability to conduct business in China .

 

In recent years, the Chinese economy has experienced periods of rapid expansion and highly fluctuating rates of inflation. During the past ten years, the rate of inflation in China has been as high as 20.7% and as low as -2.2%. These factors have led to the adoption by the Chinese government, from time to time, of various corrective measures designed to restrict the availability of credit or regulate growth and contain inflation. High inflation may in the future cause the Chinese government to impose controls on credit and/or prices, or to take other action, which could inhibit economic activity in China, and thereby harm the market for our products and our company.

 

Risks Relating to Our Common Stock and Our Status as a Public Company

 

Our common stock is quoted on OTC Pink which may have an unfavorable impact on our stock price and liquidity .

 

Our common stock is quoted on OTC Pink under the symbol "MCAR". The trading market for securities of companies quoted on OTC Pink or other quotation systems is substantially less liquid than the average trading market for companies listed on a national securities exchange.  The quotation of our shares on OTC Pink or other quotation system may result in a less liquid market available for existing and potential stockholders to trade shares of our common stock, could depress the market price of our common stock and could have a long-term adverse impact on our ability to raise capital in the future.  

 

  19  
 

 

Our Chief Executive Officer who is our principal stockholder has substantial influence over our company, and his interests may not be aligned with the interests of our other stockholders.

 

Quanzhong Lin, our President and Chief Executive Officer, owns approximately 80.78% of our outstanding shares. As a result, Mr. Lin has significant influence over our business, including decisions regarding mergers, consolidations, the sale of all or substantially all of our assets, election of directors and other significant corporate actions. As a result of this concentration of ownership, you and our other stockholders, acting alone, may not have the ability to determine the outcome of matters requiring stockholder approval, including the election of our directors or significant corporate transactions. In addition, this concentration of ownership, which is not subject to any voting restrictions, may discourage, delay or thwart efforts by third parties to take-over or effect a change in control of our company which could deprive our stockholders of an opportunity to receive a premium for their shares as part of a sale of our company, and may limit the price that investors are willing to pay for our common stock.

 

Our management is not familiar with the United States securities laws.

 

Our management is generally unfamiliar with the requirements of the U.S. securities laws and may not appreciate the need to devote the resources necessary to comply with such laws. A failure to adequately respond to applicable securities laws could lead to investigations by the SEC and other regulatory authorities that could be costly, divert management’s attention and disrupt our business.

 

Our accounting personnel who are primarily responsible for the preparation and supervision of the preparation of our financial statements under generally accepted accounting principles in the U.S. have had no education or training in U.S. GAAP and SEC rules and regulations pertaining to financial reporting, which could impact our ability to prepare our financial statements and convert our books and records to U.S. GAAP.

 

We maintain our books and records in accordance with generally accepted accounting principles in the PRC, or PRC GAAP. Our accounting personnel in the PRC who have the primary responsibilities of preparing and supervising the preparation of financial statements under U.S. GAAP have had no education or training in U.S. GAAP and related SEC rules and regulations. As such, they may be unable to identify potential accounting and disclosure issues that may arise upon the conversion of our books and records from PRC GAAP to U.S. GAAP, which could affect our ability to prepare our financial statements in accordance with U.S. GAAP. We have taken steps to ensure that our financial statements are in accordance with U.S. GAAP, including our hiring of a U.S. accounting firm to work with our PRC accounting personnel and management to convert our books and records to U.S. GAAP and prepare our financial statements. However, the measures we have taken may not be sufficient to mitigate the foregoing risks. Furthermore, the need to comply with U.S. GAAP may require us to expend substantial amounts of resources and time that could divert our management’s attention and disrupt our business.

 

We will incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance requirements, including establishing and maintaining internal controls over financial reporting, and we may be exposed to potential risks if we are unable to comply with these requirements.

 

As a public company we will incur significant legal, accounting and other expenses under the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), together with rules implemented by the Securities and Exchange Commission and applicable market regulators. These rules impose various requirements on public companies, including requiring certain corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these requirements. These rules will increase our legal and financial costs and will make some activities more time-consuming and costly.

 

  20  
 

 

PRC companies have historically not adopted a Western style of management and financial reporting concepts and practices, which include strong corporate governance, internal controls and, computer, financial and other control systems. Most of our middle and top management staff are not educated and trained in the Western system, and we may have difficulty hiring new employees in the PRC with such training. As a result of these factors, we may experience difficulty in establishing management, legal and financial controls, collecting financial data and preparing financial statements, books of account and corporate records and instituting business practices that meet Western standards.

 

The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Compliance with Section 404 may require that we incur substantial accounting expenses and expend significant management efforts. When we completed the acquisition of AiXin BVI, we adopted the financial reporting controls and disclosure controls and procedures of AiXin Zhonghong. The financial controls and disclosure controls and procedures of AiXin Zhonghong are not adequate for a public company. Among others weaknesses, the lack of familiarity of our accounting staff with US GAAP constitutes a material weakness in our controls for financial reporting. We have taken steps to rectify this weakness, including hiring a US accounting firm to work with our management and accounting personnel. There is no assurance, however, that the steps taken to date will be sufficient to rectify this material weakness. In the event that we fail to remedy the weaknesses in our controls over financial reporting and adopt appropriate disclosure controls and procedures, our financial reporting may be deficient and we may fail to comply with the reporting requirements of the Securities Exchange Act and other US securities laws, in which event, the market price of our common stock could decline if investors and others lose confidence in the reliability of our financial statements and we could be subject to sanctions or investigations by the SEC or other applicable regulatory authorities.

 

If we become directly subject to the recent scrutiny, criticism and negative publicity involving U.S. publicly-traded Chinese companies, we may have to expend significant resources to investigate and resolve the matter which could harm our business operations, stock price and reputation and could result in a loss of your investment in our stock, especially if such matter cannot be addressed and resolved favorably.

 

Recently, U.S. public companies that have substantially all of their operations in China, particularly companies that have completed reverse merger transactions, have been the subject of intense scrutiny, criticism and negative publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative publicity have focused on financial and accounting irregularities and mistakes, a lack of effective internal controls over financial accounting, inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud. As a result of the scrutiny, criticism and negative publicity, the publicly traded stock of many Chinese companies has sharply decreased in value and, in some cases, has become virtually worthless. Many of these companies are now subject to stockholder lawsuits, SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what affect this sector-wide scrutiny, criticism and negative publicity will have on our company, our business and our stock price. If we become the subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, we will have to expend significant resources to investigate such allegations and/or defend our company. This situation will be costly and time consuming and distract our management from growing our company. If such allegations are not proven to be groundless, our company and business operations will be severely impacted and your investment in our stock could be rendered worthless.

 

Techniques employed by manipulative short sellers in Chinese small-cap stocks may drive down the market price of our common stock.

 

Short selling is the practice of selling securities that the seller does not own but rather has borrowed from a third party with the intention of buying identical securities back at a later date to return to the lender. The short seller hopes to profit from the difference in the sale price of the borrowed securities and the purchase price of the replacement shares. As it is therefore in the short seller’s best interests for the price of the stock to decline, there have been incidents of short sellers publishing, or arranging to publish negative opinions in order to create negative market momentum. While traditionally these disclosed shorts have been limited in their ability to access mainstream business media or to otherwise create negative market rumors, the rise of the Internet and technological advancements regarding document creation, videotaping and publication by weblog (“blogging”) have allowed many disclosed shorts to publicly attack a company’s credibility, strategy and veracity by means of so-called research reports that mimic the type of investment analysis performed by large Wall Street firms and independent research analysts. These short attacks have, in the past, resulted in the selling of shares in the market, on occasion on a large scale and broad base. Issuers with business operations based in the PRC, that have limited trading volumes and that are susceptible to higher volatility levels than U.S. domestic large-cap stocks can be particularly vulnerable to such short attacks.

 

  21  
 

 

These short seller publications are not regulated by any governmental, self-regulatory organization or other official authority in the U.S., are not subject to the certification requirements imposed by the SEC in Regulation Analyst Certification and, accordingly, the opinions they express may be based on distortion of the actual facts or, in some cases, fabrication of the facts. In light of the limited risks involved in publishing such information, and the enormous profit that can be made from running just one successful short attack, unless the short sellers become subject to significant penalties, it is more likely than not that disclosed shorts will continue to issue such reports.

 

While we intend to strongly defend our public filings against any such short seller attacks, oftentimes we are constrained, either by principles of freedom of speech, applicable state law (often called Anti-SLAPP statutes), or issues of commercial confidentiality, in the manner in which we can proceed against the relevant short seller. You should be aware that in light of the relative freedom to operate that such persons enjoy – oftentimes blogging from outside the U.S. with little or no assets or identity requirements – should we be targeted for such an attack and the rumors not dismissed by market participants, our stock will likely suffer from a temporary, or possibly long term, decline in market price.

 

Because we do not intend to pay any cash dividends on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them.

 

We have not declared or paid any cash dividends on our common stock nor do we anticipate paying any in the foreseeable future. Furthermore, we expect to retain any future earnings to finance our operations and expansion. The payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.

 

Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. We cannot assure you that you will be able to sell shares when you desire to do so.

 

The market price of our common stock can become volatile, leading to the possibility of its value being depressed at a time when you may want to sell your holdings.

 

The market price of our common stock can become volatile. Numerous factors, many of which are beyond our control, may cause the market price of our common stock to fluctuate significantly. These factors include:

 

  our earnings releases, actual or anticipated changes in our earnings, fluctuations in our operating results or our failure to meet the expectations of financial market analysts and investors;
  changes in financial estimates by us or by any securities analysts who might cover our stock;
  speculation about our business in the press or the investment community;
  significant developments relating to our relationships with our customers or suppliers;
  stock market price and volume fluctuations of other publicly traded companies and, in particular, those that are in our industry;
  customer demand for our products;
  investor perceptions of our industry in general and our Company in particular;
  the operating and stock performance of comparable companies;
  general economic conditions and trends;
  announcements by us or our competitors of new products, significant acquisitions, strategic partnerships or divestitures;
  changes in accounting standards, policies, guidance, interpretation or principles;
  loss of external funding sources; and
  sales of our common stock, including sales by our directors, officers or significant stockholders; and departures of key personnel.

 

  22  
 

 

Securities class action litigation is often instituted against companies following periods of volatility in their stock price. Should this type of litigation be instituted against us, it could result in substantial costs to us and divert our management’s attention and resources.

 

Moreover, securities markets may from time to time experience significant price and volume fluctuations for reasons unrelated to the operating performance of particular companies. These market fluctuations may adversely affect the price of our common stock and other interests in our Company at a time when you want to sell your interest in us.

 

If we fail to develop and maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud, as a result, current and potential stockholders could lose confidence in our financial reports, which could harm our business and the trading price of our common stock.

 

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate and report on our internal controls over financial reporting. Compliance with Section 404 requires that we strengthen, assess and test our system of internal controls to provide the basis for our report. The process of strengthening our internal controls and complying with Section 404 is expensive and time consuming, and requires significant management attention. We cannot be certain that the measures we undertake will ensure that we will maintain adequate controls over our financial processes and reporting in the future. Furthermore, if we are able to rapidly grow our business, the internal controls that we will need will become more complex, and significantly more resources will be required to ensure our internal controls remain effective. Failure to implement required controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. If we discover a material weakness in our internal controls, the disclosure of that fact, even if the weakness is quickly remedied, could diminish investors’ confidence in our financial statements and harm our stock price. In addition, non-compliance with Section 404 could subject us to a variety of administrative sanctions, including the suspension of trading, ineligibility for listing on the OTC Markets, and the inability of registered broker-dealers to make a market in our common stock, which would further reduce our stock price.

 

There is no active trading market for our shares of common stock.

 

There is no active trading market for our common stock. There can be no assurance that a regular trading market for our securities will develop, or that if one develops, that it will be sustained. The trading price of our securities could be subject to wide fluctuations, in response to announcements by us or others, developments affecting us, and other events or factors. In addition, the stock market has experienced extreme price and volume fluctuations in recent years. These fluctuations have had a substantial effect on the market prices for many companies, often unrelated to the operating performance of such companies, and may adversely affect the market prices of the securities. Such risks could have an adverse effect on the stock’s future liquidity.

 

Our common stock is subject to the “Penny Stock” Rules of the SEC and the trading market in our securities is limited, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock.

 

The SEC has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person’s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.

 

  23  
 

 

In order to approve a person’s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience and objectives of the person; and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common shares and cause a decline in the market value of our stock.

 

Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

Under our Articles of Incorporation, our Board of Directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stock holders and with the ability to adversely affect stockholder voting power and perpetuate the board’s control over our company.

 

Our Board of Directors by resolution may authorize the issuance of preferred stock in one or more series with such limitations and restrictions as it may determine, in its sole discretion, with no further authorization by security holders required for the issuance of such shares. The Board may determine the specific terms of the preferred stock, including: designations; preferences; conversions rights; cumulative, relative; participating; and optional or other rights, including: voting rights; qualifications; limitations; or restrictions of the preferred stock.

 

The issuance of preferred stock may adversely affect the voting power and other rights of the holders of common stock. Preferred stock may be issued quickly with terms calculated to discourage, make more difficult, delay or prevent a change in control of our company or make removal of management more difficult. As a result, the Board of Directors’ ability to issue preferred stock may discourage the potential hostile acquirer, possibly resulting in beneficial negotiations. Negotiating with an unfriendly acquirer may result in terms more favorable to us and our stockholders. Conversely, the issuance of preferred stock may adversely affect the market price of, and the voting and other rights of the holders of the common stock. We presently have no plans to issue any preferred stock.

 

We may, in the future, issue additional shares of common stock, which would reduce investors’ percent of ownership and may dilute our share value.

 

Our Articles of Incorporation authorizes the issuance of 950 million shares of common stock. We have outstanding 317,988,089 shares of common stock. The future issuance of common stock may result in substantial dilution in the percentage of our common stock held by our then existing stockholders. We may value any common stock issued in the future on an arbitrary basis. The issuance of common stock for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our investors, and might have an adverse effect on any trading market for our common stock.

 

  24  
 

   

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Overview

 

On December 12, 2017, we entered into and closed a share exchange agreement, or the Share Exchange Agreement, with AiXin (BVI) International Group Co., Ltd. a British Virgin Islands corporation (“ AiXin BVI”) , and Quanzhong Lin, the owner of all of the outstanding shares of AiXin BVI, pursuant to which we acquired 100% of the outstanding capital stock of AiXin BVI in exchange for 227,352,604 shares of our common stock (the “Share Exchange” or the “AiXin Acquisition”).  The foregoing description of the terms of the Share Exchange Agreement is qualified in its entirety by reference to the provisions of the Share Exchange Agreement filed as Exhibit 2.1 to this report, which are incorporated herein by reference. After giving effect to the Share Exchange, we had outstanding 317,988,089 shares of common stock.

 

As a result of the Share Exchange, AiXin BVI became our wholly-owned subsidiary, and we now own all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of the outstanding shares of Chengdu AiXin Zhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXin Zhonghong”), which markets and sells premium-quality nutritional products.in China.

 

AiXin BVI was incorporated on September 21, 2017 to serve as a holding company and AiXin HK was established in Hong Kong on February 25, 2016 to serve as an intermediate holding company.  AiXin Zhonghong was established in the PRC on March 4, 2013, and on May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXin Zhonghong by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

 

Prior to the AiXin Acquisition, Quanzhong Lin, our President and Chief Executive Officer, owned all of the outstanding shares of AiXin BVI and 29,521,410 shares of our common stock, representing approximately 65% of the outstanding shares of Mercari Communications Group, Ltd. As a result of the Share Exchange, Mr. Lin now owns 256,874,014 shares of our common stock, approximately 80.78% of our outstanding shares, after giving effect to certain issuances described under the caption “Market for Registrant’s Common Equity and Related Stockholder Matters.”

 

 For accounting purposes, the acquisition has been accounted for as a reverse acquisition and has been treated as a recapitalization of Mercari Communications Group, Ltd. effected by a share exchange, with AiXin BVI as the accounting acquirer.  Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical financial statements of AiXin Zhonghong are now the historical financial statements of the registrant, Mercari Communications Group, Ltd, and have been included in Item 9.01(a) of this report. The assets and liabilities of AiXin Zhonghong have been brought forward at their book value and no goodwill has been recognized.

 

We, through our indirectly owned AiXin Zhonghong subsidiary, mainly market and sell innovative consumer products in China by offering a comprehensive line of premium-quality nutritional products. We sell the products through our sales offices, exhibition events we organize and sponsor, as well as person-to-person marketing. our revenue was primarily generated from sales of 20 products, which include Oleesa Milk Powder, CO Q10, D-Ribose Powder, and other nutritional supplements. Our business mainly focuses on proactive approach to our customers such as hosting events for clients, which we believe it’s ideally suited to marketing our products because sales of nutrition products are strengthened by ongoing personal contact and support, coaching and education among the Company, our clients, and their clients towards a healthy and active lifestyle.

 

  25  
 

 

The chart below presents our corporate structure:

 

Mercari Communications Group, Ltd. (a Colorado corporation)
           
  100%
           
AiXin (BVI) International Group Co., Ltd (BVI)
           
  100%
           

HK AiXin International Group Co., Limited (HK)

(“AiXin HK”)

           
  100%
           

Chengdu Aixin Zhonghong Biological Technology Co., Ltd (PRC)

(“AiXin Zhonghong”)

 

Results of Operations

 

Comparison of the Nine Months Ended September 30, 2017 and 2016

 

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales, certain columns may not add due to rounding:

 

    2017     2016  
    $     % of Net Sales     $     % of Net Sales  
Net sales   $ 650,348             $ 2,279,383          
Cost of sales     246,765       38 %     1,001,488       44 %
Gross profit     403,583       62 %     1,277,895       56 %
Operating expenses     1,322,161       203 %     1,511,480       66 %
Loss from operations     (918,578 )     (141 )%     (233,585 )     (10 )%
Non-operating expenses, net     (6,337 )     (1 )%     (8,998 )     (0.4 )%
Income tax expense     -       - %     -       - %
Net loss   $ (924,915 )     (142 )%   $ (242,583 )     (11 )%

 

Net Sales

 

Net sales for the nine months ended September 30, 2017, was $0.65 million, while net sales for the nine months ended September 30, 2016, was $ 2.28 million, a decrease of $1.63 million or 72%. The 72% decrease in net sales was primarily due to reduction in promotional and marketing activities in response to the government’s policy of strengthening the supervision of health products industry for avoiding false advertisement and unlawful marketing approach.

 

Cost of Sales

 

Cost of sales (“COS”) was $0.25 million in the nine months ended September 30, 2017, compared to $1.0 million in the nine months ended September 30, 2016, a decrease of $0.75 million or 75%. The decrease in our COS is attributable to the decrease in net sales. The COS as a percentage to net sales was 38% in 2017 compared to 44% in 2016, resulting from decrease in purchasing price of our products from vendors due to their reduction in price after the effect of the government’s policy on strengthening the supervision of health products industry.

 

  26  
 

 

Gross Profit

 

Gross profit was $0.40 million in the nine months ended September 30, 2017, compared to $1.28 million in the nine months ended September 30, 2016, a decrease of $0.87 million or 68%. The decrease in our gross profit was mainly due to the decrease in net sales. Gross margin was 62% for 2017and 56% for 2016.

 

Operating Expenses

 

Operating expenses were $1.32 million for the nine months ended September 30, 2017, compared to $1.51 million for the nine months ended September 30, 2016, a decrease of $0.19 million or 13%. The decrease in operating expenses was mainly due to the $0.20 million decrease in selling expenses resulting from decreased sales.

 

Non-Operating Expense, net

 

Net non-operating expense was $6,337 for the nine months ended September 30, 2017, compared to $8,998 for the nine months ended September 30, 2016, a decrease of $2,661 of 30%. The decrease was due to decreased loss from fixed assets physical counting in the nine months ended September 30, 2017.

 

Net Loss

 

Our net loss for the nine months ended September 30,2017, was $0.92 million compared to net loss of $0.24 million for the nine months ended September 30, 2016, an increase of $0.68 million or 281%. Net loss as a percentage of sales was 142% in the nine months ended September 30, 2017, compared to 11% in the nine months ended September 30, 2016. The increase in net loss as a percentage of net sales was mainly due to significantly decreased sales.

 

Comparison of the Years Ended December 31, 2016 and 2015

 

The following table sets forth the results of our operations for the periods indicated as a percentage of net sales, certain columns may not add due to rounding:

 

    2016     2015  
    $     % of Net Sales     $     % of Net Sales  
Net Sales   $ 3,082,725             $ 1,611,409          
Cost of sales     1,352,742       44 %     718,848       45 %
Gross profit     1,729,983       56 %     892,561       55 %
Operating expenses     3,799,897       123 %     1,067,326       66 %
Loss from operations     (2,069,914 )     (67 )%     (174,765 )     (11 )%
Non-operating expenses, net     (10,298 )     (0.3 )%     (17,755 )     (1 )%
Income tax expense     -       - %     -       - %
Net loss   $ (2,080,212 )     (68 )%   $ (192,520 )     (12 )%

 

Net Sales

 

Net sales for the year ended December 31, 2016, was $3.08 million, while net sales for the year ended December 31, 2015, was $1.61 million, an increase of $1.47 million or 91%. The 91% increase in total sales was primarily due to our aggressive sales inventive and promotional policy such as offering free travel, and attractive commission policy, as well as our competitive product price. We added three new products in the year ended December 31, 2016, which brought us additional sales of $0.46 million.

 

  27  
 

 

Cost of Sales

 

Cost of sales (“COS”) was $1.35 million in the year ended December 31, 2016, compared to $0.72 million in the year ended December 31, 2015, an increase of $0.63 million or 88%. The increase in our COS is attributable to increase of net sales. The COS as a percentage to the sales was 44% in 2016 compared to 45% in 2015, resulting from our stable purchase price for the inventory.

 

Gross Profit

 

Gross profit was $1.73 million in the year ended December 31, 2016, compared to $0.89 million in the year ended December 31, 2015. An increase of $0.84 million or 94%. The increase in our gross profit was mainly due to the increase of net sales. Gross margin was 56% for 2016 and 55% for 2015.

 

Operating Expenses

 

Operating expenses was $3.80 million for the year ended December 31, 2016, compared to $1.07 million for the year ended December 31, 2015, an increase of $2.73 million or 256%. The increase of operating expenses was mainly due to the $2.03 million capital market related expenses (including auditing and legal fees of $200,000, due diligence and accounting fees of $135,000, shell company expense of $300,000, travel expense of $90,000 and commission expense, and $0.24 million increase of sales commissions.

 

Non-Operating Expense, net

 

Net non-operating expense was $10,298 for the year ended December 31, 2016, compared to $17,755 for the year ended December 31, 2015, a decrease of $7,457 of 42%. The decrease in net non-operating expense was mainly due to an increase in other income of $33,157, which was mainly the rental income from leasing certain units of the Company’s office space.

 

Net Loss

 

Our net loss for the year ended December 31, 2016, was $2.08 million compared to net loss of $0.19 million for the year ended December 31, 2015, an increase of $1.89 million or 980%. Net loss as a percentage of sales was 68% in the year ended December 31, 2016 compared to 12% in the year ended December 31, 2015. This increase in net loss was attributable to increased G&A expenses for capital market related professional and consulting fee, and commission expense in the year ended December 31, 2016, despite we had increased sales by $1.47 million in 2016.

 

Liquidity and Capital Resources

 

As of September 30, 2017, cash and equivalents were $20,881, compared to $29,668 as of December 31, 2016 and $44,419 as of December 31, 2015. At September 30, 2017, we had a working capital deficit of $(5.84) million, as compared to $(4.83) million at December 31, 2016 and $(2.97) million at December 31, 2016. The increase in the working capital deficit of $1.01 million at September 30, 2017 as compared to December 31, 2016 was due to increased unearned revenue, accrued liability, other payables and an advance from shareholder, The increase in the working capital deficit of 1.86 million at December 31, 2016 as compared to December 31, 2015, was mainly due to increased tax payable and an advance from a shareholder.

 

The following is a summary of cash provided by or used in each of the indicated types of activities during the nine months ended September 30, 2017, December 31, 2016 and December 31, 2015, respectively.

 

    September 30, 2017   December 31, 2016   December 31, 2015
Net cash provided by (used in) operating activities   $ (15,792 )   $ (971,898 )   $ 711,040  
Net cash used in investing activities   $ (7,727 )   $ (272,468 )   $ (3,074,208 )
Net cash provided by financing activities   $ 13,631     $ 1,231,926     $ 2,409,086  

 

Net cash provided by (used in) operating activities

 

Cash has historically been used in operations. Net cash used in operating activities was $15,792 for the nine months ended September 30, 2017, as compared to $0.97 million for the year ended December 31, 2016. This improvement was mainly due to a decrease in the net loss for the period, a decrease in accounts receivable, an increase in accounts payable and a decrease in taxes payable.

 

  28  
 

 

Net cash used in investing activities

 

Net cash used in investing activities was $7,727 for nine months ended September 30, 2017, as compared to net cash used in investing activities of $0.27 million for 2016. We paid $7,727 for purchase of property and equipment in the nine months ended September 30, 2017, as compared to $272,468 in the year ended December 31, 2016.

 

Net cash used in investing activities was $0.27 million for 2016, compared to cash used in investing activities of $3.07 million for 2015. We paid $272,468 for purchase of property and equipment in the year ended December 31, 2016, compared to $3.07 million for purchase of property and equipment in the year ended December 31, 2015.

 

Net cash provided by financing activities

 

Net cash provided by financing activities was $13,631 for the nine months ended September 30, 2017, compared to $1.23 million for the year ended December 31, 2016. The net cash provided by financing activities in the nine months ended September 30, 2017 was due to an advance from a major shareholder for our working capital needs.

 

Net cash provided by financing activities was $1.23 million for the year ended December 31, 2016, compared to $2.41 million in the year ended December 31, 2015. The net cash provided by financing activities in 2016 and 2015 was due to an advance from a major shareholder for our working capital needs.

 

  29  
 

 

Impact of Inflation

 

The general annual inflation rate in China was 1.4% in 2015 and 3.0% in 2016 according to the National Bureau of Statistics. Our results of operations may be affected by inflation, particularly rising prices for products and other operating costs.

 

Contractual Obligations

 

We have no long-term fixed contractual obligations or commitments.

 

Off-Balance Sheet Arrangements

 

We have not entered into any financial guarantees or other commitments to guarantee the obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our combined financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an uncombined entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any uncombined entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

 

Contingencies

 

The Company’s former operations were conducted in the PRC and were subject to specific considerations and significant risks not typically associated with company in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments in China and foreign currency exchange. The Company’s results may be adversely affected by changes in PRC government policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad and rates and methods of taxation, among other things.

 

The Company’s sales, purchases and expense transactions in China are denominated in RMB and all of the Company’s assets and liabilities in China are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current PRC law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation in order to affect the remittance.

 

Significant Accounting Policies

 

While our significant accounting policies are more fully described in Note 2 to our financial statements, we believe the following accounting policies are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.

 

Basis of Presentation

 

The accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of Aixin is Chinese Renminbi (“RMB’’). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

 

Going Concern

 

The Company suffered net losses of $2.08 million for 2016 and $0.92 million for the nine months ended September 30, 2017 and had a shareholders’ deficit of $2.02 million as of December 31, 2016 and of $3.05 million as of September 30, 2017. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales inventive program, and increasing marketing and promotion activities. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

  30  
 

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. During the years ended December 31, 2016 and 2015, bad debt expense was $7,018 and $2,800, respectively. As of December 31, 2016 and 2015, the bad debt allowance for accounts receivable was $9,475 and $2,944, respectively. During the nine months ended September 30, 2017 and 2016, bad debt expense was $16,963 and $12,191, respectively. As of September 30, 2017 and December 31, 2016, the bad debt allowance was $27,279 and $9,475, respectively.

 

Revenue Recognition

 

The Company’s revenue recognition policies comply with FASB ASC Topic 605, “Revenue Recognition”. Sales are recognized when a formal arrangement exists; the price is fixed or determinable; title has passed to the buyer, which generally is at the time of delivery of the products or services; no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as unearned revenue.

 

Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

 

Foreign Currency Translation and Comprehensive Income (Loss)

 

The functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

 

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive income (loss) is comprised of net income (loss) and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive loss for the nine months ended September 30, 2017 and 2016 consisted of net loss and foreign currency translation adjustments.

 

  31  
 

 

New Accounting Pronouncements

 

In May 2014, the FASB issued No. 2014-09, Revenue from Contracts with Customers, which supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a one-year deferral of the effective date of the new revenue recognition standard. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods within that reporting period. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-11, Revenue from Contracts with Customers (Topic 606) and Derivatives and Hedging (Topic 815) - Rescission of SEC Guidance Because of ASU 2014-09 and 2014-16, and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) - Narrow Scope Improvements and Practical Expedients. These ASUs clarify the implementation guidance on a few narrow areas and adds some practical expedients to the guidance Topic 606. The Company is evaluating the effect that these ASUs will have on its financial statements and related disclosures.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures.

 

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. This ASU is effective for public business entities for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. The Company is currently assessing the potential impact of ASU 2016-15 on its financial statements and related disclosures.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, and interim period within those fiscal years. Early adoption is permitted, including adoption in an interim period. The standard should be applied using a retrospective transition method to each period presented. The Company does not anticipate the adoption of this ASU will have a significant impact on its financial statements.

 

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively on or after the effective date. The Company will evaluate the impact of adopting this standard prospectively upon any transactions of acquisitions or disposals of assets or businesses.

 

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The guidance should be adopted on a prospective basis for the annual or any interim goodwill impairment tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact of adopting this standard on its CFS.

 

  32  
 

 

DIRECTORS AND EXECUTIVE OFFICERS

 

Directors and Executive Officers

 

The following table sets forth the names and ages of all directors and executive officers of the registrant as of the end of the last fiscal year and on the date of this report:

 

Name   Age   Position
Quanzhong Lin   39   Director, President and Chief Executive Officer
Yao-Te Wang   40   Director
Guolu Li   51   Chief Financial Officer

 

Quanzhong Lin has served as a director, President and Chief Executive Officer of our company since February 2, 2017. Mr. Lin is a highly successful entrepreneur in China, and currently serves as Chairman of Ai Xin Company Group, a diversified company which he founded in 2008. In addition to Ai Xin Company, Mr. Lin has founded a number of companies located in Chengdu City, Sichuan Province, China, engaged in various types of business, including pharmacies, retail outlets, hotel management services and global tourism.

 

Yao-Te Wang has served as a director of our company since December 12, 2017. Mr. Wang has been the Chief Executive Officer of Ivy Service Group (China), which is a transnational consultant company in China, since 2015. From January 2016 to June 2016, Mr. Wang participated the overall operation planning for Chongqing Cultural Assets and Equity Exchange. From June 2015 to January 2016, Mr. Wang helped with the overall brand strategy development for Swire Group, who merged the biggest baking brand in Southwest China within more than 150 million RMB. From September 2014 to February 2015, Mr. Wang was the chairman special assistant for JECUI Health Science Company. From July 2012 to August 2014, Mr. Wang was the Chief Executive Officer of Ivy Service Group (Taipei). From August 2007 to June 2012, Mr. Wang was an instructor of National Defense University (Taipei), taught International Politics and Economic Analysis. From September 2006 to August 2007, Mr. Wang was the Public Affair Officer of Marine Corps Headquarter (Kaohsiung). From January 2005 to June 2006, Mr. Wang was a graduate internship and assistant of New York City Council/Denver City Mayor Office. From September 2005 to January 2006, Mr. Wang worked as graduate internship at the McCann Group in New York City. From December 1999 to May 2003, Mr. Wang was the First Lieutenant at Platoon Leader and Psychological Counselor (Marine Corps). Mr. Wang received a Master’s degree in International Affairs at Columbia University in New York in 2006.

 

Guolu Li became our Chief Financial Officer on December 12, 2017. Mr. Li is a CPA who has served as managing director and Senior Accountant at Chengdu Bixin, an accounting firm, since August 2016. From October 2013 to July 2016, Mr. Li was Deputy Financial Director of Chengdu Geeya Science and Technology Co. (Shenzhen Stock Exchange). From August 2010 to May 2013, he was Senior Auditor at Sichuan HengKun CPA Co., Ltd. From December 2007 to July 2010, he was Manager of the Audit Department at Sichuan Zhonglian, an accounting firm. From July 2005 to December 2007, he was Chief Accountant at Shenzhen Heneng Group. From April 2000 to July 2005, he was Manager of the Finance Department at Chengdu Unionfriend Network Co. (Shenzhen Stock Exchange). From January 1999 to March 2000, he was Assistant Auditor at Sichuan Junhe, an accounting firm. From July 1989 to December 1998, he was General Assistant at Sichuan Petroleum Administration Bureau (SPA). Mr. Li received a Bachelor degree in Engineer Management from China University of Petroleum (Beijing), in July 1989.

 

There are no family relationships among any of our officers and directors.

 

Directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified. Officers are elected by the Board of Directors (“BOD”) and hold office until the earliest of their death, resignation or removal from office.

 

  33  
 

 

Compensation of Directors

 

No member of our BOD received any compensation for his services as a director during the year ended May 31, 2017.

 

Corporate Governance

 

Audit, Nominating and Compensation Committees

 

Our BOD does not have standing audit, nominating or compensation committees. Instead, the functions that might be delegated to such committees are carried out by our BOD, to the extent required. Our BOD believes that the cost of establishing such committees, including the costs necessary to recruit and retain qualified independent directors to serve on our BOD and such committees and the legal costs to properly form and document the authority, policies and procedures of such committees, are not justified under our current circumstances.

 

Our BOD believes that its members have sufficient knowledge and experience to fulfill the duties and obligations of the audit committee for the Company. None of the current Board members is an “audit committee financial expert” within the meaning of the rules and regulations of the SEC. The Board has determined that each of its members is able to read and understand fundamental financial statements and has substantial business experience that results in that member’s financial sophistication.

 

Our BOD does not currently have a policy for the qualification, identification, evaluation, or consideration of board candidates and does not think that such a policy is necessary at this time, because it believes that, given the limited scope of the Company’s operations, a specific nominating policy would be premature and of little assistance until the Company’s business operations are at a more advanced level. Currently the entire Board decides on nominees.

 

The BOD does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. The Company does not have any restrictions on shareholder nominations under its articles of incorporation or bylaws. The only restrictions are those applicable generally under Colorado law and the federal proxy rules. The BOD will consider suggestions from individual shareholders, subject to an evaluation of the person’s merits. Shareholders may communicate nominee suggestions directly to the Board, accompanied by biographical details and a statement of support for the nominees. The suggested nominee must also provide a statement of consent to being considered for nomination. There are no formal criteria for nominees.

 

Independent Directors

 

Yao-Te Wang is independent director as the term “independent” is defined by Nasdaq Marketplace Rule 5605(a)(2).

 

Shareholders Communications

 

Shareholders may communicate with the BOD and individual directors by submitting their communications in writing to the Company’s Corporate Secretary at Hongxing International Business Building 2, 14 th FL, No. 69 Qingyun South Ave., Jinjiang District, Chengdu City, Sichuan Province, China. Any communications received that are directed to the BOD will be processed by the Corporate Secretary and distributed promptly to the BOD or individual directors, as appropriate. If it is unclear from the communication received whether it was intended or appropriate for the Board, the Corporate Secretary will (subject to any applicable regulatory requirements) use his or her business judgment to determine whether such communications should be conveyed to the BOD.

 

Code of Ethics

 

Due to the limited scope of our current operations, the Company has not yet adopted a code of ethics that applies to our principal executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar functions.

 

  34  
 

 

EXECUTIVE COMPENSATION

 

Mercari Communications Group, Ltd.

 

Summary Compensation Table

 

No compensation was paid to or earned by our executive officers for any purpose during the years ended May 31, 2017 and 2016

 

Outstanding Equity Awards at Fiscal Year-End

 

None of our executive officers was granted any options or equity awards during the year ended May 31, 2017 or held any options or other equity awards at May 31, 2017.

 

AiXin Zhonghong

 

The following table sets forth information concerning compensation awarded to, earned by or paid to the chief executive officer of AiXin Zonghong for services rendered in all capacities during the periods indicated. No other executive officer of AiXin Zhonghong received total annual salary and bonus compensation in excess of $100,000 for the years ended December 31, 2016 and 2015.

 

Summary Compensation Table

 

Name and Principal Position   Year     Salary ($)     Bonus ($)     Total ($)  
Quanzhong Lin, President     2016     $ 13,098     $ -     $ 13,098  
      2015     $ 13,723     $ 6,422     $ 20,145  

 

Mr. Lin does not have an employment agreement with AiXin Zhonghong.

 

  35  
 

 

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,

AND DIRECTOR INDEPENDENCE

 

Transactions with Related Persons

 

The following includes a summary of transactions since June 1, 2015, or any currently proposed transaction, in which we were or are to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any related person had or will have a direct or indirect material interest (other than compensation described under “Executive Compensation”). We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm’s-length transactions.

 

Mercari Communications Group, Ltd.

 

From December 14, 2011 to January 20, 2017, we received advances from Algodon, our then principal shareholder, for a total of $125,987 and $74,000 at May 31, 2017 and 2015 respectively, and aggregating $150,087 at January 20, 2017. These advances carried no interest and were intended to be converted to equity in the future. These advances included $12,000 for the value of the services, shared office and space and management oversight incurred by Algodon. At May 31, 2017 and 2016, the amounts due to our shareholders was $166,677 and $125,987, respectively.

 

On December 12, 2017, we issued 15,074,695 shares of our common stock to each of Ethan Chuang, a director of our company until the AiXin Acquisition, and Yao-Te Wang, who became a director upon consummation of the AiXin Acquisition, for executive services.

 

As of the date of this report, we do not have in place any policies with respect to whether we will enter into agreements with related persons in the future.

 

Other than the foregoing, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own beneficially more than 5% of the Company’s outstanding shares of its Common Stock, nor any associate or affiliate of such persons or companies, had any material interest, direct or indirect, in any transaction that occurred since June 1, 2015, or in any proposed transaction, which has materially affected or will affect the Company.

 

AiXin Zhonghong

 

Advance from a Shareholder

 

At December 31, 2016 and 2015, the Company had received an advance from a major shareholder of $2,095,064 and $819,702, respectively. The advance was payable on demand, and bore no interest.

 

Office Lease from a Major Shareholder

 

In May 2014, the Company entered a lease with its major shareholder for office use; the lease term is three years until May 2017 with option to renew. The monthly rent was RMB 5,000 ($721), the Company was required to prepay each year’s annual rent at 15th of May of each year. The Company renewed the lease in May 2017 for another three years until May 28, 2020 with month rent of RMB 5,000 ($721), payable quarterly.

 

  36  
 

 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

Change in Control

 

On February 2, 2017, Quanzhong Lin purchased 29,521,410 shares of our common stock, approximately 65% of our outstanding shares of common stock, for $300,000, from China Concentric pursuant to a Stock Purchase Agreement dated December 21, 2016. China Concentric had purchased 43,822,001 shares of our common stock, approximately 96.5%, of our outstanding shares of common stock, from Algodon Wines & Luxury Development Group, Inc. (“Algodon”) on January 20, 2017, for $260,000 pursuant to a Stock Purchase Agreement dated December 20, 2016, as amended. Algodon also assigned to China Concentric all its right, title and interest to amounts payable to Algodon for non-interest bearing advances to our company, which advances, as of January 20, 2017 were $150,087, and any additional advances made to our company up until the closing date as set forth in the Stock Purchase Agreement.

 

On February 2, 2017, in conjunction with the closing of the sale to Mr. Lin, our then BOD elected Mr. Lin as a director, Chairman of the BOD, President and Chief Executive Officer of our company, effective upon the closing, and Ethan Chuang, who had served as President of our company since January 20, 2017, as Vice President of our company. Mr. Chuang, who was elected to BOD on January 20, 2017, served as a director of our company until December 12, 2017, the date of the AiXin Acquisition.

 

Mr. Lin, as the sole stockholder of AiXin Zhonghong, received 227,352,604 shares of our common stock in the Share Exchange, and now owns 256,874,014 shares of our common stock, representing approximately 80.78% of our outstanding shares.

 

Security Ownership

 

The following table sets forth information concerning beneficial ownership of our common stock as of December 12, 2017, by (i) any person or group with more than 5% of our common stock, (ii) each director, (iii) our chief executive officer and each other executive officer whose cash compensation for the most recent fiscal year exceeded $100,000 and (iv) all such executive officers and directors as a group.

 

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting and investment power with respect to the securities. Subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them. In addition, shares of common stock issuable upon exercise of options, warrants and other convertible securities anticipated to be exercisable or convertible at or within sixty days of December 12, 2017, are deemed outstanding for the purpose of computing the percentage ownership of the person holding those securities, and the group as a whole, but are not deemed outstanding for computing the percentage ownership of any other person. As of December 12, 2017, we had outstanding 317,988,089 shares of common stock.

 

To our knowledge, the persons named in the table have sole voting and investment power with respect to all shares of securities shown as beneficially owned by them.

 

Name of Shareholder   Amount and Nature of
Beneficial Ownership
    Percent of
Common Stock
 
Directors and Executive Officers:                
                 
Quanzhong Lin, Chairman and CEO
9 An Rong Lu Jingniu, Bldg 4 Unit 163
Chengdu, Sichuan Province, China
    256,874,014       80.78 %
                 
Yao-Te Wang, Director
704 No.9, Lane 14, Shijian St.
Tainan City, Taiwan, R.O.C.
    15,074,695       4.74 %
                 
All directors and executive officers as a group     271,948,709       85.52 %

 

  37  
 

 

MARKET FOR REGISTRANT’S COMMON EQUITY,

RELATED STOCKHOLDER MATTERS

 

Market Information

 

Our common stock is quoted on OTC Pink under the symbol “MCAR.”

 

There exists only a very limited trading market for our common stock on the Pink tier of the OTC Markets (www.otcmarkets.com) with limited or no volume. The quotations are inter-dealer prices without retail markups, markdowns or commissions, and may not necessarily represent actual transactions.

 

Year ended May 31, 2016   Low     High  
First Quarter   $ 0.10     $ 0.10  
Second Quarter     0.06       0.15  
Third Quarter     0.07       0.15  
Fourth Quarter     0.07       0.25  

 

Year ended May 31, 2017   Low     High  
First Quarter   $ 0.36     $ 0.40  
Second Quarter     0.20       1.00  
Third Quarter     0.15       0.40  
Fourth Quarter     0.21       0.30  

 

Year ended May 31, 2018   Low     High  
First Quarter   $ 0.17     $ 0.30  
Second Quarter     0.17       0.23  

Third Quarter (through December 12, 2017)

    0.08       0.21  

 

Holders

 

As of December 13, 2017, we had approximately 26 record holders of our common stock.

 

Dividends

 

Since inception we have not paid any dividends on our common stock. We currently do not anticipate paying any cash dividends in the foreseeable future on our common stock. Although we intend to retain our earnings, if any, to finance the exploration and growth of our business, our BOD will have the discretion to declare and pay dividends in the future.

 

Payment of dividends in the future will depend upon our earnings, growth, capital requirements, and other factors, which our BOD may deem relevant.

 

  38  
 

 

Issuer Purchases of Equity Securities

 

None.

 

Securities Authorized for Issuance under Equity Compensation Plans

 

The following table sets forth information about the common stock available for issuance under compensatory plans and arrangements as of May 31, 2017.

 

              (c)  
              Number of securities  
    (a)         remaining available  
    Number of   (b)     for future issuance  
    securities to be   Weighted-average     under equity  
    issued upon   exercise price of     Compensation  
    exercise of   outstanding options     plans (excluding  
    outstanding   under equity     securities reflected in  
Plan Category   options   compensation plans     column (a))  
             
Equity compensation
plan approved by
security holders
  None         None  
                   
Equity compensation
plans not approved by
security holders
  None         None  
                   
Total   None         None  

 

Penny Stock Regulations

 

The SEC has regulations which generally define so-called “penny stocks” to be an equity security that has a market price less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exemptions. Our common stock is a “penny stock” and is subject to Rule 15g-9 under the Exchange Act, or the Penny Stock Rule. This rule imposes additional sales practice requirements on broker-dealers that sell such securities to persons other than established customers and “accredited investors” (generally, individuals with a net worth in excess of $1,000,000 or annual incomes exceeding $200,000, or $300,000 together with their spouses). For transactions covered by Rule 15g-9, a broker-dealer must make a special suitability determination for the purchaser and have received the purchaser’s written consent to the transaction prior to sale. As a result, this rule may affect the ability of broker-dealers to sell our securities and may affect the ability of purchasers to sell any of our securities in the secondary market, thus possibly making it more difficult for us to raise additional capital.

 

For any transaction involving a penny stock, unless exempt, the rules require delivery, prior to any transaction in penny stock, of a disclosure schedule required by the SEC relating to the penny stock market. Disclosure is also required to be made about sales commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements are required to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.

 

  39  
 

 

There can be no assurance that our common stock will qualify for exemption from the Penny Stock Rule. In any event, even if our common stock were exempt from the Penny Stock Rule, we would remain subject to Section 15(b)(6) of the Exchange Act, which gives the SEC the authority to restrict any person from participating in a distribution of penny stock, if the SEC finds that such a restriction would be in the public interest.

 

Recent Sales of Unregistered Equity Securities

 

On December 12, 2017, we issued 15,074,695 shares of our common stock to Ethan Chuang, a director of our company until the AiXin Acquisition, for executive services, and we issued 15,074,695 shares of our common stock to each of Yao-Te Wang, who became a director upon consummation of the AiXin Acquisition, and Wanli Liu for consulting services.

 

On December 12, 2017, we issued 227,352,604 shares of common stock to Quanzhong Lin, the sole stockholder of AiXin BVI, in exchange for his shares of AiXin BVI, pursuant to the Share Exchange Agreement.

 

The issuance of the shares to Mr. Wang, Ms. Liu and Mr. Lin, each of whom is not a “U.S. person”, as defined in Rule 902 of Regulation S under the Securities Act, was exempt from the registration requirements of the Securities Act under Regulation S. The issuance of the shares to Mr. Chuang, an “accredited investor,” was exempt from the registration requirements of the Securities Act under Rule 506 of Regulation D. The certificates evidencing the shares are endorsed with a restrictive Securities Act legend.

 

DESCRIPTION OF CAPITAL STOCK

 

We are authorized to issue 20,000,000 shares of blank check preferred stock and 950,000,000 shares of common stock, $.0001 par value per share. As of December 12, 2017, after giving effect to the AiXin Acquisition and the issuances of 15,074,695 shares of common stock to each of Messrs. Chuang and Wang and Ms. Liu described above under the caption “Recent Sales of Unregistered Equity Securities,” we had outstanding 317,988,089 shares of common stock.

 

Holders of our common stock are entitled to receive dividends when and as declared by our Board out of funds legally available therefore. Upon dissolution of our company, the holders of common stock are entitled to share, pro rata, in our net assets after payment of or provision for all of our debts and liabilities. Each share of common stock is entitled to participate on a pro rata basis with each other share of such stock in dividends and other distributions declared on shares of common stock.

 

The holders of common stock are entitled to one vote per share on all matters submitted to a vote of the stockholders and may not cumulate their votes for the election of directors. The holders of common stock do not have preemptive rights to subscribe for additional shares of any class that we may issue, and no share of common stock is entitled in any manner to any preference over any other share of such stock.

 

SHARES ELIGIBLE FOR SALE

 

As of December 12, 2017, after giving effect to the AiXin Acquisition and the issuances of 15,074,695 shares of common stock to each of Messrs. Chuang and Wang and Ms. Liu described above under the caption “Recent Sales of Unregistered Equity Securities,”, we had outstanding 317,988,089 shares of common stock, of which all but 1,588,999 shares are restricted securities under Rule 144 or owned by affiliates of our company.

 

Rule 144

 

Rule 144 permits a person who has beneficially owned restricted shares for at least six months to sell their shares provided that: (i) such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale.

 

  40  
 

 

Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or at any time during the three months preceding, a sale, are subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of shares that does not exceed the greater of either of the following:

 

  1.0% of the number of shares of common stock then outstanding, which is now 3,179,881 shares; and
  if the common stock is listed on a national securities exchange, the average weekly trading volume of the shares of common stock during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

 

Sales by affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.

 

Sales Under Rule 144 By Non-Affiliates

 

Under Rule 144, a person who is not deemed to have been one of our affiliates at the time of or at any time during the three months preceding a sale, and who has beneficially owned the restricted shares of common stock proposed to be sold for at least six months, including the holding period of any prior owner other than an affiliate, is entitled to sell their shares without complying with the manner of sale and volume limitation or notice provisions of Rule 144. We must be current in our public reporting if the non-affiliate is seeking to sell under Rule 144 after holding his shares of common stock between six months and one year. After one year, non-affiliates do not have to comply with any other Rule 144 requirements.

 

Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies

 

Rule 144 is not available for the resale of securities initially issued by companies that are, or previously were, blank check companies like us, to their promoters or affiliates despite technical compliance with the requirements of Rule 144. Rule 144 also is not for resale of securities issued by any shell companies (other than business combination related shell companies) or any issuer that has been at any time previously a shell company. The SEC has provided an exception to this prohibition, however, if the following conditions are met:

 

  the issuer of the securities that was formerly a shell company has ceased to be a shell company;
  the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;
  the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports; and
  a t least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

 

As a result, Quanzhong Lin, the former owner of AiXin BVI, will not be able to sell any of the 256,874,014 shares of common stock which he owns, including the 227,352,604 shares he acquired in the Share Exchange, pursuant to Rule 144 until December 14, 2018.

 

  41  
 

 

INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

Article IX of the Articles of Incorporation provides:

 

“A director of this corporation shall not be personally liable to the corporation or its shareholders for monetary damages for breach of fiduciary duty as a director except that this provision shall not limit the liability of a director to the corporation or to its shareholders for monetary damages for: (i) any breach of the director’s duty of loyalty to the corporation or to its shareholders; (ii) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; (iii) acts specified in Section 7-108-403 of the Colorado Business Corporation Act, as it may be amended from time to time; or (iv) any transaction from which the director derived an improper personal benefit. If the Colorado Business Corporation Act is amended to authorize corporate actions further limiting to eliminating the personal liability of directors, then the liability of a director of the corporation shall be limited or eliminated to the fullest extent permitted by the Colorado Business Corporation Act, as so amended.

 

Any repeal or modification of this Article IX by the shareholders of the corporation shall not adversely affect any right or protection of a director of the corporation existing at the time of such repeal or modification.”

 

Section 40 of our By-laws provides as follows :

 

Indemnification. “The corporation may provide indemnification of officers, directors and employees as permitted under Section Colorado Revised Statutes, 1973, as such statute may be in effect from time to time”.

 

Insofar as indemnification by us for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling the company pursuant to provisions of our certificate of incorporation and bylaws, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification by such director, officer or controlling person of us in the successful defense of any action, suit or proceeding is asserted by such director, officer or controlling person in connection with the securities being offered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

At the present time, there is no pending litigation or proceeding involving a director, officer, employee or other agent of ours in which indemnification would be required or permitted. We are not aware of any threatened litigation or proceeding, which may result in a claim for such indemnification.

 

PROPERTIES

 

AiXin Zhonghong owns the following properties:

 

#69 Qingyun South Street, Building 7, 24 th Floor, Unit # 2401 – 2413

Jinjiang District, Chengdu City

 

#69 Qingyun South Street, Building 2, 14 th Floor, Unit # 1401 – 1415

Jinjiang District, Chengdu City

 

  42  
 

 

AiXin Zhonghong leases the following properties:

 

Sales Offices :

 

Location   Size (sq meters)   Annual Rental(RMB¥)   Expiration Date  
               
#68 Linyuan Road East, Building 7                      
Peicheng District, Mianyang, Chengdu     83.36 m2   ¥ 20,000     12/19/2017  
                       
#99 Liucheng Avenue East,                      
Wenjiang District, Chengdu     126.6 m2   ¥ 66,000     06/09/2021  
                       
#236-238 Xintai Road West                      
Xindu District, Chengdu     72 m2   ¥ 36,000     12/28/2017  
                       
#287 Yihu Road West                      
Qingbaijiang District, Chengdu     70.19 m2   ¥ 33,600     10/12/2018  
                       
#17 Park Street                      
Jiangcheng Township, Jianyang, Chengdu     98 m2   ¥ 30,000     08/01/2021  
                       
#69 East Road, unit 1-4                      
Wujin Township, Xinjin County, Chengdu     227.06 m2   ¥ 33,000     05/30/2021  
                       
#69 Qingyun South Street, Building 2                      
Jinjiang District, Chengdu     248.77 m2   ¥ 60,000     05/28/2020  
                       
#1 Jianshe Road North, Jinyang Park                      
Yanjiang District, Ziyang, Chengdu     61.09 m2   ¥ 26,000     12/31/2022  
                       
#89 Anyang Road                      
Guanghan, Chengdu     25 m2   ¥ 15,600     07/03/2018  

 

LEGAL PROCEEDINGS

 

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

 

CHANGES IN REGISTERED INDEPENDENT PUBLIC ACCOUNTANT

 

a) Dismissal of BloomSchon CPAs LLC As Principal Accountant

 

1. On July 18, 2017, we dismissed BloomSchon CPAs LLC (“BloomSchon”) as our independent registered principal accounting firm. BloomSchon had been our independent registered principal accounting firm since September 29, 2015 and issued a report on our financial statements for the year ended May 31, 2016. BloomSchon’s report on our financial statements for the fiscal year ended May 31, 2016 did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to audit scope or accounting principles. Such report of BloomSchon was prepared assuming that we had the ability to continue as a going concern. The decision to change auditors was approved by our BOD.

 

  43  
 

 

 

 

2. During the year ended May 31, 2016 and the subsequent interim periods through the date of the filing of our Current Report on Form 8-K reporting the dismissal of BloomSchon, (i) we did not have any disagreements with BloomSchon on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to BloomSchon’s satisfaction, would have caused them to make reference thereto in their reports on our financial statements for such periods, and (ii) there were no reportable events, as defined in Item 304(a)(1)(v) of Regulation S-K.

 

3. We provided BloomSchon with a copy of disclosures in the Form 8-K reporting the dismissal of BloomSchon and requested that BloomSchon furnish a letter addressed to the SEC stating whether or not it agreed with the statements made therein. A copy of BloomSchon’s letter dated July 18, 2017, is filed as Exhibit 16.1 hereto.

 

(b) Engagement of MJF & Associates, APC As Principal Accountant

 

1. On July 18, 2017, we engaged MJF & Associates, APC (“MJF”) as our registered independent public accountants for the fiscal year ended May 31, 2017. The decision to engage MJF was approved by our BOD.

 

2. During our two most recent fiscal years ended May 31, 2016 and 2017, and through the date of filing of our Current Report on Form 8-K reporting the engagement of MJF, we did not consult with MJF on (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that may be rendered on our financial statements, and MJF did not provide either a written report or oral advice to us that MJF concluded was an important factor considered by us in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter the subject of any disagreement, as defined in Item 304 (a)(1)(iv) of Regulation S-K and the related instructions, or (iii) a reportable event within the meaning set forth in Item 304(a)(1)(v) of Regulation S-K.

 

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

 

Reference is made to the disclosure set forth Item 2.01 of this Current Report under the caption “Recent Sales of Unregistered Securities”, which disclosure is incorporated by reference into this section.

 

ITEM 4.01 CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT

 

Reference is made to the disclosure set forth Item 2.01 of this Current Report under the caption “Change in Registered Independent Certified Public Accountant,” which disclosure is incorporated by reference into this section.

 

ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT

 

Reference is made to the disclosure set forth under Item 2.01 of this report under the caption “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters — Change in Control,” which disclosure is incorporated herein by reference.

 

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS

 

On December 12, 2017, immediately prior to the closing of the AiXin Acquisition, Ethan Chuang resigned as a director of our company and our BOD appointed Yao-Te Wang as a director to fill the vacancy created by Mr. Chuang’s resignation and elected Guolu Li as Chief Financial Officer, effective upon the closing.

 

  44  
 

 

Yao-Te Wang, age 40, has been the Chief Executive Officer of Ivy Service Group (China), which is a transnational consultant company in China, since 2015. From January 2016 to June 2016, Mr. Wang participated the overall operation planning for Chongqing Cultural Assets and Equity Exchange. From June 2015 to January 2016, Mr. Wang helped with the overall brand strategy development for Swire Group, who merged the biggest baking brand in Southwest China within more than 150 million RMB. From September 2014 to February 2015, Mr. Wang was the chairman special assistant for JECUI Health Science Company. From July 2012 to August 2014, Mr. Wang was the Chief Executive Officer of Ivy Service Group (Taipei). From August 2007 to June 2012, Mr. Wang was an instructor of National Defense University (Taipei), taught International Politics and Economic Analysis. From September 2006 to August 2007, Mr. Wang was the Public Affair Officer of Marine Corps Headquarter (Kaohsiung). From January 2005 to June 2006, Mr. Wang was a graduate internship and assistant of New York City Council/Denver City Mayor Office. From September 2005 to January 2006, Mr. Wang worked as graduate internship at the McCann Group in New York City. From December 1999 to May 2003, Mr. Wang was the First Lieutenant at Platoon Leader and Psychological Counselor (Marine Corps). Mr. Wang received a Master degree in International Affairs at Columbia University in New York in 2006.

 

Guolu Li , age 51 , is a CPA who has served as managing director and Senior Accountant at Chengdu Bixin, an accounting firm, since August 2016. From October 2013 to July 2016, Mr. Li was Deputy Financial Director of Chengdu Geeya Science and Technology Co. (Shenzhen Stock Exchange, Ticker Symbol: 300028). From August 2010 to May 2013, he was Senior Auditor at Sichuan HengKun CPA Co., Ltd. From December 2007 to July 2010, he was Manager of the Audit Department at Sichuan Zhonglian, an accounting firm. From July 2005 to December 2007, he was Chief Accountant at Shenzhen Heneng Group. From April 2000 to July 2005, he was Manager of the Finance Department at Chengdu Unionfriend Network Co. (Shenzhen Stock Exchange). From January 1999 to March 2000, he was Assistant Auditor at Sichuan Junhe, an accounting firm. From July 1989 to December 1998, he was General Assistant at Sichuan Petroleum Administration Bureau (SPA). Mr. Li received a Bachelor degree in Engineer Management from China University of Petroleum (Beijing), in July 1989.

 

  45  
 

 

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

 

As a result of the AiXin Acquisition, our fiscal year end has changed from May 31 to December 31, the fiscal year end of AiXin Zhonghong.

 

ITEM 5.06 CHANGE IN SHELL COMPANY STATUS

 

Prior to the closing of the AiXin Acquisition, Mercari was a “shell company” as defined in Rule 12b-2 of the Exchange Act. As described in Item 2.01 above, which is incorporated by reference into this Item 5.06, Mercari Communications Group, Ltd. ceased being a shell company upon completion of the AiXin Acquisition on December 12, 2017.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(a) Financial Statements of Business Acquired

 

Financial Statements for the years ended and as at December 31, 2016 and 2015

 

  46  
 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of

Chengdu Aixin Zhonghong Biological Technology Co., Ltd.

 

We have audited the accompanying balance sheets of Chengdu Aixin Zhonghong Biological Technology Co., Ltd. (“the Company”) as of December 31, 2016 and 2015, and the related statements of operations, stockholders’ equity and other comprehensive loss, and cash flows for the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

 

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, audits of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2016 and 2015, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.

 

The accompanying financial statements were prepared assuming the Company will continue as a going concern. The Company incurred net losses of $2.08 million and $0.19 million for 2016 and 2015 respectively. The Company also had a stockholders’ deficit of $2.02 million as of December 31, 2016. These factors, among others, as discussed in Note 2 to the financial statements, raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

/s/ MJF & Associates, APC

 
MJF & Associates  
Los Angeles, California  
December 14, 2017  

 

515 S. Flower Street, Suite 3600, Los Angeles, CA 90071 Telephone: (213) 626-2701 Fax: (866) 510-6726

Los Angeles • San Diego • San Francisco • Dallas • New York

 
  47  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

BALANCE SHEETS

 

    As of December 31,  
    2016     2015  
ASSETS            
             
CURRENT ASSETS                
Cash & equivalents   $ 29,668     $ 44,419  
Accounts receivable, net     175,259       55,934  
Other receivables and prepaid expenses     3,782       962  
Advances to suppliers     105,455       273,173  
Deferred commission     335,110       223,861  
Deferred travel cost     176,187       159,532  
Inventory     46,570       201,159  
                 
Total current assets     872,031       959,039  
                 
NONCURRENT ASSETS                
Property and equipment, net     2,816,934       2,946,523  
                 
Total non-current assets     2,816,934       2,946,523  
                 
TOTAL ASSETS   $ 3,688,965     $ 3,905,562  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                
                 
CURRENT LIABILITIES                
Accounts payable   $ 35,191     $ 12,239  
Unearned revenue     2,066,550       2,256,539  
Taxes payable     1,193,050       603,531  
Accrued liability and other payables     314,475       238,683  
Advance from shareholder     2,095,064       819,702  
                 
TOTAL LIABILITIES     5,704,330       3,930,694  
               
STOCKHOLDERS’ EQUITY (DEFICIT)                
Paid in capital     16,402       16,402  
Statutory reserve     11,721       11,721  
Retained earnings (accumulated deficit)     (2,131,504 )     (51,292 )
Accumulated other comprehensive income (loss)     88,016       (1,963 )
                 
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)     (2,015,365 )     (25,132 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)   $ 3,688,965     $ 3,905,562  

 

The accompanying notes are an integral part of these financial statements

 

  48  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

    For the Years Ended December 31,  
    2016     2015  
             
Net sales   $ 3,082,725     $ 1,611,409  
Cost of sales     1,352,742       718,848  
                 
Gross profit     1,729,983       892,561  
                 
Operating expenses                
Selling expenses     1,152,555       850,264  
General and administrative expenses     2,640,324       214,262  
Provision for bad debt expense     7,018       2,800  
                 
Total operating expenses     3,799,897       1,067,326  
                 
Loss from operations     (2,069,914 )     (174,765 )
                 
Non-operating income (expenses)                
Financial expense     (669 )     (803 )
Other income     51,445       18,288  
Other expense     (61,074 )     (35,240 )
                 
Total non-operating expenses, net     (10,298 )     (17,755 )
                 
Loss before income tax     (2,080,212 )     (192,520 )
                 
Income tax expense     -       -  
                 
Net loss     (2,080,212 )     (192,520 )
                 
Other comprehensive items                
Foreign currency translation gain (loss)     89,979       (1,904 )
               
Comprehensive loss   $ (1,990,233 )   $ (194,424 )

 

The accompanying notes are an integral part of these financial statements

 

  49  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)

YEARS ENDED DECEMBER 31, 2016 AND 2015

 

    Paid in capital     Statutory reserves     Accumulated other comprehensive income (loss)     Retained earnings (accumulated deficit)     Total  
                               
Balance at January 1, 2015   $ 16,402     $ 11,721     $ (59 )   $ 141,228     $ 169,292  
                                         
Net loss for year     -       -       -       (192,520 )     (192,520 )
                                         
Foreign currency translation loss     -       -       (1,904 )     -       (1,904 )
                                         
Balance at December 31, 2015     16,402       11,721       (1,963 )     (51,292 )     (25,132 )
                                         
Net loss for year     -       -       -       (2,080,212 )     (2,080,212 )
                                         
Foreign currency translation gain     -       -       89,979       -       89,979  
                                         
Balance at December 31, 2016   $ 16,402     $ 11,721     $ 88,016     $ (2,131,504 )   $ (2,015,365 )

 

The accompanying notes are an integral part of these financial statements

 

  50  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

STATEMENTS OF CASH FLOWS

 

    For the Years Ended December 31,  
    2016     2015  
             
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net loss   $ (2,080,212 )   $ (192,520 )
Depreciation     211,114       70,371  
Provision for bad debts     7,018       2,800  
Increase (decrease) in assets                
Accounts receivable     (135,369 )     (55,993 )
Other receivables and prepaid expenses     (3,010 )     (235 )
Advances to suppliers     156,923       (46,059 )
Deferred commission     (131,129 )     (233,393 )
Deferred travel cost     (28,044 )     (166,324 )
Inventory     148,020       (141,351 )
Increase (decrease) in liabilities:                
Accounts payable     24,789       -  
Unearned revenue     (47,785 )     867,825  
Taxes payable     655,962       394,973  
Accrued liability and other payables     249,826       210,946  
                 
Net cash provided by (used in) operating activities     (971,897 )     711,040  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Purchase of property and equipment     (272,468 )     (3,074,208 )
                 
Net cash used in investing activities     (272,468 )     (3,074,208 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Advance from shareholder     1,231,926       2,409,086  
                 
Net cash provided by financing activities     1,231,926       2,409,086  
                 
EFFECT OF EXCHANGE RATE CHANGE ON CASH & EQUIVALENTS     (2,312 )     (1,897 )
                 
NET INCREASE (DECREASE) IN CASH & EQUIVALENTS     (14,751 )     44,021  
                 
CASH & EQUIVALENTS, BEGINNING OF YEAR     44,419       398  
                 
CASH & EQUIVALENTS, END OF YEAR   $ 29,668     $ 44,419  
                 
Supplemental Cash flow data:                
Income tax paid   $ -     $ 3,322  
Interest paid   $ -     $ -  

 

The accompanying notes are an integral part of these financial statements

 

  51  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

NOTES TO FINANCIAL STATEMENTS

DECEMBER 31, 2016 AND 2015

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Chengdu Aixin Zhonghong Biological Technology Co., Ltd. (“the Company” or “Aixin”) was incorporated in 2013 in Chengdu, China. The Company mainly develops and distributes consumer products by offering a comprehensive line of premium-quality nutritional products. The Company sells the products through exhibition events, conferences, as well as person-to-person marketing.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of Aixin is Chinese Renminbi (“RMB’’). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

 

Going Concern

 

The Company incurred net losses of $2.08 million and $0.19 million for 2016 and 2015 respectively. The Company also had a stockholders’ deficit of $2.02 million as of December 31, 2016. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Cash and Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. During the years ended December 31, 2016 and 2015, bad debt expense was $7,018 and $2,800, respectively. As of December 31, 2016 and 2015, the bad debt allowance for accounts receivable was $9,475 and $2,944, respectively.

 

  52  
 

 

Inventory

 

Inventory mainly consists of health supplement products. Inventory is valued at the lower of average cost or market, cost being determined on a moving weighted average method. Management compares the cost of inventories with the net realizable value and an allowance is made for writing down their inventories to market value, if lower. The Company did not record any write-downs of inventory at December 31, 2016 and 2015.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated lives as follows:

 

Building     20 years  
Office furniture     5 years  
Electronic Equipment     3 years  
Vehicles     5 years  

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but at least annually.

 

Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of December 31, 2016 and 2015, there was no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

  53  
 

 

At December 31, 2016 and 2015, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

 

Revenue Recognition

 

The Company’s revenue recognition policies comply with FASB ASC Topic 605, “Revenue Recognition”. Sales are recognized when a formal arrangement exists; the price is fixed or determinable; title has passed to the buyer, which generally is at the time of delivery of the products or services; no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as unearned revenue.

 

Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

 

The Company’s sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As alternatives for the product return option, the customers have options of asking an exchange of the products with same value. The amount for return of products was immaterial for the years ended December 31, 2016 and 2015.

 

Cost of Sales

 

Cost of sales (“COS”) consists primarily of cost of purchasing inventory. Write-down of inventory to lower of cost or market is also recorded in COS.

 

Concentration of Credit Risk

 

The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

 

The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. The Company have not experienced any losses in such accounts and believe they are not exposed to any risks on their cash in these bank accounts.

 

Statement of Cash Flows

 

In accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

 

  54  
 

 

Fair Value (“FV”) of Financial Instruments

 

Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:

 

  Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
  Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
  Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.

 

As of December 31, 2016 and 2015, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV.

 

Foreign Currency Translation and Comprehensive Income (Loss)

 

The functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

 

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive income (loss) is comprised of net income (loss) and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive loss for 2016 and 2015 consisted of net loss and foreign currency translation adjustments.

 

Basic and Diluted Earnings per Share

 

The Company is a limited Company (“LC”) formed under the laws of the PRC. Like limited liability company in the US, limited company in the PRC do not issue shares to the owners. The owners however, are called shareholders. Ownership interest is determined in proportion to capital contributed. Accordingly, earnings per share data is not presented.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

  55  
 

 

Management determined that the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: sale of health supplement products.

 

New Accounting Pronouncements

 

In May 2014, the FASB issued No. 2014-09, Revenue from Contracts with Customers, which supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a one-year deferral of the effective date of the new revenue recognition standard. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods within that reporting period. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-11, Revenue from Contracts with Customers (Topic 606) and Derivatives and Hedging (Topic 815) - Rescission of SEC Guidance Because of ASU 2014-09 and 2014-16, and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) - Narrow Scope Improvements and Practical Expedients. These ASUs clarify the implementation guidance on a few narrow areas and adds some practical expedients to the guidance Topic 606. The Company is evaluating the effect that these ASUs will have on its financial statements and related disclosures.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures.

 

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. This ASU is effective for public business entities for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. The Company is currently assessing the potential impact of ASU 2016-15 on its financial statements and related disclosures.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, and interim period within those fiscal years. Early adoption is permitted, including adoption in an interim period. The standard should be applied using a retrospective transition method to each period presented. The Company does not anticipate the adoption of this ASU will have a significant impact on its financial statements.

 

3. DEFERRED COMMISSION

 

The Company paid commissions to its salesmen based on cash collected from the sales. The Company calculated and paid commission based on certain proportion of monthly cash receipts from sales; however, the customers sometimes delays taking delivery of the products after payment is made to the Company, which is recorded as unearned revenue. Accordingly, the Company only recognizes current commission cost as the related revenue is recognized. Commission expenses are recorded as selling expenses. As of December 31, 2016 and 2015, the Company had deferred commission of $335,110 and $223,861 respectively.

 

  56  
 

 

4. DEFERRED TRAVEL COST

 

As part of the Company’s sales incentive program, the Company occasionally provided free travel to its customers whose prepayment to purchase the Company’s products reached to certain amount. There are different travel incentive offering to its customers based on amount received from each customer. The Company recorded the to-be-provided free travel cost when cash is collected from customers as deferred travel cost with corresponding account of accrued travel cost, and recorded as net of sales once the prepayment from customers was recognized as revenue. As of December 31, 2016 and 2015, the Company had deferred travel cost of $176,187 and $159,532 respectively.

 

5. INVENTORY

 

Inventory consisted of the following at December 31, 2016 and 2015:

 

    2016     2015  
Finished goods – health supplements   $ 46,570     $ 201,159  
Less: Inventory impairment allowance     -       -  
Total   $ 46,570     $ 201,159  

 

6. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at December 31, 2016 and 2015:

 

    2016     2015  
Office furniture   $ 226,385     $ 37,238  
Building     2,641,211       2,821,560  
Vehicle     211,639       150,940  
Electronic equipment     6,776       8,287  
Total     3,086,012       3,018,026  
Less: Accumulated depreciation     (269,078 )     (71,503 )
Net   $ 2,816,934     $ 2,946,523  

 

Depreciation for the years ended December 31, 2016 and 2015 was $211,114 and $70,371, respectively.

 

7. TAXES PAYABLES

 

Taxes payable consisted of the following at December 31, 2016 and 2015:

 

    2016     2015  
Income   $ 35,295     $ 90,021  
Value-added     1,075,161       465,193  
City construction     47,137       27,271  
Education     33,680       19,479  
Other     1,777       1,567  
Taxes payable   $ 1,193,050     $ 603,531  

 

  57  
 

 

8. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following at December 31, 2016 and 2015:

 

    2016     2015  
Accrued liability – travel cost (see Note 4)   $ 114,726     $ 108,795  
Salary payable     53,714       34,300  
Other payables     146,035       95,588  
Total   $ 314,475     $ 238,683  

 

Other payable mainly consisted of payables for employees’ social insurance and disabled employment security fund of $128,927 and $67,253 at December 31, 2016 and 2015, respectively.

 

9. RELATED PARTY TRANSACTIONS

 

Advance from a Shareholder

 

At December 31, 2016 and 2015, the Company had advance from a major shareholder of $2,095,064 and $819,702, respectively. The advance was payable on demand, and bore no interest.

 

Office lease from a Major Shareholder

 

In May 2014, the Company entered a lease with its major shareholder for office use; the lease term is three years until May 2017 with option to renew. The monthly rent was RMB 5,000 ($721), the Company was required to prepay each year’s annual rent at 15th of May of each year. The rental expense for the year ended December 31, 2016 and 2015 was $9,033 each. The Company renewed lease in May 2017 for another three years until May 28, 2020 with month rents of RMB 5,000 ($721), payable quarterly.

 

10. INCOME TAXES

 

The Company is governed by the Income Tax Laws of the PRC and various local tax laws. Effective January 1, 2008, China adopted a uniform tax rate of 25% for all enterprises (including foreign-invested enterprises). The following table reconciles the PRC statutory rates to the Company’s effective tax rate for 2016 and 2015:

 

    2016     2015  
PRC statutory rates (benefit)     (25.0 )%     (25.0 )%
Valuation allowance on NOL     25.0 %     25.0 %
Tax (benefit) per financial statements     -   %     - %

 

11. STATUTORY RESERVES

 

Pursuant to the PRC corporate law effective January 1, 2006, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

 

Surplus reserve fund

 

The Company is now required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus reserve fund until such reserve balance reaches 50% of the Company’s registered capital.

 

The surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance after such issue is not less than 25% of the registered capital.

 

  58  
 

 

Common welfare fund

 

Common welfare fund is a voluntary fund that the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting rules and regulations, to this fund. The Company did not make any contribution to this fund during 2016 or 2015.

 

This fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories, cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

 

12. OPERATING RISKS

 

The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with company in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to effect the remittance.

 

13. SUBSEQUENT EVENTS    

 

On May 26, 2017, HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”) established on February 25, 2016 to serve as an intermediate holding company, entered an acquisition agreement with the Company and its shareholders to acquire 100% ownership of the Company for RMB 100,000,000 ($14.56 million). On May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXin Zhonghong by AiXin HK.

 

AiXin (BVI) International Group Co., Ltd. (“Aixin BVI”) was incorporated in British Virgin Islands on September 21, 2017 to serve as a holding company. On November 17, 2017, AiXin BVI and AiXin HK entered a share exchange agreement, wherein AiXin BVI acquired 100% ownership of AiXin HK in exchange for the issuance of 10 shares of the commons stock of Aixin BVI.

 

On December 12, 2017, AiXin BVI and its shareholders entered into and closed a share exchange agreement, with Mercari Communications Group, Ltd (“Mercari”), pursuant to which Mercari acquired 100% of the issued and outstanding capital stock of Aixin BVI in exchange for a total of 227,352,604 shares of Mercari’s common stock. In addition, the Company desired to issue 45,224,085 shares of Mercari’s common stock to three individuals for services rendered to the Company. After giving effect to the Share Exchange and new shares issued to three individuals, Mercari had outstanding 317,988,089 shares of common stock, representing all of Mercari’s authorized shares of common stock.

As a result of the Share Exchange described above, AiXin BVI became the wholly-owned subsidiary of Mercari, and AiXin BVI owns all of the outstanding shares of AiXin HK, which in turn owns all of the outstanding shares of AiXin Zhonghong. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

 

For accounting purposes, the acquisition of AiXin BVI by Mercari was accounted for as a reverse acquisition and has been treated as a recapitalization of Mercari, effected by a share exchange, with AiXin BVI as the accounting acquirer.  Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical financial statements of AiXin Zhonghong are now the historical financial statements of the registrant, Mercari. The assets and liabilities of AiXin Zhonghong have been brought forward at their book value and no goodwill has been recognized.

  59  
 

 

Financial Statements for the nine months ended September 30, 2017 and 2016, and as at September 30, 2017 and December 31, 2016

 

  60  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

BALANCE SHEETS

unaudited

 

    September 30, 2017     December 31, 2016  
             
ASSETS                
                 
CURRENT ASSETS                
Cash & equivalents   $ 20,881     $ 29,668  
Accounts receivable, net     83,802       175,259  
Other receivables and prepaid expenses     6,378       3,782  
Advances to suppliers     26,850       105,455  
Deferred commissions     399,533       335,110  
Deferred travel cost     274,100       176,187  
Inventory     76,636       46,570  
                 
Total current assets     888,180       872,031  
                 
NONCURRENT ASSETS                
Property and equipment, net     2,786,335       2,816,934  
                 
Total non-current assets     2,786,335       2,816,934  
                 
TOTAL ASSETS   $ 3,674,515     $ 3,688,965  
                 
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)                
                 
CURRENT LIABILITIES                
Accounts payable   $ 138,655     $ 35,191  
Unearned revenue     2,560,895       2,066,550  
Taxes payable     1,252,744       1,193,050  
Accrued liabilities and other payables     572,364       314,475  
Advance from shareholder     2,203,759       2,095,064  
                 
TOTAL LIABILITIES     6,728,417       5,704,330  
                 
STOCKHOLDERS’ (DEFICIT)                
Paid in capital     16,402       16,402  
Statutory reserve     11,721       11,721  
Accumulated deficit     (3,056,419 )     (2,131,504 )
Accumulated other comprehensive income (loss)     (25,606 )     88,016  
                 
TOTAL STOCKHOLDERS’ (DEFICIT)     (3,053,902 )     (2,015,365 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT)   $ 3,674,515     $ 3,688,965  

 

The accompanying notes are an integral part of these financial statements

 

  61  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

unaudited

 

    For the Nine Months Ended September 30,  
    2017     2016  
             
Net sales   $ 650,348     $ 2,279,383  
Cost of sales     246,765       1,001,488  
                 
Gross profit     403,583       1,277,895  
                 
Operating expenses                
Selling expenses     576,984       778,480  
General and administrative expenses     728,214       720,809  
Provision for bad debts     16,963       12,191  
                 
Total operating expenses     1,322,161       1,511,480  
                 
Loss from operations     (918,578 )     (233,585 )
                 
Non-operating income (expenses)                
Financial expense     (527 )     (462 )
Other income     35,661       38,966  
Other expense     (41,471 )     (47,502 )
                 
Total non-operating expenses, net     (6,337 )     (8,998 )
                 
Loss before income tax     (924,915 )     (242,583 )
                 
Income tax expense     -       -  
                 
Net loss     (924,915 )     (242,583 )
                 
Other comprehensive items                
Foreign currency translation gain (loss)
    (113,622 )     4,352  
                 
Comprehensive loss   $ (1,038,537 )   $ (238,231 )

 

The accompanying notes are an integral part of these financial statements

 

  62  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

STATEMENTS OF CASH FLOWS

unaudited

 

    For the Nine Months Ended September 30,  
    2017     2016  
             
CASH FLOWS FROM OPERATING ACTIVITIES:                
Net loss   $ (924,915 )   $ (242,583 )
Depreciation     161,949       157,624  
Provision for bad debts     16,963       12,191  
Increase (decrease) in assets                
Accounts receivable     80,058       (210,880 )
Other receivables and prepaid expenses     (2,367 )     (1,152 )
Advances to suppliers     81,394       161,775  
Deferred commissions     (48,100 )     (177,417 )
Deferred travel cost     (87,810 )     (101,676 )
Inventory     (27,297 )     71,453  
Increase (decrease) in liabilities:                
Accounts payable     99,453       78,429  
Unearned revenue     391,384       210,397  
Taxes payable     5,612       496,048  
Accrued liabilities and other payables     237,884       55,413  
                 
Net cash provided by (used in) operating activities     (15,792 )     509,622  
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Purchase of property and equipment     (7,727 )     (273,640 )
                 
Net cash used in investing activities     (7,727 )     (273,640 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Advance from (repayment to) shareholder     13,631       (261,683 )
                 
Net cash provided by (used in) financing activities     13,631       (261,683 )
                 
EFFECT OF EXCHANGE RATE CHANGE ON CASH & EQUIVALENTS     1,101       (838 )
                 
NET DECREASE IN CASH & EQUIVALENTS     (8,787 )     (26,539 )
                 
CASH & EQUIVALENTS, BEGINNING OF PERIOD     29,668       44,419  
                 
CASH & EQUIVALENTS, END OF PERIOD   $ 20,881     $ 17,881  
                 
Supplemental Cash flow data:                
Income tax paid   $ -          
Interest paid   $ -     $ -  

 

The accompanying notes are an integral part of these financial statements

 

  63  
 

 

CHENGDU AIXIN ZHONGHONG BIOLOGICAL TECHNOLOGY CO., LTD

NOTES TO FINANCIAL STATEMENTS

SEPTEMBER 30, 2017 (UNAUDITED) and DECEMBER 31, 2016

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Chengdu Aixin Zhonghong Biological Technology Co., Ltd. (“the Company” or “Aixin”) was incorporated in 2013 in Chengdu, China. The Company mainly develops and distributes consumer products by offering a comprehensive line of premium-quality nutritional products. The Company sells the products through exhibition events, conferences, as well as person-to-person marketing.

 

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements are prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of Aixin is Chinese Renminbi (“RMB’’). The accompanying financial statements are translated from RMB and presented in U.S. dollars (“USD”).

 

Going Concern

 

The Company incurred net losses of $0.92 million and $0.24 million for the nine months ended September 30, 2017 and 2016 respectively. The Company also had a stockholders’ deficit of $3.05 million as of September 30, 2017. These conditions raise a substantial doubt about the Company’s ability to continue as a going concern. The Company plans to increase its income by strengthening its sales force, providing attractive sales incentive program, and increasing marketing and promotion activities. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Use of Estimates

 

In preparing financial statements in conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period.

 

Significant estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve for obsolete and slow-moving inventories. Actual results could differ from those estimates.

 

Cash and Equivalents

 

For financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Accounts Receivable

 

The Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. During the nine months ended September 30, 2017 and 2016, bad debt expense was $16,963 and $12,191, respectively. As of September 30, 2017 and December 31, 2016, the bad debt allowance was $27,279 and $9,475, respectively.

 

  64  
 

 

Inventory

 

Inventory mainly consists of health supplement products. Inventory is valued at the lower of average cost or market, cost being determined on a moving weighted average method. Management compares the cost of inventories with the net realizable value and an allowance is made to write down their inventories to market value, if lower. The Company did not record any write-downs of inventory at September 30, 2017 and December 31,2016.

 

Property and Equipment

 

Property and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated lives as follows:

 

Building     20 years  
Office furniture     5 years  
Electronic Equipment     3 years  
Vehicles     5 years  

 

Impairment of Long-Lived Assets

 

Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, but at least annually.

 

Recoverability of long-lived assets to be held and used is measured by comparing of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value (“FV”). FV is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review, the Company believes that, as of September 30, 2017 and December 31, 2016, there was no significant impairments of its long-lived assets.

 

Income Taxes

 

Income taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

 

The Company follows ASC Topic 740, which prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.

 

Under the provisions of ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative expenses in the statement of income.

 

  65  
 

 

At September 30, 2017 and December 31, 2016, the Company did not take any uncertain positions that would necessitate recording a tax related liability.

 

Revenue Recognition

 

The Company’s revenue recognition policies comply with FASB ASC Topic 605, “Revenue Recognition”. Sales are recognized when a formal arrangement exists; the price is fixed or determinable; title has passed to the buyer, which generally is at the time of delivery of the products or services; no other significant obligations of the Company exist and collectability is reasonably assured. Payments received before all of the relevant criteria for revenue recognition are recorded as unearned revenue.

 

Sales revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold in China are subject to the PRC VAT of 17% of the gross sales price. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.

 

The Company’s sales policy allows for the return of unopened products for cash after deducting certain service and transaction fees. As alternatives for product returns, the customers can ask for an exchange of the products with same value. The amount for return of products was immaterial for the nine months ended September 30, 2017 and 2016.

 

Cost of Sales

 

Cost of sales (“COS”) consists primarily of cost of purchasing inventory. Write-down of inventory to lower of cost or market is also recorded in COS.

 

Concentration of Credit Risk

 

The operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.

 

The Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks is covered by insurance up to RMB 500,000 ($72,500) per bank. The Company have not experienced any losses in such accounts and believe they are not exposed to any risks on their cash in these bank accounts.

 

Statement of Cash Flows

 

In accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the statements of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheets.

 

  66  
 

 

Fair Value (“FV”) of Financial Instruments

 

Certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts payable, carrying amounts approximate their FV due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires disclosure of the FV of financial instruments held by the Company. The carrying amounts reported in the balance sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and the current market rate of interest.

 

Fair Value Measurements and Disclosures

 

ASC Topic 820, “Fair Value Measurements and Disclosures,” defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The three levels are defined as follow:

 

   Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
   Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
   Level 3 inputs to the valuation methodology are unobservable and significant to the FV measurement.

 

As of September 30, 2017 and December 31, 2016, the Company did not identify any assets and liabilities that are required to be presented on the balance sheet at FV.

 

Foreign Currency Translation and Comprehensive Income (Loss)

 

The functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period.

 

Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.

 

The Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive income (loss) is comprised of net income (loss) and all changes to the statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions to stockholders. Comprehensive loss for the nine months ended September 30, 2017 and 2016 consisted of net loss and foreign currency translation adjustments.

 

Basic and Diluted Earnings per Share

 

The Company is a limited Company (“LC”) formed under the laws of the PRC. Like limited liability company in the US, limited company in the PRC do not issue shares to the owners. The owners however, are called shareholders. Ownership interest is determined in proportion to capital contributed. Accordingly, earnings per share data is not presented.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

 

  67  
 

 

Management determined that the Company’s operations constitute a single reportable segment in accordance with ASC 280. The Company operates exclusively in one business and industry segment: sale of health supplement products.

 

New Accounting Pronouncements

 

In May 2014, the FASB issued No. 2014-09, Revenue from Contracts with Customers, which supersedes the revenue recognition requirements in Accounting Standards Codification 605 - Revenue Recognition and most industry-specific guidance throughout the Codification. The standard requires that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In August 2015, the FASB approved a one-year deferral of the effective date of the new revenue recognition standard. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 31, 2016, including interim reporting periods within that reporting period. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue versus Net). In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing. In May 2016, the FASB issued ASU 2016-11, Revenue from Contracts with Customers (Topic 606) and Derivatives and Hedging (Topic 815) - Rescission of SEC Guidance Because of ASU 2014-09 and 2014-16, and ASU 2016-12, Revenue from Contracts with Customers (Topic 606) - Narrow Scope Improvements and Practical Expedients. These ASUs clarify the implementation guidance on a few narrow areas and adds some practical expedients to the guidance Topic 606. The Company is evaluating the effect that these ASUs will have on its financial statements and related disclosures.

 

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its financial statements and related disclosures.

 

In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 clarifies the presentation and classification of certain cash receipts and cash payments in the statement of cash flows. This ASU is effective for public business entities for fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted. The Company is currently assessing the potential impact of ASU 2016-15 on its financial statements and related disclosures.

 

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash. The guidance requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for fiscal years beginning after December 15, 2017, and interim period within those fiscal years. Early adoption is permitted, including adoption in an interim period. The standard should be applied using a retrospective transition method to each period presented. The Company does not anticipate the adoption of this ASU will have a significant impact on its financial statements.

 

In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, which clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted. The standard should be applied prospectively on or after the effective date. The Company will evaluate the impact of adopting this standard prospectively upon any transactions of acquisitions or disposals of assets or businesses.

 

  68  
 

 

In January 2017, the FASB issued ASU 2017-04, Simplifying the Test for Goodwill Impairment. The guidance removes Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The guidance should be adopted on a prospective basis for the annual or any interim goodwill impairment tests beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact of adopting this standard on its CFS.

 

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future CFS.

 

3. DEFERRED COMMISSION

 

The Company pays commissions to its salesmen based on cash collected from the sales. The Company calculated and paid commission based on certain proportion of monthly cash receipts from sales; however, the customers sometimes delays taking delivery of the products after payment is made to the Company, which is recorded as unearned revenue. Accordingly, the Company only recognizes current commission cost as the related revenue is recognized. Commission expenses are recorded as selling expenses. As of September 30, 2017 and December 31, 2016, the Company had deferred commissions of $399,533 and $335,110 respectively.

 

4. DEFERRED TRAVEL COST

 

As part of the Company’s sales incentive program, the Company occasionally provided free travel to its customers whose prepayment to purchase the Company’s products reached to certain amount. There are different travel incentive offering to its customers based on amount received from each customer. The Company recorded the to-be-provided free travel cost when cash is collected from customers as deferred travel cost with corresponding account of accrued travel cost, and recorded as net of sales once the prepayment from customers was recognized as revenue. As of September 30, 2017 and December 31, 2016, the Company had deferred travel cost of $274,100 and $176,187, respectively.

 

5. INVENTORY

 

Inventory consisted of the following at September 30, 2017 and December 31, 2016:

 

    2017     2016  
Finished goods – health supplements   $ 76,636     $ 46,570  
Less: Inventory impairment allowance     -       -  
Total   $ 76,636     $ 46,570  

 

6. PROPERTY AND EQUIPMENT, NET

 

Property and equipment consisted of the following at September 30, 2017 and December 31, 2016:

 

    2017     2016  
Office furniture   $ 237,853     $ 226,385  
Building     2,760,639       2,641,211  
Vehicle     221,209       211,639  
Electronic equipment     13,766       6,776  
Total     3,233,467       3,086,012  
Less: Accumulated depreciation     (447,132 )     (269,078 )
Net   $ 2,786,335     $ 2,816,934  

 

  69  
 

 

Depreciation for the nine months ended September 30, 2017 and 2016 was $161,949 and $157,624, respectively.

 

7. TAXES PAYABLE

 

Taxes payable consisted of the following at September 30, 2017 and December 31, 2016:

 

    2017     2016  
Income   $ 36,890     $ 35,295  
Value-added     1,129,223       1,075,161  
City construction     49,445       47,137  
Education     35,329       33,680  
Other     1,857       1,777  
Taxes payable   $ 1,252,744     $ 1,193,050  

 

8. ACCRUED LIABILITIES AND OTHER PAYABLES

 

Accrued liabilities and other payables consisted of the following at September 30, 2017 and December 31, 2016:

 

    2017     2016  
Accrued liability – travel cost (see Note 4)   $ 86,049     $ 114,726  
Salary payable     58,031       53,714  
Other payables     428,284       146,035  
Total   $ 572,364     $ 314,475  

 

Other payable mainly consisted of payables for employees’ social insurance and disabled employment security fund of $242,385 and commission payable of $174,121 at September 30, 2017; and payables of employees’ social insurance and disables employment security fund of $128,927 at December 31, 2016, respectively.

 

9. RELATED PARTY TRANSACTIONS

 

Advance from a Shareholder

 

At September 30, 2017 and December 31, 2016, the Company had advance from a major shareholder of $2,203,759 and $2,095,064, respectively. The advance was payable on demand, and bore no interest.

 

Office lease from a Major Shareholder

 

In May 2014, the Company entered a lease with its major shareholder for office use; the lease term is three years until May 2017 with option to renew. The monthly rent was RMB 5,000 ($721), the Company was required to prepay each year’s annual rent at 15th of May of each year. The Company renewed lease in May 2017 for another three years until May 28, 2020 with month rents of RMB 5,000 ($721), payable quarterly. The future annual minimum lease payment at September 30, 2017 is: $8,652 for each of the year ending September 30, 2018, and 2019, and $3,605 for the year ending September 30, 2020. The renal expense for this lease was $6,490 for the nine months ending September 30, 2017 and 2016, respectively.

 

10. INCOME TAXES

 

The Company is governed by the Income Tax Laws of the PRC and various local tax laws. Effective January 1, 2008, China adopted a uniform tax rate of 25% for all enterprises (including foreign-invested enterprises). The following table reconciles the PRC statutory rates to the Company’s effective tax rate for nine months ended September 30, 2017 and 2016:

 

  70  
 

 

    2017     2016  
PRC statutory rates (benefit)     (25.0 )%     (25.0 )%
Valuation allowance on NOL     25.0 %     25.0 %
Tax (benefit) per financial statements     -     - %

 

11. STATUTORY RESERVES

 

Pursuant to the PRC corporate law effective January 1, 2006, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.

 

Surplus reserve fund

 

The Company is now required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus reserve fund until such reserve balance reaches 50% of the Company’s registered capital.

 

The surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any, and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance after such issue is not less than 25% of the registered capital.

 

Common welfare fund

 

Common welfare fund is a voluntary fund that the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting rules and regulations, to this fund. The Company did not make any contribution to this fund during the nine month ended September 30, 2017 or 2016.

 

This fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories, cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.

 

12. OPERATING RISKS

 

The Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with company in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.

 

The Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain supporting documentation to effect the remittance.

 

13. SUBSEQUENT EVENTS

 

On May 26, 2017, HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”) established on February 25, 2016 to serve as an intermediate holding company, entered an acquisition agreement with the Company and its shareholders to acquire 100% ownership of the Company for RMB 100,000,000 ($14.56 million). On May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXin Zhonghong by AiXin HK.  

AiXin (BVI) International Group Co., Ltd. (“Aixin BVI”) was incorporated in British Virgin Islands on September 21, 2017 to serve as a holding company. On November 17, 2017, AiXin BVI and AiXin HK entered a share exchange agreement, wherein AiXin BVI acquired 100% ownership of AiXin HK in exchange for the issuance of 10 shares of the commons stock of Aixin BVI.

 

On December 12, 2017, AiXin BVI and its shareholders entered into and closed a share exchange agreement, with Mercari Communications Group, Ltd (“Mercari”), pursuant to which Mercari acquired 100% of the issued and outstanding capital stock of Aixin BVI in exchange for a total of 227,352,604 shares of Mercari’s common stock. In addition, the Company desired to issue 45,224,085 shares of Mercari’s common stock to three individuals for services rendered to the Company. After giving effect to the Share Exchange and new shares issued to three individuals, Mercari had outstanding 317,988,089 shares of common stock, representing all of Mercari’s authorized shares of common stock.

 

As a result of the Share Exchange described above, AiXin BVI became the wholly-owned subsidiary of Mercari, and AiXin BVI owns all of the outstanding shares of AiXin HK, which in turn owns all of the outstanding shares of AiXin Zhonghong. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.

 

For accounting purposes, the acquisition of AiXin BVI by Mercari was accounted for as a reverse acquisition and has been treated as a recapitalization of Mercari, effected by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017, the historical financial statements of AiXin Zhonghong are now the historical financial statements of the registrant, Mercari. The assets and liabilities of AiXin Zhonghong have been brought forward at their book value and no goodwill has been recognized.

 

(b) Pro Forma Financial Information

 

  71  
 

 

MERCARI COMMUNICATIONS GROUP, LTD

AND AIXIN (BVI) INTERNATIONAL GROUP CO., LTD

Pro Forma Consolidated Balance Sheet

As of September 30, 2017

(unaudited)

 

      (1)       (2)       Pro forma       Pro forma  
      MERCARI        AIXIN BVI        Adjustments       Consolidated  
      (historical)       (historical)                  
ASSETS                                
CURRENT ASSETS                                
Cash & equivalents   $ --     $ 20,881             $ 20,881  
Accounts receivable, net     --       83,802               83,802  
Other receivables and prepaid expenses     --       6,378               6,378  
Advances to suppliers     --       26,850               26,850  
Deferred commissions     --       399,533               399,533  
Deferred travel cost     --       274,100               274,100  
Inventory     --       76,636               76,636  
                                 
Total current assets     --       888,180               888,180  
                                 
NONCURRENT ASSETS                                
Property and equipment, net     --       2,786,335               2,786,335  
                                 
Total noncurrent assets     --       2,786,335               2,786,335  
                                 
TOTAL ASSETS   $ --     $ 3,674,515             $ 3,674,515  
                                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                                
                                 
CURRENT LIABILITIES                                
Accounts payable   $ --     $ 138,655             $ 138,655  
Unearned revenue     --       2,560,895               2,560,895  
Accrued liabilities and other payables     57,246       572,364               629,610  
Tax payable     --       1,252,744               1,252,744  
Due to related parties     181,546       2,203,759               2,385,305  
                                 
Total current liabilities     238,792       6,728,417               6,967,209  
                                 
Total liabilities     238,792       6,728,417               6,967,209  
                                 
CONTINGENCIES AND COMMITMENTS                                
                                 
STOCKHOLDERS’ DEFICIT                                
Common stock     454       --       31,345 (A)(B)     31,799  
Paid in capital     158,722       16,402       3,188,614 (A)(B)(C)      3,363,738  
Statutory reserve     --       11,721               11,721  
Accumulated other comprehensive income     --       (25,606 )             (25,606 )
Accumulated deficit     (397,968 )     (3,056,419 )     (3,219,959 )(B)(C)     (6,674,346 )
                                 
Total stockholders’ deficit     (238,792 )     (3,053,902 )             (3,292,694 )
                                 
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT   $ --     $ 3,674,515             $ 3,674,515  

 

(1) Source: unaudited financial statements of Mercari as of September 30, 2017.
(2) Source: unaudited financial statements of Aixin Zhonghong as of September 30, 2017, as filed in this Form 8-K filed with the SEC.
(A) Reflection of the issuance of 227,352,604 shares to the shareholders of Aixin BVI;
(B) Reflection of the issuance of 45,224,085 shares to three individuals for services rendered, resulting in 317,988,089 total shares outstanding of Mercari after the reverse merger and new issuance of the shares;
(C) Elimination of Mercari’s capital accounts and accumulated deficit as result of recapitalization.

 

See accompanying notes to pro forma consolidated financial statements

 

  72  
 

 

MERCARI COMMUNICATIONS GROUP, LTD

AND AIXIN (BVI) INTERNATIONAL GROUP CO., LTD

Pro Forma Consolidated Statement of Operations

For the Nine Months Ended September 30, 2017

(unaudited)

 

      (1)     (2)     Pro forma       Pro forma  
      MERCARI       AIXIN BVI       Adjustments       Consolidated  
      (historical)       (historical)                  
                                 
Net sales   $ --     $ 650,348     $ --     $ 650,348  
                                 
Cost of sales     --       246,765       --       246,765  
                                 
Gross profit     --       403,583       --       403,583  
                                 
Operating expenses                                
Selling     --       576,984       --       576,984  
Provision for bad debts     --       16,963               16,963  
General and administrative     91,328       728,214       --       819,542  
                                 
Total operating expenses     91,328       1,322,161       --       1,413,489  
                                 
Income (loss) from operations     (91,328 )     (918,578 )     --       (1,009,906 )
                                 
Non-operating income (expenses)                                
Other income     --       35,661       --       35,661  
Other expenses     --       (41,471 )     --       (41,471 )
Financial expense     --       (527 )     --       (527 )
                                 
Total non-operating expenses, net     --       (6,337 )     --       (6,337 )
                                 
Loss before income tax     (91,328 )     (924,915 )     --       (1,016,243 )
                                 
Income tax expense     --       --       --       --  
                                 
Net loss   $ (91,328 )   $ (924,915 )   $ --     $ (1,016,243 )
                                 
Other comprehensive items                                
Foreign currency translation loss     --       (113,622 )     --       (113,622 )
                                 
Comprehensive loss   $ (91,328 )   $ (1,038,537 )   $ --     $ (1,129,865 )
                                 
Loss per share   $ (0.002 )   $ (0.004 )   $ --     $ (0.003 )
                                 
Weighted average shares outstanding     45,411,400       227,352,604       45,224,085       317,988,089  

 

(1) Source: unaudited financial statements of Mercari for the nine month ended and as of September 30, 2017.
(2) Source: unaudited financial statements of Aixin Zhonghong for the nine months ended and as of September 30, 2017, as filed in this Form 8-K filed with the SEC.

 

See accompanying notes to pro forma consolidated financial statements

 

  73  
 

 

MERCARI COMMUNICATIONS GROUP, LTD

AND AIXIN (BVI) INTERNATIONAL GROUP CO., LTD

Pro Forma Consolidated Statement of Operations

For the Year Ended December 31, 2016

(unaudited)

 

      (1)     (2)     Pro forma       Pro forma  
      MERCARI       AIXIN BVI       Adjustments       Consolidated  
      (historical)       (historical)                  
                                 
Net sales   $ --     $ 3,082,725     $ --     $ 3,082,725  
                                 
Cost of sales     --       1,352,742       --       1,352,742  
                                 
Gross profit     --       1,729,983       --       1,729,983  
                                 
Operating expenses                                
Selling     --       1,152,555       --       1,152,555  
Provision for bad debt expense             7,018       --       7,018  
General and administrative     41,579       2,640,324       3,617,927 (A)     6,299,830  
                                 
Total operating expenses     41,579       3,799,897       3,617,927       7,459,403  
                                 
Income from operations     (41,579 )     (2,069,914 )     (3,617,927 )     (5,729,420 )
                                 
Non-operating income (expenses)                                
Other income     --       51,445       --       51,445  
Other expenses     --       (61,074 )     --       (61,074 )
Financial expense     --       (669 )     --       (669 )
                                 
Total non-operating expenses, net     --       (10,298 )     --       (10,298 )
                                 
Loss before income tax     (41,579 )     (2,080,212 )     (3,617,927 )     (5,739,718 )
                                 
Income tax benefit     --       --       --       --  
                                 
Net loss   $ (41,579 )   $ (2,080,212 )   $ (3,617,927 )   $ (5,739,718 )
                                 
Other comprehensive items                                
Foreign currency translation gain (loss)
    --       89,979       --       89,979  
                                 
Comprehensive loss   $ (41,579 )   $ (1,990,233 )   $ (3,617,927 )   $ (5,649,739 )
                                 
Loss per share   $ (0.001 )   $ (0.009 )   $ (0.080 )   $ (0.018 )
                                 
Weighted average shares outstanding     45,411,400       227,352,604       45,224,085 (A)     317,988,089  

 

(1) Source: unaudited financial statements of Mercari for the year ended and as of December 31, 2016.
(2) Source: audited financial statements of Aixin Zhonghong for the year ended and as of December 31, 2016, as filed in this Form 8-K filed with the SEC.
(A) Reflection of the issuance of 45,224,085 shares to three individuals for services rendered, resulting in 317,988,089 total shares outstanding of Mercari after the reverse merger and new issuance of the shares.

 

See accompanying notes to pro forma consolidated financial statements

 

  74  
 

 

Mercari Communications Group, Ltd

And AiXin (BVI) International Group Co., Ltd

Notes to Pro Forma Consolidated Financial Statements

 

NOTE 1 - BASIS OF PRESENTATION

 

On December 12, 2017, AiXin (BVI) International Group Co., Ltd. (“Aixin BVI”) and its shareholders entered into and closed a share exchange agreement, with Mercari Communications Group, Ltd (“Mercari”), pursuant to which Mercari acquired 100% of the issued and outstanding capital stock of Aixin BVI in exchange for a total of 227,352,604 shares of Mercari’s common stock. In addition, the Company desired to issue 45,224,085 shares of Mercari’s common stock to three individuals for services rendered to the Company. After giving effect to the Share Exchange and new shares issued to three individuals, Mercari had outstanding 317,988,089 shares of common stock, representing all of Mercari’s authorized shares of common stock.

 

As a result of the Share Exchange, Aixin BVI and its subsidiaries became Mercari’s wholly-owned subsidiaries.

 

The acquisition of Aixin BVI was accounted for as a recapitalization effected by a share exchange, wherein Aixin BVI is considered the acquirer for accounting and financial reporting purposes with no adjustment to the historical basis of its assets and liabilities. Aixin BVI’s shareholders become the majority shareholders and have control of the Company and, Mercari was a non-operating public shell prior to the acquisition. As a result of the acquisition of Aixin BVI, Mercari is no longer a shell company. Pursuant to Securities and Exchange Commission (“SEC”) rules, the merger or acquisition of a private operating company into a non-operating public shell with nominal net assets is considered a capital transaction in substance, rather than a business combination.

 

The accompanying pro forma consolidated statements of operations present the accounts of Mercari and Aixin BVI, and its wholly-owned subsidiaries HK Aixin International Group Co., Litmited (“Aixin HK”), a company incorporated and registered in Hong Kong on February 25, 2016 to serve as an intermediate holding company. On May 26, 2017, Aixin HK acquired Aixin Zhonghong Biological Technology Co., Ltd (Aixin Zhonghong) for RMB 100,000,000 (US$14.56 million), Aixin Zhonghong is an operating entity incorporated in China in 2013.

 

The accompanying pro forma consolidated statements of operations are for the nine months ended September 30, 2017 and for the year ended December 31, 2016, as if the acquisition occurred on January 1, 2017 and January 1, 2016, for the purpose of the statements of operations, respectively. The accompanying pro forma consolidated balance sheet presents the accounts of Mercari and Aixin BVI and its wholly-owned subsidiaries as if the acquisition of Aixin BVI by Mercari occurred on September 30, 2017.

 

The following adjustments would be required if the acquisition occurred as indicated above:

 

  A. Reflection of the issuance of 227,352,604 shares to the shareholders of Aixin BVI.
     
  B.

Reflection of the issuance of 45,224,085 shares to three individuals for services rendered to the Company, resulting in 317,988,089 total shares outstanding of Mercari after the reverse merger and new issuance of the shares to three individuals

     
  C. Elimination of Mercari’s capital accounts and accumulated deficit as result of recapitalization.

 

  75  
 

 

(c) Exhibits. The following exhibits have been filed as part of, or incorporated by reference into, this Report:

 

Exhibit

No.

   Description
     
2.1   Share Exchange Agreement, dated as of December 12, 2017, among the Company, AiXin BVI, AiXin  HK, AiXin Zhonghong and the stockholders of Aixin Zhonghong.  
     
3.1   Articles of Incorporation (incorporated by reference to the Company’s Annual Report on Form 10-KSB for the fiscal year ended May 31, 2006 as filed with the SEC on March 7, 2007).
     
3.2   Articles of Amendment to Articles of Incorporation (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 3, 2008).
     
3.3   Bylaws of the Registrant (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on June 3, 2008).
     
10.1   Stock Purchase Agreement dated December 20, 2016, between Algodon and China Concentric, as amended (incorporated by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2017 as filed with the SEC on September 6, 2017). 
     
10.2   Stock Purchase Agreement dated December 21, 2016, between China Concentric and Quanzhong Lin. (incorporated by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2017 as filed with the SEC on September 6, 2017).
     
10.3   Executive Services And Separation Agreement with Ethan Chuang.
     
10.4   Consulting Agreement with Yao-Te Wang.
     
10.5   Consulting Agreement with Wanli Liu.
     
16.1   Letter from BloomSchoen, the Company’s former registered independent public accountants, dated July 18, 2017 (incorporated by reference to the Company’s Current Report on Form 8-K filed with the SEC on July 18, 2017.)
     
21.1    Subsidiaries

 

  76  
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MERCARI COMMUNICATIONS GROUP, LTD.
      
Date: December 14, 2017 By: /s/ Quanzhong Lin
   

Quanzhong Lin

President and Chief Executive Officer

(Principal Executive Officer)

 

  77  
 

 

SHARE EXCHANGE AGREEMENT

 

THIS SHARE EXCHANGE AGREEMENT (hereinafter referred to as this “ Agreement ”) is entered into as of this 12th day of December, 2017, by and among Mercari Communications Group, Ltd., a Colorado corporation (the “Company”), AiXin (BVI) International Group Co., Ltd., a British Virgin Islands corporation (“ AiXin BVI”) , and Quanzhong Lin, the owner of all of the outstanding shares of AiXin BVI (the “ Stockholder ”).

 

Preliminary Statement

 

The Company is a publicly traded company whose shares of common stock are quoted on OTC Pink under the symbol “MCAR.” The Company is a “shell company,” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), without active business operations or significant assets.

 

AiXin BVI was recently organized for the sole purpose of acquiring, and now owns, all of the outstanding shares of HK AiXin International Group Co., Limited, a Hong Kong company (“AiXin HK”). AiXin HK was formed as an intermediate holding company in February 2016 for the sole purpose of acquiring, and it now owns, all of the outstanding shares of Chengdu AiXin Zhonghong Biological Technology Co., Ltd., a Chinese company (“AiXin Zhonghong”), which markets and sells premium-quality nutritional products in China.

 

The Stockholder owns all of the outstanding shares of AiXin BVI (the “AiXin BVI Shares”).

 

The Company desires to acquire 100% of the issued and outstanding shares of AiXin BVI from the Stockholder in exchange for the issuance of an aggregate of 227,352,604 shares of the common stock of the Company (the “ Exchange Shares ”), and the Stockholder is willing to exchange the AiXin BVI Shares for the Exchange Shares on the terms and subject to the conditions set forth herein (the “ Exchange ”). Upon consummation of the Exchange, AiXin BVI will become a wholly-owned subsidiary of the Company.

 

The boards of directors of the Company and AiXin BVI have determined, subject to the terms and conditions set forth in this Agreement, that the transaction contemplated hereby is desirable and in the best interests of their respective stockholders. This Agreement is being entered into for the purpose of setting forth the terms and conditions of the proposed acquisition.

 

NOW THEREFORE , on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and the mutual benefits to the parties to be derived here from, and intending to be legally bound hereby, it is hereby agreed as follows:

 

ARTICLE I

REPRESENTATIONS, COVENANTS, AND WARRANTIES OF AIXIN BVI

 

As an inducement to, and to obtain the reliance of the Company, except as set forth in the AiXin BVI Schedules (as defined in Section 1.11 below) annexed hereto, AiXin BVI (which for purposes of this Article I includes AiXin HK and AiXin Zhonghong, unless the context requires otherwise) represents and warrants as follows:

 

Section 1.01 Incorporation . AiXin BVI is a corporation duly incorporated, validly existing, and in good standing under the laws of the British Virgin Islands and has the corporate power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities to carry on its business in all material respects as it is now being conducted. AiXin BVI has delivered to the Company or its representatives complete and correct copies of the Memorandum of Association and Articles of Association of AiXin BVI, each as in effect on the date hereof (collectively, the “ AiXin BVI Charter Documents ”). The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of AiXin BVI’s Charter Documents. AiXin BVI has taken all actions required by law, the AiXin BVI Charter Documents, or otherwise to authorize the execution and delivery of this Agreement. AiXin BVI has full power, authority, and legal capacity and has taken all action required by law, the AiXin BVI Charter Documents, and otherwise to consummate the transactions herein contemplated.

 

1
 

 

Section 1.02 Subsidiaries . Except for AiXin HK and its wholly-owned subsidiary, AiXin Zhonghong (for purposes of this Agreement together with AiXin HK, the “Subsidiaries”), AiXin BVI does not own, beneficially or of record, any shares of or control any other corporation.

 

Section 1.03 Approval of Agreement. The Board of Directors of AiXin BVI has authorized the execution and delivery of this Agreement by AiXin BVI and the transactions contemplated hereby, and has recommended to the Stockholders that the Exchange be accepted.

 

Section 1.04 Valid Obligation. This Agreement and all other agreements executed by AiXin BVI in connection herewith constitute valid and binding obligations of AiXin BVI, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

Section 1.05 No Conflict With Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate, accelerate or modify the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which AiXin BVI or the Subsidiaries is a party or to which any of their respective assets, properties or operations are subject.

 

Section 1.06 Capitalization . As of the date hereof, the authorized capital of AiXin BVI consists of 50,000 common shares, of which 10 common shares are issued and outstanding. The issued and outstanding common shares of AiXin BVI are validly issued, fully paid, and non-assessable and have not been issued in violation of the preemptive or other rights of any person. There are no existing options, warrants, calls, or commitments of any character relating to the authorized and unissued stock of AiXin BVI.

 

Section 1.07 Financial Statements .

 

(a) AiXin BVI has made available to the Company correct and complete copies of (i) the audited balance sheets of AiXin Zhonghong as of December 31, 2016 and 2015 (the “ AiXin Zhonghong Balance Sheets ”) and the related audited statements of operations and comprehensive loss, stockholders’ equity (deficit) and cash flows for the fiscal years ended December 31, 2016 and December 31,2015, together with the notes to such statements and the report of its independent certified public accountants with respect thereto, and the unaudited interim balance sheets of AiXin Zhonghong as of September 30, 2017 and 2016 and the related unaudited statements of operations and comprehensive loss and cash flows for the nine months ended September 30, 2017 and September 30, 2016, together with the notes to such statements (collectively, the “ AiXin Zhonghong Financial Statements ”).

 

(b) The AiXin Zhonghong Financial Statements (including any related notes thereto) were prepared in accordance with U.S. GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and each fairly presents in all material respects the financial positions of AiXin Zhonghong at the respective dates thereof and the results of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements were or are subject to normal adjustments which were not or are not expected to have a material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of AiXin Zhonghong (“ Material Adverse Effect ”). The balance sheets of AiXin Zhonghong included in the AiXin Zhonghong Financial Statements are true and accurate and present fairly as of their respective dates the financial condition of AiXin Zhonghong. As of the date of such balance sheets, except as and to the extent reflected or reserved against therein, AiXin Zhonghong had no liabilities or obligations (absolute or contingent) which should be reflected in the balance sheets of AiXin Zhonghong or the notes thereto prepared in accordance with U.S. GAAP, and all assets reflected therein are properly reported and present fairly the value of the assets of AiXin Zhonghong, in accordance with U.S. GAAP. The statements of operations, stockholders’ equity and cash flows of AiXin Zhonghong reflect fairly the information required to be set forth therein by U.S. GAAP. All of AiXin Zhonghong’s assets are reflected in the AiXin Zhonghong Financial Statements, and, except as set forth in the AiXin BVI Schedules or the AiXin Zhonghong Financial Statements or the notes thereto, AiXin Zhonghong has no material liabilities, direct or indirect, matured or unmatured, contingent or otherwise.

 

2
 

 

(c) AiXin BVI and each of the Subsidiaries has duly and punctually paid all governmental fees and taxes which it has become liable to pay and has duly allowed for all taxes reasonably foreseeable and is under no liability to pay any penalty or interest in connection with any claim for governmental fees or taxation and AiXin BVI and each of the Subsidiaries has made any and all proper declarations and returns for taxation purposes and all information contained in such declarations and returns is true and complete and full provision or reserves have been made in its financial statements for all governmental fees and taxation.

 

(d) The books and records, financial and otherwise, of AiXin BVI and each of the Subsidiaries are in all material aspects complete and correct and have been maintained in accordance with generally accepted accounting principles consistently applied throughout the periods involved.

 

(e) AiXin BVI and AiXin HK have not conducted any business operations and as of the date hereof the liabilities and commitments of AiXin BVI and AiXin HK in the aggregate are not in excess of $10,000.

 

Section 1.08 Absence of Certain Changes or Events. Since September 30, 2017 (the “ Cut-Off Date ”):

 

(a) There has not been (i) any material adverse change in the business, operations, properties, assets or condition of AiXin BVI or the Subsidiaries, or (ii) any damage, destruction or loss suffered by AiXin BVI or the Subsidiaries (whether or not covered by insurance), materially and adversely affecting the business, operations, properties, assets or condition of AiXin BVI or the Subsidiaries.

 

(b) AiXin BVI has not (i) amended the AiXin BVI Charter Documents; (ii) declared or made, or agreed to declare or make any payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed to purchase or redeem, any of its capital stock; (iii) waived any rights of value which in the aggregate are outside of the ordinary course of its business or material considering its business; (iv) made any material change in its method of management, operation, or accounting; (v) entered into any transactions or agreements other than in the ordinary course of business; (vi) made any accrual or arrangement for or payment of bonuses or special compensation of any kind or any severance or termination pay to any present or former officer or employee; (vii) increased the rate of compensation payable or to become payable by it to any of its officers or directors or any of its salaried employees whose monthly compensation exceed $1,000; or (viii) made any increase in any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit plan, payment, or arrangement, made to, for or with its officers, directors, or employees.

 

(c) Neither AiXin BVI nor the Subsidiaries has (i) granted any options, warrants or rights to purchase, or issued any of its securities; (ii) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent), except liabilities incurred in the ordinary course of business; (iii) paid or agreed to pay any material obligations or liabilities (absolute or contingent) other than current liabilities reflected in or shown on the Balance Sheet and current liabilities incurred since the Cut-Off Date in the ordinary course of business and professional and other fees and expenses in connection with the preparation of this Agreement and the consummation of the transaction contemplated hereby; (iv) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights (except assets, properties, or rights not used or useful in its business which, in the aggregate have a value of less than $1,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which in the aggregate are of a value less than $1,000); (v) made or permitted any amendment or termination of any contract, agreement, or license to which it is a party if such amendment or termination is material, considering its business; or (vi) issued, delivered or agreed to issue or deliver, any stock, bonds or other corporate securities including debentures (whether authorized and unissued or held as treasury stock), except in connection with this Agreement.

 

(d) Neither AiXin BVI nor either Subsidiary has become subject to any law or regulation which materially and adversely affects, or in the future, may adversely affect, its business, operations, properties, assets or condition.

 

3
 

 

Section 1.09 Litigation and Proceedings . There are no actions, suits, proceedings, or investigations pending or, to the knowledge of AiXin BVI after reasonable investigation, threatened by or against it or either of the Subsidiaries or affecting them or their properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind. AiXin BVI does not have any knowledge of any material default on its part or on the part of either of the Subsidiaries with respect to any judgment, order, injunction, decree, award, rule, or regulation of any court, arbitrator, or governmental agency or instrumentality or of any circumstances which, after reasonable investigation, would result in the discovery of such a default. Neither AiXin BVI nor either of the Subsidiaries is a party to or bound by, and none of its or their properties are subject to, any judgment, order, writ, injunction, decree, or award.

 

Section 1.10 Compliance With Laws and Regulations. AiXin BVI and each of the Subsidiaries has complied with all applicable statutes and regulations of any national, provincial, municipal or other applicable governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect its business, operations, properties, assets, or condition, except to the extent that noncompliance would not result in the occurrence of any material liability.

 

Section 1.11 AiXin BVI Disclosure Schedules. AiXin BVI has delivered to the Company a schedule of any exceptions to the representations made herein (the “ AiXin BVI Schedules ”), certified by the chief executive officer of AiXin BVI as complete, true, and correct as of the date of this Agreement in all material respects. AiXin BVI shall cause the AiXin BVI Schedules and the instruments and data delivered to the Company hereunder to be promptly updated after the date hereof up to and including the Closing Date.

 

Section 1.12 PRC Laws and Regulations . To the best knowledge AiXin BVI, AiXin Zhonghong is in compliance with all applicable laws and regulations of the PRC and the provincial and local governments in which it is located or conducts business, and all material consents, approvals, authorizations or licenses requisite under PRC law for the due and proper establishment and operation of their respective businesses have been duly obtained from the relevant PRC governmental authorities and are in full force and effect.

 

Section 1.13 Information . The information concerning AiXin BVI and each of the Subsidiaries set forth in this Agreement and in the AiXin BVI Schedules is complete and accurate in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact required to make the statements made, in light of the circumstances under which they were made, not misleading. In addition, AiXin BVI has fully disclosed in writing to Company (through this Agreement or the AiXin BVI Schedules) all information relating to matters involving AiXin BVI and the Subsidiaries or their respective assets or present or past operations or activities which (i) indicated or may indicate, in the aggregate, the existence of a greater than $50,000 liability, (ii) have led or may lead to a competitive disadvantage on the part of AiXin BVI and the Subsidiaries considered as a single entity or (iii) either alone or in aggregation with other information covered by this Section, otherwise have led or may lead to a material adverse effect on AiXin BVI and the Subsidiaries considered as a single entity, their respective assets, operations or activities as presently conducted or as contemplated to be conducted after the Closing Date, including, but not limited to, information relating to governmental, employee, environmental, litigation and securities matters and transactions with affiliates.

 

ARTICLE II

REPRESENTATIONS AND WARRANTIES OF THE STOCKHOLDER

 

The Stockholder hereby represents and warrants to the Company as follows:

 

Section 2.01 Good Title . The Stockholder is the record and beneficial owner, and has good title to the AiXin BVI Shares, with the right and authority to sell and deliver the AiXin BVI Shares, free and clear of all liens, claims, charges, encumbrances, pledges, mortgages, security interests, options, rights to acquire, proxies, voting trusts or similar agreements, restrictions on transfer or adverse claims of any nature whatsoever. Upon delivery of any certificate or certificates duly assigned, representing the same as herein contemplated and/or upon registering of the Company as the new owner of the AiXin BVI Shares in the share register of AiXin BVI, the Company will receive good title to the AiXin BVI Shares, free and clear of all liens. Upon consummation of the Exchange, all of the outstanding shares of AiXin BVI will be held by the Company.

 

4
 

 

Section 2.02 Power and Capacity; Binding Effect . The Stockholder has the legal power and capacity to execute and deliver this Agreement, to consummate the transactions contemplated by this Agreement, and to perform the Stockholder’s obligations under this Agreement. This Agreement constitutes a legal, valid and binding obligation of the Stockholder, enforceable against the Stockholder in accordance with the terms hereof.

 

Section 2.03 No Conflicts. The execution and delivery of this Agreement by the Stockholder and the performance by the Stockholder of the Stockholder’s obligations hereunder in accordance with the terms hereof: (a) will not require the consent of any third party or governmental entity under any laws; (b) will not violate any laws applicable to the Stockholder and (c) will not violate or breach any contractual obligation to which the Stockholder is a party.

 

Section 2.04 Stockholder is Not a U.S Person and is Acquiring Exchange Shares in an Off-Shore Transaction .

 

(a) The Stockholder understands that it is intended that, and the Company is offering and issuing the Exchange Shares to the Stockholder in reliance on an exemption from the registration requirements of the Securities Act under Regulation S promulgated under the Securities Act (“Regulation S”) based upon the following representations and warranties of the Stockholder: The Stockholder is not a “U.S. Person,” as defined in Rule 902(k) of Regulation S and the issuance and sale of the Exchange Shares will occur in an “off-shore transaction,” as defined in Rule 902 (h) of Regulation S. The Stockholder has no intention of becoming a U.S. Person, and at the time of the origination of contact concerning this Agreement and the date of the execution and delivery of this Agreement, the Stockholder was outside of the United States.

 

Stockholder understands and acknowledges that each certificate representing the Exchange Shares will be endorsed with the following legends, in addition to any other legend required to be placed thereon by applicable federal or state securities laws:

 

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE BEEN OFFERED TO INVESTORS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”)) AND WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT IN RELIANCE UPON REGULATION S PROMULGATED UNDER THE SECURITIES ACT.”

 

“TRANSFER OF THESE SECURITIES IS PROHIBITED, EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO AVAILABLE EXEMPTION FROM REGISTRATION. HEDGING TRANSACTIONS MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.”

 

(b) The Stockholder acknowledges that neither the SEC, nor the securities regulatory body of any state or other jurisdiction, has received, considered or passed upon the accuracy or adequacy of the information and representations made in this Agreement.

 

(c) The Stockholder acknowledges that he has carefully reviewed such information as he has deemed necessary to evaluate an investment in the Company and its securities. To the full satisfaction of the Stockholder, the Stockholder has been furnished all materials that he has requested relating to the Company and the issuance of the Exchange Shares hereunder, and the Stockholder has been afforded the opportunity to ask questions of the Company’s representatives to obtain any information necessary to verify the accuracy of any representations or information made or given to the Stockholder. Notwithstanding the foregoing, nothing herein shall derogate from or otherwise modify the representations and warranties of the Company set forth in this Agreement, on which the Stockholder has relied in making an exchange of the AiXin BVI Shares for the Exchange Shares.

 

(d) The Stockholder understands that the Exchange Shares may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Exchange Shares or any available exemption from registration under the Securities Act, the Exchange Shares may have to be held indefinitely. The Stockholder further acknowledges that the Exchange Shares may not be sold pursuant to Rule 144 promulgated under the Securities Act unless all of the conditions of Rule 144 are satisfied (including, without limitation, the Company’s compliance with the reporting requirements under the Exchange Act).

 

5
 

 

(g) The Stockholder agrees that, notwithstanding anything contained herein to the contrary, the warranties, representations, agreements and covenants of the Stockholder under this Section 2.04 shall survive the Closing for the period set forth in Section 6.11.

 

Section 2.05 Additional Legends; Consent . The Stockholder consents to the Company making a notation on its records or giving instructions to any transfer agent of Exchange Shares in order to implement the restrictions on transfer of the Exchange Shares.

 

 

ARTICLE III

REPRESENTATIONS, COVENANTS, AND WARRANTIES OF THE COMPANY

 

As an inducement to, and to obtain the reliance of AiXin BVI and the Stockholder, except as set forth in the Company Schedules or the Company SEC Reports (as each of those terms is hereinafter defined), the Company represents and warrants as follows:

 

Section 3.01 Organization . The Company is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Colorado and has the corporate power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities to carry on its business in all material respects as it is now being conducted. The Company has made available to AiXin BVI and the Stockholder or there is included on the Securities and Exchange Commission’s website (“EDGAR”) complete and correct copies of the articles of incorporation and bylaws of the Company, each as in effect on the date hereof (together, the “ Company Charter Documents ”). The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of Company Charter Documents. The Company has taken all action required by law, its Charter Documents, or otherwise to authorize the execution and delivery of this Agreement, and the Company has full power, authority, and legal right and has taken all action required by law, its Charter Documents, or otherwise to consummate the transactions herein contemplated.

 

Section 3.02 Subsidiaries. Except as disclosed in the Company SEC Reports (as defined in Section 3.07 below), the Company does not have any subsidiaries, and does not own, beneficially or of record, any shares of any other corporation.

 

Section 3.03 Approval of Agreement. The Board of Directors of the Company has authorized the execution and delivery of this Agreement by the Company and has approved this Agreement and the transactions contemplated hereby.

 

Section 3.04 Valid Obligation . This Agreement and all agreements and other documents executed by Acquirer in connection herewith constitute the valid and binding obligation of the Company, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

Section 3.05 No Conflict With Other Instruments. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate, accelerate or modify the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or to which any of its assets, properties or operations are subject.

 

Section 3.06 Capitalization.

 

6
 

 

(a) The authorized capital stock of the Company consists of 950,000,000 shares of common stock, par value $0.00001 per share, of which there will be 317,988,089 common shares outstanding, after giving effect to the transaction contemplated hereby and the issuance of an aggregate of 45,224,085 shares to three individuals for services rendered to the Company, and 20,000,000 shares of preferred stock, par value $0.001 per share, none of which are outstanding. All issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued in violation of the preemptive or other rights of any person. There are no existing options, warrants, calls, or commitments of any character relating to the authorized and unissued stock of the Company. No shares of the Company’s common stock were reserved for issuance upon the exercise of outstanding options to purchase the common stock; no shares of common stock were reserved for issuance upon the exercise of outstanding warrants to purchase shares of Company common stock; and no shares of common stock were reserved for issuance upon the conversion of any outstanding convertible notes, debentures or other securities. All outstanding shares of the Company’s common stock have been issued and granted in compliance with all applicable securities laws and (in all material respects) other applicable laws and regulations.

 

(b) There are no equity securities, partnership interests or similar ownership interests of any class of any equity security of the Company, or any securities exchangeable or convertible into or exercisable for such equity securities, partnership interests or similar ownership interests, issued, reserved for issuance or outstanding. There are no subscriptions, options, warrants, equity securities, partnership interests or similar ownership interests, calls, rights (including preemptive rights), commitments or agreements of any character to which the Company is a party or by which it is bound obligating the Company to issue, deliver or sell, or cause to be issued, delivered or sold, or repurchase, redeem or otherwise acquire, or cause the repurchase, redemption or acquisition of, any shares of capital stock, partnership interests or similar ownership interests of the Company or obligating the Company to grant, extend, accelerate the vesting of or enter into any such subscription, option, warrant, equity security, call, right, commitment or agreement. There is no plan or arrangement to issue shares of the Company’s common stock, except as set forth in this Agreement.

 

Except as contemplated by this Agreement, there are no registration rights, and there is no voting trust, proxy, rights plan, anti-takeover plan or other agreement or understanding to which the Company is a party or by which it is bound with respect to any equity security of any class of the Company, and there are no agreements to which Company is a party, or of which the Company has knowledge, which conflict with this Agreement or the transactions contemplated herein or otherwise prohibit the consummation of the transactions contemplated hereunder.

 

Section 3.07 SEC Filings; Financial Statements .

 

(a) The Company has made available to AiXin BVI and the Stockholders a correct and complete copy, or there has been available on EDGAR, copies, of each report, registration statement and definitive proxy and information statement filed by the Company with the SEC since June 1, 2016 (the “ Company SEC Reports ”). As of their respective dates, the Company SEC Reports: (i) were prepared in accordance and complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of the SEC thereunder applicable to such Company SEC Reports, and (ii) did not at the time they were filed (and if amended or superseded by a filing prior to the date of this Agreement then on the date of such filing and as so amended or superseded) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(b) Included in the Company SEC Reports are the audited balance sheets of the Company as of May 31, 2017 and 2016 and the related audited statements of operations, stockholders’ equity and cash flows for May 31, 2017 and 2016, together with the notes to such statements and the opinion of its independent certified public accountants, with respect thereto.

 

7
 

 

(c) Each set of financial statements (including, in each case, any related notes thereto) contained in the Company SEC Reports comply as to form in all material respects with the published rules and regulations of the SEC with respect thereto, were prepared in accordance with U.S. GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and each fairly presents in all material respects the financial position of the Company at the respective dates thereof and the results of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements were or are subject to normal adjustments which were not or are not expected to have a material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole (“ Material Adverse Effect ”). The balance sheets of the Company included in the Company SEC Reports are true and accurate and present fairly as of their respective dates the financial condition of the Company. As of the date of such balance sheets, except as and to the extent reflected or reserved against therein, the Company had no liabilities or obligations (absolute or contingent) which should be reflected in the balance sheets or the notes thereto prepared in accordance with U.S. GAAP, and all assets reflected therein are properly reported and present fairly the value of the assets of the Company, in accordance with U.S. GAAP. The statements of operations, stockholders’ equity and cash flows reflect fairly the information required to be set forth therein by U.S GAAP. Except as set forth in the Company Schedules, the Company has no material liabilities, direct or indirect, matured or unmatured, contingent or otherwise.

 

(d) The Company has no material liabilities with respect to the payment of any federal, state, county, local or other taxes (including any deficiencies, interest or penalties), except for taxes accrued but not yet due and payable.

 

(e) Except as set forth in the Company Schedules, the Company has timely filed (or filed requests for extensions of time within which to file) all state, federal or local income and/or franchise tax returns required to be filed by it from inception to the date hereof. Each of such income tax returns reflects the taxes due for the period covered thereby, except for amounts which, in the aggregate, are immaterial.

 

(f) The books and records, financial and otherwise, of the Company are in all material aspects complete and correct and have been maintained in accordance with U.S. GAAP consistently applied throughout the periods involved.

 

Section 3.08 Absence of Certain Changes or Events. Since August 31, 2017:

 

(a) There has not been (i) any material adverse change in the business, operations, properties, assets or condition of the Company or (ii) any damage, destruction or loss to the Company (whether or not covered by insurance) materially and adversely affecting the business, operations, properties, assets or condition of the Company.

 

(b) The Company has not (i) amended the Company Charter Documents, except as may be required by this Agreement; (ii) declared or made, or agreed to declare or make any payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed to purchase or redeem, any of its capital stock; (iii) waived any rights of value which in the aggregate are outside of the ordinary course of business or material considering the business of the Company; (iv) made any material change in its method of management, operation, or accounting; (v) entered into any transactions or agreements other than in the ordinary course of business and as contemplated hereby; (vi) made any accrual or arrangement for or payment of bonuses or special compensation of any kind or any severance or termination pay to any present or former officer or employee; (vii) increased the rate of compensation payable or to become payable by it to any of its officers or directors or any of its salaried employees whose monthly compensation exceed $1,000; or (viii) made any increase in any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit plan, payment, or arrangement, made to, for or with its officers, directors, or employees.

 

(c) The Company has not (i) granted or agreed to grant any options, warrants, or other rights for its stock, bonds, or other corporate securities calling for the issuance thereof; (ii) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent) except liabilities incurred in the ordinary course of business; (iii) paid or agreed to pay any material obligations or liabilities (absolute or contingent) other than current liabilities reflected in or shown on the most recent Company balance sheet and current liabilities incurred since that date in the ordinary course of business and professional and other fees and expenses in connection with the preparation of this Agreement and the consummation of the transaction contemplated hereby; (iv) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights (except assets, properties, or rights not used or useful in its business which, in the aggregate have a value of less than $1,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which in the aggregate are of a value less than $1,000); (v) made or permitted any amendment or termination of any contract, agreement, or license to which it is a party if such amendment or termination is material, considering the business of the Company; or (vi) issued, delivered or agreed to issue or deliver, any stock, bonds or other corporate securities including debentures (whether authorized and unissued or held as treasury stock), except in connection with this Agreement.

 

8
 

 

(d) The Company has not become subject to any law or regulation which materially and adversely affects, or in the future, may adversely affect, the business, operations, properties, assets or condition of the Company.

 

Section 3.09 Litigation and Proceedings. There are no actions, suits, proceedings or investigations pending or, to the knowledge of the Company, threatened against the Company, or affecting the Company or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind, except as disclosed in the Company Schedule 3.09 . The Company is not in default with respect to any judgment, order, writ, injunction, decree, award, rule or regulation of any court, arbitrator, or governmental agency or instrumentality.

 

Section 3.10 Compliance With Laws and Regulations. The Company has complied with all applicable statutes and regulations of any federal, state, or other applicable governmental entity or agency thereof.

 

Section 3.11 Company Schedules. The Company has delivered to AiXin BVI and the Stockholder the following schedules, which are collectively referred to as the “ Company Schedules ” and which consist of separate schedules, which are dated the date of this Agreement, all certified by the chief executive officer of the Company to be complete, true, and accurate in all material respects as of the date of this Agreement.

 

(a) a schedule of any exceptions to the representations made herein; and

 

(e) a schedule containing the other information requested herein.

 

The Company shall cause the Company Schedules and the instruments and data delivered to AiXin BVI and the Stockholder hereunder to be promptly updated after the date hereof up to and including the Closing Date.

 

ARTICLE IV

PLAN OF EXCHANGE

 

Section 4.01 The Exchange . On the terms and subject to the conditions set forth in this Agreement, the Stockholder by executing this Agreement, shall assign, transfer and deliver, free and clear of all liens, pledges, encumbrances, charges, restrictions or known claims of any kind, nature, or description, the AiXin BVI Shares, constituting all of the outstanding shares of AiXin BVI. In exchange for the AiXin BVI Shares, the Company shall issue to the Stockholder 227,352,604 shares of the Company’s common stock. Upon the surrender of the certificate or certificates representing the AiXin BVI Shares to the Company or its registrar or transfer agent, the Stockholder shall be entitled to receive a certificate or certificates evidencing the Exchange Shares.

 

Section 4.02 Closing. The closing (the “ Closing ” or the “ Closing Date ”) of the transactions contemplated by this Agreement shall occur contemporaneously with the execution of this Agreement by the Company, AiXin BVI and the Stockholder and the delivery of the AiXin BVI Shares to the Company or its transfer agent in exchange for the Exchange Shares, as described in Section 4.01 herein.

 

Section 4.03 Closing Events. At the Closing, or as soon as reasonably practicable thereafter, the Company, AiXin BVI and the Stockholder shall execute, acknowledge, and deliver (or shall ensure to be executed, acknowledged, and delivered), any and all certificates, opinions, financial statements, schedules, agreements, resolutions, rulings or other instruments required by this Agreement to be so delivered at or prior to the Closing, together with such other items as may be reasonably requested by the parties hereto and their respective legal counsel in order to effectuate or evidence the transactions contemplated hereby.

 

9
 

 

ARTICLE V

SPECIAL COVENANTS

 

Section 5.01 Delivery of Books and Records. At the Closing, AiXin BVI shall deliver to the Company, the originals of the corporate minute books, books of account, contracts, records, and all other books or documents of AiXin BVI and of the Subsidiaries which is now in the possession of AiXin BVI or its representatives.

 

Section 5.02 Third Party Consents and Certificates. AiXin BVI and the Company agree to cooperate with each other in order to obtain any required third party consents to this Agreement and the transactions herein contemplated.

 

Section 5.03 Indemnification .

 

(a) AiXin BVI hereby agrees to indemnify the Company and each of the officers, agents and directors of the Company as of the date of execution of this Agreement against any loss, liability, claim, damage, or expense (including, but not limited to, any and all expense whatsoever reasonably incurred in investigating, preparing, or defending against any litigation, commenced or threatened, or any claim whatsoever) (the “ Loss ”), to which it or they may become subject arising out of or based on any inaccuracy appearing in or misrepresentations made under Article I of this Agreement. The indemnification provided for in this paragraph shall survive the Closing and consummation of the transactions contemplated hereby and termination of this Agreement for one year following the Closing.

 

(b) The Stockholder agrees to indemnify the Company and each of the officers, agents and directors of the Company as of the date of execution of this Agreement against any Loss, to which he may become subject arising out of or based on any inaccuracy appearing in or misrepresentations made under Article II of this Agreement. The indemnification provided for in this paragraph shall survive the Closing and consummation of the transactions contemplated hereby and termination of this Agreement for one year following the Closing.

 

Section 5.04 The Acquisition of Exchange Shares.

 

(a) AiXin BVI and the Company understand and agree that the consummation of this Agreement including the issuance of the Exchange Shares to the Stockholder in exchange for the AiXin BVI Shares as contemplated hereby constitutes the offer and sale of securities under the Securities Act and applicable state statutes. AiXin BVI and the Company agree that such transactions shall be consummated in reliance on exemptions from the registration and prospectus delivery requirements of such statutes, which depend, among other items, on the circumstances under which such securities are acquired.

 

(b) In connection with the transaction contemplated by this Agreement, AiXin BVI and the Company shall each file, with the assistance of the other and their respective legal counsel, such notices, applications, reports, or other instruments as may be deemed by them to be necessary or appropriate in an effort to document reliance on such exemptions, all to the extent and in the manner as may be deemed by such parties to be appropriate.

 

(c) In order to more fully document reliance on the exemptions as provided herein, the Company, AiXin BVI and the Stockholder shall execute and deliver to the other, at or prior to the Closing, such further letters of representation, acknowledgment, suitability, or the like as the Company or AiXin BVI and their respective counsel may reasonably request in connection with reliance on exemptions from registration under such securities laws.

 

(cd) The Stockholder acknowledges that the basis for relying on exemptions from registration or qualifications are factual, depending on the conduct of the various parties, and that no legal opinion or other assurance will be required or given to the effect that the transactions contemplated hereby are in fact exempt from registration or qualification.

 

10
 

 

ARTICLE VI

MISCELLANEOUS

 

Section 6.01 Brokers. AiXin BVI, the Stockholder and the Company agree that, except as set out on Schedule 6.01 attached hereto, there were no finders or brokers involved in bringing the parties together or who were instrumental in the negotiation, execution or consummation of this Agreement. AiXin BVI and the Stockholder, on the one hand, and the Company, on the other hand, agree to indemnify the other against any claim by any third person other than those described above for any commission, brokerage, or finder’s fee arising from the transactions contemplated hereby based on any alleged agreement or understanding between the indemnifying party and such third person, whether express or implied from the actions of the indemnifying party.

 

Section 6.02 Governing Law. This Agreement shall be governed by, enforced, and construed under and in accordance with the laws of the United States of America and, with respect to the matters of state law, with the laws of the State of Colorado. Venue for all matters shall be in New York, New York, without giving effect to principles of conflicts of law thereunder. Each of the parties (a) irrevocably consents and agrees that any legal or equitable action or proceedings arising under or in connection with this Agreement shall be brought exclusively in the federal courts of the United States. By execution and delivery of this Agreement, each party hereto irrevocably submits to and accepts, with respect to any such action or proceeding, generally and unconditionally, the jurisdiction of the aforesaid court, and irrevocably waives any and all rights such party may now or hereafter have to object to such jurisdiction.

 

Section 6.03 Notices. Any notice or other communications required or permitted hereunder shall be in writing and shall be sufficiently given if personally delivered to it or sent by telecopy, overnight courier or registered mail or certified mail, postage prepaid, addressed to the recipient at such address as it has provided to the other parties hereto at the time of execution of this Agreement or such other addresses as shall be furnished in writing by any party in the manner for giving notices hereunder, and any such notice or communication shall be deemed to have been given (i) upon receipt, if personally delivered, (ii) on the day after dispatch, if sent by overnight courier, (iii) upon dispatch, if transmitted by telecopy and receipt is confirmed by telephone and (iv) three (3) days after mailing, if sent by registered or certified mail.

 

Section 6.04 Attorney’s Fees. In the event that either party institutes any action or suit to enforce this Agreement or to secure relief from any default hereunder or breach hereof, the prevailing party shall be reimbursed by the losing party for all costs, including reasonable attorney’s fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.

 

Section 6.05 Schedules; Knowledge. Each party is presumed to have full knowledge of all information set forth in the other party’s schedules delivered pursuant to this Agreement.

 

Section 6.06 Third Party Beneficiaries. This Agreement is strictly between AiXin BVI, the Stockholder and the Company, and, except as specifically provided, no director, officer, stockholder (other than the Stockholder), employee, agent, independent contractor or any other person or entity shall be deemed to be a third party beneficiary of this Agreement.

 

Section 6.07 Expenses. Each of AiXin BVI and the Company will bear their own respective expenses, including legal, accounting and professional fees, incurred in connection with the Exchange or any of the other transactions contemplated hereby.

 

Section 6.08 Entire Agreement. This Agreement represents the entire agreement between the parties relating to the subject matter thereof and supersedes all prior agreements, understandings and negotiations, written or oral, with respect to such subject matter.

 

Section 6.09 Survival; Termination. The representations, warranties, and covenants of the respective parties shall survive the Closing Date and the consummation of the transactions herein contemplated for a period of one year.

 

Section 6.10 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.

 

Section 6.11 Amendment or Waiver. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any party of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing.

 

[signature page is on following page]

 

11
 

 

IN WITNESS WHEREOF , the parties hereto have executed this Agreement as of the date first-above written.

 

 

AiXin (BVI) International Group Co., Ltd.  
     
By: /s/Quanzhong Lin  
  Quanzhong Lin  
  Chief Executive Officer  
     
Mercari Communications Group, Ltd.  
     
By: /s/Quanzhong Lin  
  Quanzhong Lin  
  President and Chief Executive Officer  
     
The Stockholder  
     
  /s/Quanzhong Lin  
   Quanzhong Lin  

 

12
 

 

Share Exchange Agreement

AiXin BVI Schedules

Exceptions to Representations

 

13
 

 

Share Exchange Agreement

Company Schedules

Exceptions to Representations

 

14
 

 

 

EXECUTIVE SERVICES AND SEPARATION AGREEMENT

 

This Executive Services and Separation Agreement (the “ Agreement ”) is entered into as of this 11th day of December 2017 between Ethan Chuang (the “ Executive ”) and Mercari Communications Group, Ltd. (the “ Company ”).

 

The Executive has been employed by the Company as an officer and has served as a director of the Company;

 

The Company and the Executive have agreed to terminate their relationship and the Company has determined to compensate the Executive for services rendered as provided herein.

 

NOW, THEREFORE, in consideration of the mutual covenants and promises herein, the receipt and sufficiency of which are hereby acknowledged by each party, the Executive and the Company agree as follows:

 

1. Termination of Relationship . The Executive’s engagement by the Company and his service as a director of the Company shall terminate on the date the Company acquires AiXin (BVI) International Group Co., Ltd. (the “ Separation Date ”). The Executive acknowledges that he has received, or will receive pursuant to the terms of this Agreement, any and all payment for wages, accrued unused vacation, if any, other fringe benefits, if any, equity compensation, if any, and reimbursable and properly documented and submitted business expenses, if any, to which the Executive is entitled through the Separation Date.
   
2. Release . Except as provided in this Agreement, the Company hereby releases Executive from, and agrees not to bring any action, suit or proceedings against Executive, with respect to any acts or omissions disclosed by Executive to, or known by, independent members of the Company’s Board of Directors prior to the Separation Date.
   
3. Consideration . In consideration for the Executive’s services, releases, promises, and representations in this Agreement and provided the Executive complies with his obligations under this Agreement, the Company will issue to Executive 15,074,695 shares of the common stock of the Company.
   
4. General Release and Agreement Not to Sue . In exchange for the issuance of the shares provided for herein, the Executive hereby releases the Company from, and agrees not to bring any action, suit or proceedings against the Company, with respect to any acts or omissions prior to the Separation Date.
   
5. Consulting, Cooperation and Assistance .

 

  A. Cooperation and Assistance . For 12 months following the Separation Date, the Executive will voluntarily cooperate with the Company in connection with any matters or issues related to his engagement with the Company and his service as a director of the Company. Executive will voluntarily provide thorough and accurate information and testimony to or on behalf of the Company or any of its subsidiaries or any other entity related to the Company as relates to matters in which he was involved, regarding any investigation, litigation, or claims initiated by or brought or threatened against the Company, including any government agency investigation, or any dispute between the Company and any current employee, former employee, agent, consultant, vendor, supplier, or customer of the Company arising from or related to any act or omission that actually or allegedly occurred during the Executive’s engagement by the Company. Except as may be required by law, the Executive will not disclose or discuss with anyone who is not directing or assisting the Company in any investigation, litigation, claim, or dispute covered by the previous sentence, other than the Executive’s attorney, the fact of or the subject matter of the investigation, litigation, claim, or dispute. The Executive will cooperate fully with the Company as relates to matters in which he was involved, in promptly supplying thorough and accurate information and testimony during the handling or resolution of any such investigation, litigation, claim, or dispute. If the Executive receives a subpoena, becomes subject to any legal obligation that may require him to take any action otherwise prohibited by this section, or receives any request, whether informal or formal, to provide information he shall, as soon as possible but in any case within five days, provide notice of that fact to the Company.

 

 
 

 

  B. Other Employment. Nothing in this Section prevents Executive from accepting and beginning full time employment with another employer.

 

6. Confidential Information and Return of Company Property .

 

  a. The Executive acknowledges and agrees that the Confidential Information (as defined below) of the Company obtained during the course of his employment by the Company is the property of the Company. The Executive will never, directly or indirectly, disclose, publish or use any Confidential Information of which the Executive has become aware, whether or not such information was developed by him. All duties and obligations set forth in this Agreement regarding Confidential Information shall be in addition to those which exist under the common law.
  b. As used in this Agreement, “ Confidential Information ” means information that is not generally known to the public and that was or is used, developed or obtained by the Company, in connection with its businesses, including but not limited to:

 

  i. products or services, unannounced products or services, product or service development information (or other proprietary product or service information);
     
  ii. fees, costs, bids and pricing structures and quotations or proposals given to agents, customers, sureties, suppliers, or prospective customers, agents, sureties or suppliers, or received from any such person or entity;
     
  iii. accounting or financial records;
     
  iv. strategic business plans;
     
  v. information system applications or strategies;
     
  vi. customer and vendor lists and employee lists and directories;
     
  vii. marketing plans, bidding strategies and processes, and negotiation strategies, whether past, current, or future;
     
  viii. accounting and business methods;
     
  ix. legal advice and/or attorney work product;
     
  x. trade secrets and other proprietary information;
     
  xi. information, analysis or strategies regarding acquisitions, mergers, other business combinations, divestitures, recapitalizations, or new ventures; and
     
  xii. nonpublic information that was acquired by the Executive concerning the requirements and specifications of the Company’s or any other GLDD Entity’s agents, vendors, contractors, customers, or potential customers.

 

  c. Notwithstanding Section 6.b, Confidential Information does not include any information that: (i) is publicly disclosed by law or pursuant to, and to the extent required by, an order of a court of competent jurisdiction or governmental agency; (ii) becomes publicly available through no fault of the Executive; or (iii) has been published in a form generally available to the public before the Executive proposes to disclose, publish, or use such information.
     
  d. The Executive agrees that on the Separation Date he will return to the Company all Confidential Information and all property of the Company that is in the Executive’s possession, custody or control, including but not limited to all originals, copies, or embodiments of any:

 

  i. keys and access cards;
     
  ii. computer hardware (including but not limited to all personal computers, laptop computers, iPhones, Blackberries, other personal data assistants, back-up drives and the contents thereof, as well as any passwords or codes needed to operate such equipment;
     
  iii. computer software and programs, data, diskettes, CDs, DVDs, thumb-drives or other removable data storage devices, and other embodiments of electronic data (including, without limitation, any materials in any online or other third party storage media, as well as any passwords or codes needed to access such software, programs, data, and storage media);

 

 
 

 

  iv. materials, papers, books, files, memoranda, correspondence, e-mails, notes, documents, records, photographs, manuals, notebooks, program listings, flow charts, policies, customer information, customer lists, vendor information and lists, pricing information, marketing information, specifications, plans, data base information and/or lists, and mailing lists, that the Executive has or had relating to the Company, or any customers, contractors, vendors, agents, employees, plans, designs, contracts, agreements, strategies, inventions, systems, policies, and/or practices (whether those materials are on paper or in an electronic format).

 

The Executive agrees not to keep any originals, copies, or embodiments of any such property or information in any form, and not to disclose their contents to any other person.

 

7 . No Admission . This Agreement is not an admission by any of the either party to this Agreement that any action that either or any of them has taken or has failed to take with respect to the other party was wrongful, unlawful, in violation of any local, state, or federal constitution, law, statute or regulation, or capable of inflicting any damages or injury on such other party, and Executive and the Company specifically deny any such wrongdoing or violation.
   
8. Mutual Non-Disparagement. The Executive agrees not to make any oral or written statement to anyone that disparages the Company. The Company agrees that its officers and directors will not make any oral or written statement to anyone that disparages the Executive.
   
9. Entire Agreement . This Agreement (including the Appendices) contains the entire agreement and understanding between the Executive and the Company concerning any of the matters described herein, and supersedes any and all prior agreements (including any employment agreement), discussions, negotiations, understandings, and proposals of the parties. The terms of this Agreement cannot be changed except in a later document signed by the Executive and an authorized officer of the Company.
   
10. Governing Law; Venue . This Agreement shall be governed by the laws of the State of New York, without giving effect to any principles regarding conflicts of laws. The parties will bring and pursue any legal or equitable proceeding relating to or arising under this Agreement only in the courts of New York County, New York. Each party consents to and agrees never to challenge the personal jurisdiction or venue of those courts, and agrees that they are a fair and convenient place to conduct any such proceeding.
   
11. No Presumption . This Agreement shall be interpreted and construed as if all of its provisions were drafted jointly by the parties, and no party is entitled to the benefit of any rule of construction with respect to the interpretation of any term, condition, or provision in favor or against any drafter of this Agreement. This Agreement shall be interpreted and construed in accordance with the plain meaning of its terms and not strictly for or against either party.
   
12. Headings . The headings in this Agreement are for the convenience of the parties and shall not affect its meaning or interpretation.
   
13. No Waiver . Either party’s failure to insist upon strict compliance with any part of this Agreement, or its failure to assert any right it may have hereunder, will not be considered a waiver of that or any other part of or right under this Agreement unless the waiver is in writing and signed by the party that is waiving its rights.
   
14. Binding . The terms of this Agreement shall be binding upon and inure to the benefit of the heirs, estates, predecessors, affiliates, assigns, attorneys, officers, directors, employees, agents and representatives of the parties.
   
15. Knowing and Voluntary Waiver . The Executive acknowledges and agrees that:

 

  a. he has carefully read all parts of this Agreement and fully understands their meaning;
     
  b. he had the opportunity to take up to 21 days after receiving this Agreement to decide whether to sign it;
     
  c. the Company hereby has advised him that he should consult with an attorney before signing it;
     
  d. he is signing this Agreement knowingly, voluntarily, and without any coercion or duress; and
     
  e.

the only consideration the Executive is receiving for signing this Agreement is described in the Agreement itself, and no other promises or representations of any kind have been made to cause her to sign it.

 

 
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date written above.

 

Mercari Communications Group, Ltd.    
       
By: /s/ Quanzhong Lin   /s/ Ethan Chuang
  Quanzhong Lin   Ethan Chuang
  Chief Executive Officer    

 

 
 

 

 

CONSULTING AGREEMENT

 

THIS CONSULTING AGREEMENT (this “Agreement”) is entered into as of this 11th day of December 2017 between Mercari Communications Group, Inc., a Nevada corporation (the “Company”), and Yao-Te Wang (the “Consultant”).

 

Preliminary Statement

 

Consultant has performed consulting services for the Company and has agreed to serve as a member of its Board of Directors (collectively, the “Services”).

 

The Company desires to issue to the Consultant, and the Consultant is willing to accept from the Company, 15,074,695 restricted shares of the common stock of the Company (the “Shares”), in consideration for the Services, on the terms and subject to the conditions set forth in this Agreement.

 

NOW THEREFORE, in consideration of the mutual promises, covenants and representations contained herein, the parties herewith agree as follows:

 

1. ISSUANCE OF SHARES. Upon the terms and subject to the conditions set forth in this Agreement, the Company hereby issues to the Consultant, and Consultant hereby accepts, the Shares, in payment for the Services.

 

2. DELIVERIES. The Company has instructed its transfer agent to issue a certificate evidencing the Shares registered in the name of the Consultant or its nominee.

 

3. REPRESENTATIONS OF COMPANY. The Company hereby represents and warrants to the Consultant as follows:

 

3.01 Organization . The Company is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Colorado and has the corporate power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities to carry on its business in all material respects as it is now being conducted. The Company has made available to the Consultant or there is included on the Securities and Exchange Commission’s website (“EDGAR”) complete and correct copies of the articles of incorporation and bylaws of the Company, each as in effect on the date hereof (together, the “Company Charter Documents”). The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of Company Charter Documents. The Company has taken all action required by law, its Charter Documents, or otherwise to authorize the execution and delivery of this Agreement, and the Company has full power, authority, and legal right and has taken all action required by law, its Charter Documents, or otherwise to consummate the transactions contemplated hereby.

 

3.02 Approval of Agreement. The Board of Directors of the Company has authorized the execution and delivery of this Agreement by the Company and has approved this Agreement and the issuance of the Shares to the Consultant pursuant to this Agreement.

 

 
 

 

3.03 Valid Obligation . This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

3.04 No Conflict With Other Instruments. The execution of this Agreement and the issuance of the Shares to the Consultant contemplated by this Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate, accelerate or modify the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or to which any of its assets, properties or operations are subject.

 

3.05 SEC Filings; Financial Statements .

 

(a) The Company has made available to the Consultant a correct and complete copy, or there has been available on EDGAR, copies, of each report, registration statement and definitive proxy and information statement filed by the Company with the U.S. Securities and exchange Commission (the “SEC”) since June 1, 2016 (the “SEC Reports”). As of their respective dates, the SEC Reports: (i) were prepared in accordance and complied in all material respects with the requirements of the Securities Act of 1933, as amended (the “Securities Act”) or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as the case may be, and the rules and regulations of the SEC thereunder applicable to such SEC Reports, and (ii) did not at the time they were filed (and if amended or superseded by a filing prior to the date of this Agreement then on the date of such filing and as so amended or superseded) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(b) Included in the SEC Reports are the audited balance sheets of the Company as of May 31, 2017 and 2016 and the related audited statements of operations, stockholders’ equity and cash flows for the years ended May 31, 2017 and 2016, together with the notes to such statements and the opinion of its independent certified public accountant thereon, and the unaudited balance sheet of the Company as of August 31, 2017 and the related unaudited statements of operations and cash flows for nine and three month periods ended August 31, 2017 and 2016, together with the notes to such unaudited statements.

 

 
 

 

(c) Each set of financial statements (including, in each case, any related notes thereto) contained in the SEC Reports comply as to form in all material respects with the published rules and regulations of the SEC with respect thereto, were prepared in accordance with U.S. GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and each fairly presents in all material respects the financial position of the Company at the respective dates thereof and the results of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements were or are subject to normal adjustments which were not or are not expected to have a material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole (“Material Adverse Effect”).

 

4. REPRESENTATIONS OF CONSULTANT. The Consultant hereby represents and warrants to the Company as follows:

 

4.01 Power and Capacity; Binding Effect . The Consultant has the legal power and capacity to execute and deliver this Agreement. This Agreement constitutes a legal, valid and binding obligation of the Consultant, enforceable against the Consultant in accordance with the terms hereof.

 

4.02 No Conflicts. The execution and delivery of this Agreement by the Consultant: (a) does not require the consent of any third party or governmental entity under any laws; (b) does not violate any laws applicable to the Consultant and (c) does not violate or breach any contractual obligation to which the Consultant is a party.

 

4.03 Acquisition of Shares Exempt from Registration .

 

(a) The Consultant understands that the Shares are being offered and sold in reliance on an exemption from the registration requirements of the Securities Act under Regulation S promulgated under the Securities Act (“Regulation S”), based upon the representations and warranties of the Consultant as set forth below that the Consultant is not a “U.S. Person,” as defined in Rule 902(k) of Regulation S and that the issuance and sale of the Shares occurred in an “off-shore transaction,” as defined in Rule 902 (h) of Regulation S, and that the Company is relying upon the truth and accuracy of the representations, warranties, acknowledgments and understandings of the Consultant set forth herein in order to determine the applicability of such exemptions and the suitability of the Consultant to acquire the Shares. In this regard, the Consultant represents, warrants and agrees that he is not a “U.S. Person” as defined in Rule 902(k) of Regulation S and understands that the Shares are not registered under the Securities Act and that the issuance thereof to Consultant is intended to be exempt from registration under the Securities Act pursuant to Regulation S. The Consultant has no intention of becoming a U.S. Person, and at the time of the origination of contact concerning this Agreement and the date of the execution and delivery of this Agreement, the Consultant was outside of the United States.

 

The Consultant understands and acknowledges that the certificate representing the Shares will be endorsed with the following legends, in addition to any other legend required to be placed thereon by applicable federal or state securities laws:

 

 
 

 

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE BEEN OFFERED TO INVESTORS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”)) AND WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT IN RELIANCE UPON REGULATION S PROMULGATED UNDER THE SECURITIES ACT.”

 

“TRANSFER OF THESE SECURITIES IS PROHIBITED, EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO AVAILABLE EXEMPTION FROM REGISTRATION. HEDGING TRANSACTIONS MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.”

 

(b) The Consultant acknowledges that neither the SEC, nor the securities regulatory body of any state or other jurisdiction, has received, considered or passed upon the accuracy or adequacy of the information and representations made in this Agreement.

 

(c) The Consultant acknowledges that Consultant has carefully reviewed such information as Consultant has deemed necessary to evaluate an investment in the Company and its securities. To the full satisfaction of Consultant, the Consultant has been furnished all materials that he has requested relating to the Company and the issuance of the Shares hereunder, and Consultant has been afforded the opportunity to ask questions of the Company’s representatives to obtain any information necessary to verify the accuracy of any representations or information made or given to the Consultant. Notwithstanding the foregoing, nothing herein shall derogate from or otherwise modify the representations and warranties of the Company set forth in this Agreement, on which the Consultant has relied in accepting the Shares in consideration for the Services.

 

(d) The Consultant understands that the Shares may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Shares or any available exemption from registration under the Securities Act, the Shares may have to be held indefinitely. The Consultant further acknowledges that the Shares may not be sold pursuant to Rule 144 promulgated under the Securities Act unless all of the conditions of Rule 144 are satisfied (including, without limitation, the Company’s compliance with the reporting requirements under the Exchange Act).

 

4.04 Additional Legends; Consent . The Consultant consents to the Company making a notation on its records or giving instructions to any transfer agent of the Shares in order to implement the restrictions on transfer of the Shares.

 

 
 

 

5. MISCELLANEOUS.

 

(a) This Agreement represents the entire agreement between the parties hereto with respect to the transactions contemplated hereby and supersedes all prior agreements with respect thereto, whether written or oral.

 

(b) Survival. The representations and warranties of the respective parties shall survive the purchase and sale of the Shares contemplated hereby for a period of one year.

 

(c) This Agreement shall be governed by and construed in accordance with the laws of the Peoples’ Republic of China.

 

(d) This Agreement may be executed in counterparts, each of which shall be an original, but all of which shall constitute but one Agreement.

 

 
 

 

IN WITNESS WHEREOF, the parties have executed this agreement as of the date of first written above.

 

  MERCARI COMMUNICATIONS GROUP, LTD.:
     
  By: /s/ Quanzhong Lin
     Quanzhong Lin
    Chief Executive Officer
     
  CONSULTANT:
     
    /s/Yao-Te Wang
    Yao-Te Wang

 

 
 

 

 

 

 

CONSULTING AGREEMENT

 

THIS CONSULTING AGREEMENT (this “Agreement”) is entered into as of this 11th day of December 2017 between Mercari Communications Group, Ltd., a Colorado corporation (the “Company”), and Wanli Liu (the “Consultant”).

 

Preliminary Statement

 

Consultant has performed consulting services for Chengdu AiXin Zhonghong Biological Technology Co., Ltd., a Chinese company (“AiXin Zhonghong”), and assisted the Company in connection with its acquisition of AiXin Zhonghong (collectively, the “Services”).

 

The Company desires to issue to the Consultant, and the Consultant is willing to accept from the Company, 15,074,695 restricted shares of the common stock of the Company (the “Shares”), in consideration for the Services, on the terms and subject to the conditions set forth in this Agreement.

 

NOW THEREFORE, in consideration of the mutual promises, covenants and representations contained herein, the parties herewith agree as follows:

 

1. ISSUANCE OF SHARES. Upon the terms and subject to the conditions set forth in this Agreement, the Company hereby issues to the Consultant, and Consultant hereby accepts, the Shares, in payment for the Services.

 

2. DELIVERIES. The Company has instructed its transfer agent to issue a certificate evidencing the Shares registered in the name of the Consultant or its nominee.

 

3. REPRESENTATIONS OF COMPANY. The Company hereby represents and warrants to the Consultant as follows:

 

3.01 Organization . The Company is a corporation duly incorporated, validly existing, and in good standing under the laws of the State of Colorado and has the corporate power and is duly authorized under all applicable laws, regulations, ordinances, and orders of public authorities to carry on its business in all material respects as it is now being conducted. The Company has made available to the Consultant or there is included on the Securities and Exchange Commission’s website (“EDGAR”) complete and correct copies of the articles of incorporation and bylaws of the Company, each as in effect on the date hereof (together, the “Company Charter Documents”). The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of Company Charter Documents. The Company has taken all action required by law, its Charter Documents, or otherwise to authorize the execution and delivery of this Agreement, and the Company has full power, authority, and legal right and has taken all action required by law, its Charter Documents, or otherwise to consummate the transactions contemplated hereby.

 

 
 

 

3.02 Approval of Agreement. The Board of Directors of the Company has authorized the execution and delivery of this Agreement by the Company and has approved this Agreement and the issuance of the Shares to the Consultant pursuant to this Agreement.

 

3.03 Valid Obligation . This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefore may be brought.

 

3.04 No Conflict With Other Instruments. The execution of this Agreement and the issuance of the Shares to the Consultant contemplated by this Agreement will not result in the breach of any term or provision of, constitute a default under, or terminate, accelerate or modify the terms of, any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or to which any of its assets, properties or operations are subject.

 

3.05 SEC Filings; Financial Statements .

 

(a) The Company has made available to the Consultant a correct and complete copy, or there has been available on EDGAR, copies, of each report, registration statement and definitive proxy and information statement filed by the Company with the U.S. Securities and exchange Commission (the “SEC”) since June 1, 2016 (the “SEC Reports”). As of their respective dates, the SEC Reports: (i) were prepared in accordance and complied in all material respects with the requirements of the Securities Act of 1933, as amended (the “Securities Act”) or the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as the case may be, and the rules and regulations of the SEC thereunder applicable to such SEC Reports, and (ii) did not at the time they were filed (and if amended or superseded by a filing prior to the date of this Agreement then on the date of such filing and as so amended or superseded) contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

(b) Included in the SEC Reports are the audited balance sheets of the Company as of May 31, 2017 and 2016 and the related audited statements of operations, stockholders’ equity and cash flows for the years ended May 31, 2017 and 2016, together with the notes to such statements and the opinion of its independent certified public accountant thereon, and the unaudited balance sheet of the Company as of August 31, 2017 and the related unaudited statements of operations and cash flows for nine and three month periods ended August 31, 2017 and 2016, together with the notes to such unaudited statements.

 

 
 

 

(c) Each set of financial statements (including, in each case, any related notes thereto) contained in the SEC Reports comply as to form in all material respects with the published rules and regulations of the SEC with respect thereto, were prepared in accordance with U.S. GAAP applied on a consistent basis throughout the periods involved (except as may be indicated in the notes thereto) and each fairly presents in all material respects the financial position of the Company at the respective dates thereof and the results of its operations and cash flows for the periods indicated, except that the unaudited interim financial statements were or are subject to normal adjustments which were not or are not expected to have a material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of the Company, taken as a whole (“Material Adverse Effect”).

 

4. REPRESENTATIONS OF CONSULTANT. The Consultant hereby represents and warrants to the Company as follows:

 

4.01 Power and Capacity; Binding Effect . The Consultant has the legal power and capacity to execute and deliver this Agreement. This Agreement constitutes a legal, valid and binding obligation of the Consultant, enforceable against the Consultant in accordance with the terms hereof.

 

4.02 No Conflicts. The execution and delivery of this Agreement by the Consultant: (a) does not require the consent of any third party or governmental entity under any laws; (b) does not violate any laws applicable to the Consultant and (c) does not violate or breach any contractual obligation to which the Consultant is a party.

 

4.03 Acquisition of Shares Exempt from Registration .

 

(a) The Consultant understands that the Shares are being offered and sold in reliance on an exemption from the registration requirements of the Securities Act under Regulation S promulgated under the Securities Act (“Regulation S”), based upon the representations and warranties of the Consultant as set forth below that the Consultant is not a “U.S. Person,” as defined in Rule 902(k) of Regulation S and that the issuance and sale of the Shares occurred in an “off-shore transaction,” as defined in Rule 902 (h) of Regulation S, and that the Company is relying upon the truth and accuracy of the representations, warranties, acknowledgments and understandings of the Consultant set forth herein in order to determine the applicability of such exemptions and the suitability of the Consultant to acquire the Shares. In this regard, the Consultant represents, warrants and agrees that he is not a “U.S. Person” as defined in Rule 902(k) of Regulation S and understands that the Shares are not registered under the Securities Act and that the issuance thereof to Consultant is intended to be exempt from registration under the Securities Act pursuant to Regulation S. The Consultant has no intention of becoming a U.S. Person, and at the time of the origination of contact concerning this Agreement and the date of the execution and delivery of this Agreement, the Consultant was outside of the United States.

 

 
 

 

The Consultant understands and acknowledges that the certificate representing the Shares will be endorsed with the following legends, in addition to any other legend required to be placed thereon by applicable federal or state securities laws:

 

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE BEEN OFFERED TO INVESTORS WHO ARE NOT U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”)) AND WITHOUT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES ACT IN RELIANCE UPON REGULATION S PROMULGATED UNDER THE SECURITIES ACT.”

 

“TRANSFER OF THESE SECURITIES IS PROHIBITED, EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO AVAILABLE EXEMPTION FROM REGISTRATION. HEDGING TRANSACTIONS MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.”

 

(b) The Consultant acknowledges that neither the SEC, nor the securities regulatory body of any state or other jurisdiction, has received, considered or passed upon the accuracy or adequacy of the information and representations made in this Agreement.

 

(c) The Consultant acknowledges that Consultant has carefully reviewed such information as Consultant has deemed necessary to evaluate an investment in the Company and its securities. To the full satisfaction of Consultant, the Consultant has been furnished all materials that he has requested relating to the Company and the issuance of the Shares hereunder, and Consultant has been afforded the opportunity to ask questions of the Company’s representatives to obtain any information necessary to verify the accuracy of any representations or information made or given to the Consultant. Notwithstanding the foregoing, nothing herein shall derogate from or otherwise modify the representations and warranties of the Company set forth in this Agreement, on which the Consultant has relied in accepting the Shares in consideration for the Services.

 

(d) The Consultant understands that the Shares may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering the Shares or any available exemption from registration under the Securities Act, the Shares may have to be held indefinitely. The Consultant further acknowledges that the Shares may not be sold pursuant to Rule 144 promulgated under the Securities Act unless all of the conditions of Rule 144 are satisfied (including, without limitation, the Company’s compliance with the reporting requirements under the Exchange Act).

 

 
 

 

4.04 Additional Legends; Consent . The Consultant consents to the Company making a notation on its records or giving instructions to any transfer agent of the Shares in order to implement the restrictions on transfer of the Shares.

 

5. MISCELLANEOUS.

 

(a) This Agreement represents the entire agreement between the parties hereto with respect to the transactions contemplated hereby and supersedes all prior agreements with respect thereto, whether written or oral.

 

(b) Survival. The representations and warranties of the respective parties shall survive the purchase and sale of the Shares contemplated hereby for a period of one year.

 

(c) This Agreement shall be governed by and construed in accordance with the laws of the Peoples’ Republic of China.

 

(d) This Agreement may be executed in counterparts, each of which shall be an original, but all of which shall constitute but one Agreement.

 

 
 

 

IN WITNESS WHEREOF, the parties have executed this agreement as of the date of first written above.

 

  MERCARI COMMUNICATIONS GROUP, LTD.:
     
  By: /s/ Quanzhong Lin
    Quanzhong Lin
    Chief Executive Officer
     
  CONSULTANT:
     
    /s/Wanli Liu
    Wanli Liu

 

 
 

 

Exhibit 21.1

 

SUBSIDIARIES

 

Name of Subsidiary   Jurisdiction   Ownership  
           
AiXin (BVI) International Group Co., Ltd   British Virgin Islands     100 %(1)
           
HK AiXin International Group Co., Limited   Hong Kong     100 %(2)
             
Chengdu AiXin Zhonghong Biological Technology Co., Ltd.,   China     100 %(3)
             
AiXin Life International Group, Inc. (4)   Nevada     100 %

 

 

(1) Holding company which owns all of the outstanding shares of HK AiXin International Group Co., Limited.

 

(2) Intermediate holding company which owns all of the outstanding shares of Chengdu AiXin Zhonghong Biological Technology Co., Ltd.,

 

(3) Operating company.

 

(4) Inactive. Has no assets and conducts no operations.